package_date,short_name,bc_id,ncit_code,parent_bc_id,bc_categories,synonyms,result_scales,definition,system,system_name,code,dec_id,ncit_dec_code,dec_label,data_type,example_set
2024-12-16,Waist Circumference,C100948,C100948,,Vital Signs,WSTCIR,Quantitative,"A circumferential measurement of the waist, which may be classified as the area immediately below the lowest rib, at the narrowest part of the torso, midpoint between the lowest rib and the iliac crest, or immediately above the iliac crest.",http://loinc.org/,LOINC,56115-9,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Waist Circumference,C100948,C100948,,Vital Signs,WSTCIR,Quantitative,"A circumferential measurement of the waist, which may be classified as the area immediately below the lowest rib, at the narrowest part of the torso, midpoint between the lowest rib and the iliac crest, or immediately above the iliac crest.",http://loinc.org/,LOINC,56115-9,C13717,C13717,Anatomic Site,string,Waist
2024-12-16,Waist Circumference,C100948,C100948,,Vital Signs,WSTCIR,Quantitative,"A circumferential measurement of the waist, which may be classified as the area immediately below the lowest rib, at the narrowest part of the torso, midpoint between the lowest rib and the iliac crest, or immediately above the iliac crest.",http://loinc.org/,LOINC,56115-9,C42578,C42578,Unit of Length,string,
2024-12-16,Waist Circumference,C100948,C100948,,Vital Signs,WSTCIR,Quantitative,"A circumferential measurement of the waist, which may be classified as the area immediately below the lowest rib, at the narrowest part of the torso, midpoint between the lowest rib and the iliac crest, or immediately above the iliac crest.",http://loinc.org/,LOINC,56115-9,C70856,C70856,Observation Result,decimal,
2024-06-27,New Lesion Progression,C103420,C103420,C35461,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;RAJKUMAR MYELOMA 2011,NEWLPROG,Nominal,An assessment of the equivocality of disease progression based on a newly identified lesion.,,,,C25372,C25372,Category,string,RECIST 1.1;RAJKUMAR MYELOMA 2011
2024-06-27,New Lesion Progression,C103420,C103420,C35461,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;RAJKUMAR MYELOMA 2011,NEWLPROG,Nominal,An assessment of the equivocality of disease progression based on a newly identified lesion.,,,,C70856,C70856,Observation Result,string,Equivocal;Unequivocal;N;Y;U
2024-06-27,New Lesion Progression,C103420,C103420,C35461,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;RAJKUMAR MYELOMA 2011,NEWLPROG,Nominal,An assessment of the equivocality of disease progression based on a newly identified lesion.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,New Lesion Progression,C103420,C103420,C35461,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;RAJKUMAR MYELOMA 2011,NEWLPROG,Nominal,An assessment of the equivocality of disease progression based on a newly identified lesion.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,New Lesion Progression,C103420,C103420,C35461,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;RAJKUMAR MYELOMA 2011,NEWLPROG,Nominal,An assessment of the equivocality of disease progression based on a newly identified lesion.,,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Failure to Meet Randomization Criteria,C105448,C105448,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Failure to Meet Randomization Criteria,C105448,C105448,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Failure to Meet Randomization Criteria,C105448,C105448,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.,,,,C25692,C25692,Subcategory,string,Study Participation
2023-12-12,Failure to Meet Randomization Criteria,C105448,C105448,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Failure to Meet Randomization Criteria,C105448,C105448,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.,,,,C82977,C82977,Dictionary-derived Term,string,Failure to Meet Randomization Criteria
2025-04-01,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;g/L;mmol/L
2025-04-01,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Glucose Measurement,C105585,C105585,C49237,Laboratory Tests;Chemistry Tests,Glucose,Quantitative;Ordinal,The determination of the amount of glucose present in a sample.,,,,C82535,C82535,Test Method,string,Test Strip;Dipstick
2025-04-01,Cholesterol Measurement,C105586,C105586,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,CHOL;Cholesterol;Total Cholesterol,Quantitative,The determination of the amount of total cholesterol present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Cholesterol Measurement,C105586,C105586,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,CHOL;Cholesterol;Total Cholesterol,Quantitative,The determination of the amount of total cholesterol present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Cholesterol Measurement,C105586,C105586,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,CHOL;Cholesterol;Total Cholesterol,Quantitative,The determination of the amount of total cholesterol present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;umol/L;mg/dL;ug/dL
2025-04-01,Cholesterol Measurement,C105586,C105586,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,CHOL;Cholesterol;Total Cholesterol,Quantitative,The determination of the amount of total cholesterol present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum;Urine
2025-04-01,High Density Lipoprotein Cholesterol Measurement,C105587,C105587,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,HDL;HDL Cholesterol,Quantitative,The determination of the amount of high-density lipoprotein cholesterol present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,High Density Lipoprotein Cholesterol Measurement,C105587,C105587,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,HDL;HDL Cholesterol,Quantitative,The determination of the amount of high-density lipoprotein cholesterol present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,High Density Lipoprotein Cholesterol Measurement,C105587,C105587,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,HDL;HDL Cholesterol,Quantitative,The determination of the amount of high-density lipoprotein cholesterol present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;umol/L;mg/dL;ug/dL
2025-04-01,High Density Lipoprotein Cholesterol Measurement,C105587,C105587,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,HDL;HDL Cholesterol,Quantitative,The determination of the amount of high-density lipoprotein cholesterol present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum
2025-04-01,Low Density Lipoprotein Cholesterol Measurement,C105588,C105588,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,LDL;LDL Cholesterol,Quantitative,The determination of the amount of low-density lipoprotein cholesterol present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Low Density Lipoprotein Cholesterol Measurement,C105588,C105588,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,LDL;LDL Cholesterol,Quantitative,The determination of the amount of low-density lipoprotein cholesterol present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Low Density Lipoprotein Cholesterol Measurement,C105588,C105588,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,LDL;LDL Cholesterol,Quantitative,The determination of the amount of low-density lipoprotein cholesterol present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum
2025-04-01,Low Density Lipoprotein Cholesterol Measurement,C105588,C105588,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,LDL;LDL Cholesterol,Quantitative,The determination of the amount of low-density lipoprotein cholesterol present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;umol/L;mg/dL;ug/dL
2025-04-01,Very Low Density Lipoprotein Cholesterol Measurement,C105589,C105589,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,VLDL;VLDL Cholesterol,Quantitative,The determination of the amount of very low-density lipoprotein cholesterol present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum
2025-04-01,Very Low Density Lipoprotein Cholesterol Measurement,C105589,C105589,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,VLDL;VLDL Cholesterol,Quantitative,The determination of the amount of very low-density lipoprotein cholesterol present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Very Low Density Lipoprotein Cholesterol Measurement,C105589,C105589,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,VLDL;VLDL Cholesterol,Quantitative,The determination of the amount of very low-density lipoprotein cholesterol present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;umol/L;mg/dL;ug/dL
2025-04-01,Very Low Density Lipoprotein Cholesterol Measurement,C105589,C105589,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,VLDL;VLDL Cholesterol,Quantitative,The determination of the amount of very low-density lipoprotein cholesterol present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C42578,C42578,Unit of Length,string,Millimeters;Centimeters;Inches
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C70713,C70713,Biospecimen Type,string,Tumor Tissue
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C25372,C25372,Category,string,
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Tumor Size Measurement,C106303,C106303,,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,,Quantitative,The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Age at Menopause,C106497,C106497,C25150,Reproductive Findings;Age,MENOAGE;Menopause Age,Quantitative,The age at which permanent cessation of menses occurs.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Age at Menopause,C106497,C106497,C25150,Reproductive Findings;Age,MENOAGE;Menopause Age,Quantitative,The age at which permanent cessation of menses occurs.,,,,C50400,C50400,Age Unit,integer,Years
2024-12-17,Age at Menopause,C106497,C106497,C25150,Reproductive Findings;Age,MENOAGE;Menopause Age,Quantitative,The age at which permanent cessation of menses occurs.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Birth Control Method,C106501,C106501,C71460,Reproductive Findings,BCMETHOD,Nominal,"The method by which conception or impregnation is prevented. This may be achieved through the use of devices, drugs or surgery.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Birth Control Method,C106501,C106501,C71460,Reproductive Findings,BCMETHOD,Nominal,"The method by which conception or impregnation is prevented. This may be achieved through the use of devices, drugs or surgery.",,,,C70856,C70856,Observation Result,string,Condom;Spermicide;Vaginal Ring;IUD;Oral Contraception;Contraceptive Injection;Contraceptive Patch;Tubal Ligation
2024-12-17,Childbearing Potential,C106508,C106508,C19332,Reproductive Findings,CHILDPOT,Ordinal,An indicator as to whether the female subject has the potential to become pregnant.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Childbearing Potential,C106508,C106508,C19332,Reproductive Findings,CHILDPOT,Ordinal,An indicator as to whether the female subject has the potential to become pregnant.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Menopause Status,C106541,C106541,C117720,Reproductive Findings,MENOSTAT,Nominal,An indicator as to whether the female subject is in menopause.,,,,C70856,C70856,Observation Result,string,Perimenopausal;Premenopausal;Postmenopausal
2024-12-17,Menopause Status,C106541,C106541,C117720,Reproductive Findings,MENOSTAT,Nominal,An indicator as to whether the female subject is in menopause.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Abortions,C106550,C106550,C25337,Reproductive Findings,ABORTN,Quantitative,A measurement of the total number of instances in which there has been a termination of pregnancy happening before the fetus is able to sustain independent life.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Abortions,C106550,C106550,C25337,Reproductive Findings,ABORTN,Quantitative,A measurement of the total number of instances in which there has been a termination of pregnancy happening before the fetus is able to sustain independent life.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Pregnancies,C106551,C106551,C25337,Reproductive Findings,PREGNN;Maternal Gravity;Pregnancy Count;Total Number of Pregnancies,Quantitative,A measurement of the total number of pregnancy events experienced by the female subject.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Pregnancies,C106551,C106551,C25337,Reproductive Findings,PREGNN;Maternal Gravity;Pregnancy Count;Total Number of Pregnancies,Quantitative,A measurement of the total number of pregnancy events experienced by the female subject.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Pregnant During the Study,C106561,C106561,C19332,Reproductive Findings;Clinical Findings Indicator;Indicator,PREGST,Ordinal,An indicator as to whether the female subject is pregnant during the study period.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Pregnant During the Study,C106561,C106561,C19332,Reproductive Findings;Clinical Findings Indicator;Indicator,PREGST,Ordinal,An indicator as to whether the female subject is pregnant during the study period.,,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Trial Site Terminated by Sponsor,C106576,C106576,,Subject Disposition;Protocol Disposition Events,Site Terminated By Sponsor,Nominal,An indication that a clinical study was stopped at a particular site by its sponsor.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Trial Site Terminated by Sponsor,C106576,C106576,,Subject Disposition;Protocol Disposition Events,Site Terminated By Sponsor,Nominal,An indication that a clinical study was stopped at a particular site by its sponsor.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Trial Site Terminated by Sponsor,C106576,C106576,,Subject Disposition;Protocol Disposition Events,Site Terminated By Sponsor,Nominal,An indication that a clinical study was stopped at a particular site by its sponsor.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Trial Site Terminated by Sponsor,C106576,C106576,,Subject Disposition;Protocol Disposition Events,Site Terminated By Sponsor,Nominal,An indication that a clinical study was stopped at a particular site by its sponsor.,,,,C82977,C82977,Dictionary-derived Term,string,Site Terminated By Sponsor
2023-12-12,Trial Site Terminated by Sponsor,C106576,C106576,,Subject Disposition;Protocol Disposition Events,Site Terminated By Sponsor,Nominal,An indication that a clinical study was stopped at a particular site by its sponsor.,,,,C25372,C25372,Category,string,Disposition Event
2025-04-01,Musculoskeletal Finding,C110937,C110937,,Musculoskeletal Finding,,,"Symptoms, physical examination results, and/or laboratory rest results related to the muscles and bones.",,,,,,,,
2024-04-02,Clot Detection,C111095,C111095,,Clot Detection,,,Any of several methods used to detect the presence of or quantify the formation of a thrombus in a specimen.,,,,,,,,
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C70856,C70856,Observation Result,string,Atrioventricular Dissociation;AV Mobitz 1;AV Mobitz II;Isorhythmic Dissociation;Paroxysmal AV Block;PR Segment Depression;Short PR Interval;Nonconducted P-Wave Physiology Not Defined
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Atrioventricular Conduction ECG Assessment,C111131,C111131,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AVCOND;Atrioventricular Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C70856,C70856,Observation Result,string,Dextrocardia;Early R Wave Transition;Electrical Alternans;Indeterminate QRS Axis;Late R Wave Transition;Low QRS Voltage;Low Voltage Limb Leads Only;Northwest Axis;Poor R Wave Progression;Q Axis Left Axis Deviation;Q Axis Right Axis Deviation;QRS Complex Abnormality;R Wave Notched
2024-12-17,Axis and Voltage ECG Assessment,C111132,C111132,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,AXISVOLT;Axis and Voltage,Nominal,An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C25372,C25372,Category,string,
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C70856,C70856,Observation Result,integer,
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Cellularity Measurement,C111153,C111153,C48938,Oncology Standards;Tumor Results;Tumor Measurements;Breast Cancer TAUG,CELLULAR;Cellularity Grade;Cellularity Index;Percent Cellularity,Quantitative,"The determination of the amount of degree, quality or condition of cells present in a sample.",,,,C70713,C70713,Biospecimen Type,string,Tissue
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C70856,C70856,Observation Result,string,Atrial Enlargement;Biventricular Hypertrophy;Left Atrial Abnormality;Left Ventricular Hypertrophy;Left Ventricular Hypertrophy With Strain;Right Atrial Abnormality;Right Ventricular Hypertrophy;Voltage Criteria Suggesting left Ventricular Hypertrophy Without Secondary ECG Findings
2024-12-17,Chamber Hypertrophy or Enlargement ECG Assessment,C111155,C111155,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,CHYPTENL;Chamber Hypertrophy or Enlargement,Nominal,An electrocardiographic assessment of chamber hypertrophy or enlargement.,,,,C25372,C25372,Category,string,Finding
2025-04-01,Hemoglobin A1C to Hemoglobin Ratio Measurement,C111207,C111207,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C/Hemoglobin;HBA1CHGB,Quantitative,The determination of the ratio of the glycosylated hemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Hemoglobin A1C to Hemoglobin Ratio Measurement,C111207,C111207,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C/Hemoglobin;HBA1CHGB,Quantitative,The determination of the ratio of the glycosylated hemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Hemoglobin A1C to Hemoglobin Ratio Measurement,C111207,C111207,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C/Hemoglobin;HBA1CHGB,Quantitative,The determination of the ratio of the glycosylated hemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C81268,C81268,Molar Ratio,string,mmol/mol;%
2025-04-01,Hemoglobin A1C to Hemoglobin Ratio Measurement,C111207,C111207,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C/Hemoglobin;HBA1CHGB,Quantitative,The determination of the ratio of the glycosylated hemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70713,C70713,Biospecimen Type,string,Blood
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C70856,C70856,Observation Result,string,Bifascicular Block;Brugada Syndrome Pattern;Delta Wave;Incomplete Left Bundle Branch Block;Incomplete Right Bundle Branch Block;Intraatrial Conduction Delay;Intraventricular Conduction Delay Nonspecific;Left Anterior Fascicular Block;Left Bundle Branch Block;Left Posterior Fascicular Block;Left Ventricular Conduction Delay;P Wave Abnormality;P Wave Notched;Pre-Excitation;Right Bundle Branch Block;Right Ventricular Conduction Delay;RSR Prime;Wolff-Parkinson-White Syndrome
2024-12-17,Intraventricular and Intraatrial Conduction ECG Assessment,C111238,C111238,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,IVTIACD;Intraventricular-Intraatrial Conduction,Nominal,An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C70856,C70856,Observation Result,string,Acute Anterior Wall Myocardial Infarction;Acute Anterolateral Wall Myocardial Infarction;Acute Anteroseptal Wall Myocardial Infarction;Acute Extensive Anterior Wall Myocardial Infarction;Acute High Lateral Wall Myocardial Infarction;Acute Inferior Wall Myocardial Infarction;Acute Lateral Wall Myocardial Infarction;Acute Myocardial Infarction;Acute Posterior Wall Myocardial Infarction;Acute Right Ventricular Wall Myocardial Infarction;Acute Septal Wall Myocardial Infarction;Anterior Wall Myocardial Infarction;Anterolateral Wall Myocardial Infarction;Anteroseptal Wall Myocardial Infarction;Extensive Anterior Wall Myocardial Infarction;High Lateral Wall Myocardial Infarction;Inferior Wall Myocardial Infarction;Lateral Wall Myocardial Infarction;Myocardial Infarction;New Anterior Wall Myocardial Infarction;New Anterolateral Wall Myocardial Infarction;New Anteroseptal Wall Myocardial Infarction;New Extensive Anterior Wall Myocardial Infarction;New High Lateral Wall Myocardial Infarction;New Inferior Wall Myocardial Infarction;New lateral Wall Myocardial Infarction;New Myocardial Infarction;New Posterior Wall Myocardial Infarction;New Septal Wall Myocardial Infarction;Non Q Wave Myocardial Infarction;Non-Diagnostic Q Waves;Old or Age Indeterminate Anterior Wall Myocardial Infarction;Old or Age Indeterminate Anterolateral Wall Myocardial Infarction;Old or Age Indeterminate Anteroseptal Wall Myocardial Infarction;Old or Age Indeterminate Extensive Anterior Wall Myocardial Infarction;Old or Age Indeterminate High Lateral Wall Myocardial Infarction;Old or Age Indeterminate Inferior Wall Myocardial Infarction;Old or Age Indeterminate Lateral Wall Myocardial Infarction;Old or Age Indeterminate Posterior Wall Myocardial Infarction;Old or Age Indeterminate Septal Wall Myocardial Infarction;Old or Age Indeterminate Wall Myocardial Infarction;Old or Age Undetermined Right Ventricular Myocardial Infarction;Posterior Wall Myocardial Infarction;Septal Myocardial Infarction
2024-12-17,Myocardial Infarction ECG Assessment,C111280,C111280,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,MI;Myocardial Infarction,Nominal,An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C70856,C70856,Observation Result,string,Paced Atrial and Ventricular Rhythm;Paced Atrial Rhythm;Paced Rhythm;Paced Ventricular Rhythm
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C25372,C25372,Category,string,Finding
2024-12-17,Pacemaker ECG Assessment,C111285,C111285,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,PACEMAKR;Pacemaker,Nominal,"An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.",,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C70856,C70856,Observation Result,string,Asystole;Bradycardia;Pause;Pause > 3.0 Seconds;Tachycardia;Undetermined Rhythym;Undetermined Supraventricular Rhythm
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Rhythm Not Otherwise Specified ECG Assessment,C111307,C111307,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,RHYNOS;Rhythm Not Otherwise Specified,Nominal,An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C70856,C70856,Observation Result,string,Normal Sinus Rhythm;Sinoatrial Exit Block;Sinus Arrest/Pause;Sinus Arrhythmia;Sinus Bradycardia;Sinus Rhythm;Sinus Tachycardia
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Sinus Node Rhythm and Arrhythmia ECG Assessment,C111312,C111312,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SNRARRY;Sinus Node Rhythms and Arrhythmias,Nominal,An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C70856,C70856,Observation Result,string,Atrial Bigeminy;Atrial Couplets;Atrial Trigeminy;Ectopic Atrial Rhythm;Junctional Bradycardia;Junctional Escape Complexes;Junctional Premature Complex;Junctional Rhythm;Premature Atrial Complexes;Premature Atrial Complexes Blocked;Premature Atrial Complexes Multifocal;Premature Atrial Complexes Unifocal;Supraventricular Couplet;Wandering Atrial Pacemaker;Junctional Escape Rhythm;Supraventricular Escape Beat;Supraventricular Premature Complex Origin Unknown;Supraventricular Bigeminy;Supraventricular Run;Supraventricular Trigeminy
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C25372,C25372,Category,string,Finding
2024-12-17,Supraventricular Arrhythmia ECG Assessment,C111320,C111320,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRARRY;Supraventricular Arrhythmias,Nominal,"An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.",,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Supraventricular Tachyarrhythmia ECG Assessment,C111321,C111321,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,SPRTARRY;Supraventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.,,,,C70856,C70856,Observation Result,string,Atrial Fibrillation;Atrial Flutter;Atrial Tachycardia;Atrial Tachycardia With AV Block;AV Node Re-Entry;AV Re-Entrant Tachycardia;Junctional Tachycardia;Multifocal Atrial Tachycardia;Non-sustained Atrial Tachycardia;Supraventricular Tachycardia
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C70856,C70856,Observation Result,string,Accelerated Idioventricular Rhythm;Ectopic Ventricular Rhythm;Fusion Complex;Idioventricular Rhythm;Premature Ventricular Complex;Premature Ventricular Complex Interpolated;Premature Ventricular Complexes Multifocal;Premature Ventricular Complexes Unifocal;R and T Phenomenon;Ventricular Bigeminy;Ventricular Couplet;Ventricular Escape Beat;Ventricular Parasystole;Ventricular Trigeminy;Ventricular Run
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Ventricular Arrhythmia ECG Assessment,C111330,C111330,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTARRY;Ventricular Arrhythmias,Nominal,An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C25372,C25372,Category,string,Finding
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Ventricular Tachyarrhythmia ECG Assessment,C111331,C111331,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,VTTARRY;Ventricular Tachyarrhythmias,Nominal,An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.,,,,C70856,C70856,Observation Result,string,Non-Sustained Ventricular Tachycardia;Paroxysmal Ventricular Tachycardia;Sustained Ventricular Tachycardia;Torsades De Pointes;Ventricular Fibrillation;Ventricular Flutter;Ventricular Tachycardia;Ventricular Tachycardia Monomorphic;Ventricular Tachycardia Polymorphic;Wide QRS Tachycardia
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C70856,C70856,Observation Result,string,CV Endpoints Ischemic ECG Changes;Borderline QTcB;Borderline QTcF;Early Repolarization;J Point Elevation;Non-Specific ST-T Changes;Notched T Waves;Prolonged QT;Prolonged ST Segment;QTc Prolongation;QTcB Prolongation;QTcF Prolongation;Repolarization Abnormality;Repolarization Abnormality Secondary To Ventricular Hypertrophy;Short QTc Interval;Short QTcB;Short QTcF;Short ST Segment;ST Depression;ST Elevation;ST Elevation Pericarditis;T Wave Alternans;T Wave inversion;T Wave Peaked;T Waves Biphasic;T Waves Flat;U Wave Abnormality
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C25372,C25372,Category,string,Finding
2024-12-17,"ST Segment, T wave, and U wave ECG Assessment",C111363,C111363,C83146,Electrocardiogram Findings;Electrocardiogram Abnormalities;ECG Findings;ECG Abnormalities,"STSTWUW;ST Segment, T wave, and U wave",Nominal,"An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.",,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2025-04-01,Mass Measurement,C112025,C112025,,Musculoskeletal Finding;Mass Measurement,,,Mass Measurement.,,,,,,,,
2024-12-17,Allergen Skin Response Index,C112221,C112221,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINDEX,Quantitative,The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Allergen Skin Response Index,C112221,C112221,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINDEX,Quantitative,The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.,,,,C82535,C82535,Test Method,string,
2024-12-17,Allergen Skin Response Index,C112221,C112221,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINDEX,Quantitative,The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.,,,,C25185,C25185,Laterality,string,
2024-12-17,Allergen Skin Response Index,C112221,C112221,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINDEX,Quantitative,The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Allergen Skin Response Index,C112221,C112221,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINDEX,Quantitative,The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.,,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Allergen Skin Response Index,C112221,C112221,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINDEX,Quantitative,The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Allergen Skin Response Intensity,C112222,C112222,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINT,Quantitative;Nominal,The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Allergen Skin Response Intensity,C112222,C112222,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINT,Quantitative;Nominal,The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Allergen Skin Response Intensity,C112222,C112222,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINT,Quantitative;Nominal,The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.,,,,C82535,C82535,Test Method,string,
2024-12-17,Allergen Skin Response Intensity,C112222,C112222,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINT,Quantitative;Nominal,The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Allergen Skin Response Intensity,C112222,C112222,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINT,Quantitative;Nominal,The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Allergen Skin Response Intensity,C112222,C112222,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,ASRINT,Quantitative;Nominal,The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.,,,,C25185,C25185,Laterality,string,
2024-12-17,Estrogen Receptor Measurement,C112274,C112274,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Allred Proportion Positive Score;Allred  Staining Intensity Score;Allred Total Score
2024-12-17,Estrogen Receptor Measurement,C112274,C112274,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Estrogen Receptor Measurement,C112274,C112274,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2024-12-17,Estrogen Receptor Measurement,C112274,C112274,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2024-12-17,Estrogen Receptor Measurement,C112274,C112274,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Estrogen Receptor Measurement,C112274,C112274,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ESTRCPT;ESR;ER;Estrogen Receptor;Oestrogen Receptor,Nominal;Quantitative,The determination of the amount of estrogen receptor present in a sample.,,,,C170500,C170500,Result Anatomical Location,string,Breast
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C42578,C42578,Unit of Length,string,mm;cm;in
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82535,C82535,Test Method,string,Ruler
2024-12-17,Antigenic Skin Flare Longest Diameter,C112281,C112281,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Longest Diameter;FLRLDIAM,Quantitative,The longest diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C25185,C25185,Laterality,string,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82535,C82535,Test Method,string,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C25185,C25185,Laterality,string,
2024-12-17,Antigenic Skin Flare Mean Diameter,C112282,C112282,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Mean Diameter;FLRMDIAM,Quantitative,The mean diameter of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C42578,C42578,Unit of Length,string,mm;cm;in
2024-12-17,Antigenic Skin Flare Size,C112283,C112283,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Size;FLARESZ,Ordinal,The size of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Antigenic Skin Flare Size,C112283,C112283,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Size;FLARESZ,Ordinal,The size of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C70856,C70856,Observation Result,string,Large;Medium;Small
2024-12-17,Antigenic Skin Flare Size,C112283,C112283,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Size;FLARESZ,Ordinal,The size of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Antigenic Skin Flare Size,C112283,C112283,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Size;FLARESZ,Ordinal,The size of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82535,C82535,Test Method,string,
2024-12-17,Antigenic Skin Flare Size,C112283,C112283,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Size;FLARESZ,Ordinal,The size of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C25185,C25185,Laterality,string,
2024-12-17,Antigenic Skin Flare Size,C112283,C112283,C15260,Immunology Tests;Immunodiagnostic Procedure;Skin Response,Flare Size;FLARESZ,Ordinal,The size of the area of redness that forms around the site of an antigenic challenge to the skin.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Staining Intensity
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C82498,C82498,Result Category,string,Positive;Negative
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C170500,C170500,Result Anatomical Location,string,Breast
2024-12-17,Human Epidermal Growth Factor Receptor 2 Measurement,C112312,C112312,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,ERBB2;HER2;HER2/NEU;Receptor Tyrosine-Protein Kinase erbB-2 Measurement,Quantitative,The determination of the amount of human epidermal growth factor receptor 2 present in a sample.,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82535,C82535,Test Method,string,Ruler
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C42578,C42578,Unit of Length,string,mm;cm;in
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82546,C82546,Observation Object,string,
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C25185,C25185,Laterality,string,
2024-12-17,Wheal Longest Diameter,C112427,C112427,C96684,Longest Diameter;Skin Response,WHLLDIAM,Quantitative,"The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82546,C82546,Observation Object,string,
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C42578,C42578,Unit of Length,string,mm;cm;in
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C25185,C25185,Laterality,string,
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82535,C82535,Test Method,string,
2024-12-17,Wheal Mean Diameter,C112428,C112428,C120716,Mean Diameter;Skin Response,WHLMDIAM,Quantitative,"The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Wheal Size,C112429,C112429,C15260,Diagnostic Procedure;Skin Response,WHEALSZ,Ordinal,"The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82546,C82546,Observation Object,string,
2024-12-17,Wheal Size,C112429,C112429,C15260,Diagnostic Procedure;Skin Response,WHEALSZ,Ordinal,"The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Wheal Size,C112429,C112429,C15260,Diagnostic Procedure;Skin Response,WHEALSZ,Ordinal,"The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C25185,C25185,Laterality,string,
2024-12-17,Wheal Size,C112429,C112429,C15260,Diagnostic Procedure;Skin Response,WHEALSZ,Ordinal,"The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82535,C82535,Test Method,string,
2024-12-17,Wheal Size,C112429,C112429,C15260,Diagnostic Procedure;Skin Response,WHEALSZ,Ordinal,"The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Wheal Size,C112429,C112429,C15260,Diagnostic Procedure;Skin Response,WHEALSZ,Ordinal,"The size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.",,,,C70856,C70856,Observation Result,string,Large;Medium;Small
2023-12-12,Subject is Randomized,C114209,C114209,,Subject Disposition;Protocol Milestones,Randomized,Nominal,A status indication that a subject is already assigned to an arm of a clinical trial by chance.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Subject is Randomized,C114209,C114209,,Subject Disposition;Protocol Milestones,Randomized,Nominal,A status indication that a subject is already assigned to an arm of a clinical trial by chance.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Subject is Randomized,C114209,C114209,,Subject Disposition;Protocol Milestones,Randomized,Nominal,A status indication that a subject is already assigned to an arm of a clinical trial by chance.,,,,C82977,C82977,Dictionary-derived Term,string,Randomized
2023-12-12,Subject is Randomized,C114209,C114209,,Subject Disposition;Protocol Milestones,Randomized,Nominal,A status indication that a subject is already assigned to an arm of a clinical trial by chance.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Subject is Randomized,C114209,C114209,,Subject Disposition;Protocol Milestones,Randomized,Nominal,A status indication that a subject is already assigned to an arm of a clinical trial by chance.,,,,C25372,C25372,Category,string,Protocol Milestone
2024-12-16,Secondary Cause of Death,C116142,C116142,C81239,Death Diagnosis and Details;Cause of Death,SECDTH,Nominal,The second significant event which ultimately led to death.,,,,C70856,C70856,Observation Result,string,Congestive Heart Failure
2024-12-16,Secondary Cause of Death,C116142,C116142,C81239,Death Diagnosis and Details;Cause of Death,SECDTH,Nominal,The second significant event which ultimately led to death.,,,,C82515,C82515,Collection Date Time,datetime,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117473,C117473,Exposure as Collected Name of Treatment,string,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117497,C117497,Exposure as Collected End Date and Time of Treatment,datetime,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117496,C117496,Exposure as Collected Start Date and Time of Treatment,datetime,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117490,C117490,Exposure as Collected Directionality,string,Upper;Lower
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117489,C117489,Exposure as Collected Laterality,string,Left;Right
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117486,C117486,Exposure as Collected Route of Administration,string,Oral;Intravenous;Intramuscular;Intraocular;Nasal
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117469,C117469,Exposure as Collected Reference Identifier,string,Kit number;Bottle label;Vial identifier
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117479,C117479,Exposure as Collected Dose,decimal,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117480,C117480,Exposure as Collected Dose Description,string,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117488,C117488,Exposure as Collected Location,string,Arm;Buttock
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117482,C117482,Exposure as Collected Dose Form,string,Tablet;Capsule;Film;Emulsion;Elixer;Extract
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117481,C117481,Exposure as Collected Dose Units,string,Milligram;Tablet;Capsule
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117485,C117485,Exposure as Collected Intended Dose Regimen,string,
2023-10-03,Exposure as Collected Domain,C117466,C117466,,Exposure as Collected,EC;Exposure as Collected,Nominal,"This interventions domain model reflects protocol-specified study treatment administrations, as collected.",,,,C117483,C117483,Exposure as Collected Dosing Frequency per Interval,string,QD;BID;QID;Q2H;Continuous;PRN
2024-12-17,Female Reproductive System Finding,C117720,C117720,,Reproductive Findings,,,"Symptoms, physical examination results, and/or laboratory test results related to the female reproductive system.",,,,,,,,
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C25372,C25372,Category,string,Interval
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Single Measurement PP Interval,C117772,C117772,C62085,Electrocardiogram Findings,"PP Interval, Single Measurement;Single Measurement PP Interval;PPSM",Quantitative,An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC),http://loinc.org/,LOINC,8624-9,C25330,C25330,Duration,integer,
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C25330,C25330,Duration,integer,
2024-12-17,Aggregate PR Interval,C117773,C117773,C62085,Electrocardiogram Findings,PR Interval Aggregate;PQ Interval Aggregate;PRAG;PQAG,Quantitative,"An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8625-6,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C25330,C25330,Duration,integer,
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C25372,C25372,Category,string,Interval
2024-12-17,Single Beat PR Interval,C117774,C117774,C62085,Electrocardiogram Findings,"Single Beat PR Interval;PQ Interval, Single Beat;PQSB;PR Interval, Single Beat;PR Interval, Single Beat;PRSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8625-6,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C25330,C25330,Duration,integer,
2024-12-17,Single Beat P Wave Duration,C117776,C117776,C62085,Electrocardiogram Findings,"P Wave Duration, Single Beat;Single Beat P Wave Duration;PWDURSB",Quantitative,An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8627-2,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C25330,C25330,Duration,integer,
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Aggregate QRS Duration,C117779,C117779,C62085,Electrocardiogram Findings,QRS Aggregate Duration;QRSAG,Quantitative,"An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8633-0,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C25330,C25330,Duration,integer,
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C25372,C25372,Category,string,Interval
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Beat QRS Duration,C117780,C117780,C62085,Electrocardiogram Findings,"QRS Duration, Single Beat;Single Beat QRS Duration;QRSSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8633-0,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C25330,C25330,Duration,integer,
2024-12-17,Aggregate QT Interval,C117783,C117783,C62085,Electrocardiogram Findings,QT Interval Aggregate;QTAG,Quantitative,"An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8634-8,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C25330,C25330,Duration,integer,
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Aggregate QTCB Interval,C117784,C117784,C62085,Electrocardiogram Findings,QTCB Interval Aggregate;QTCBAG,Quantitative,A QT aggregate interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C25330,C25330,Duration,integer,
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C25372,C25372,Category,string,Interval
2024-12-17,Single Beat QTCB Interval,C117785,C117785,C62085,Electrocardiogram Findings,"QTcB Interval, Single Beat;Single Beat QTCB Interval;QTCBSB",Quantitative,A QT single beat interval corrected for heart rate using Bazett's formula.,http://loinc.org/,LOINC,76635-2,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C25330,C25330,Duration,integer,
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate QTCF Interval,C117786,C117786,C62085,Electrocardiogram Findings,QTCF Interval Aggregate;QTCFAG,Quantitative,A QT aggregate interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C25330,C25330,Duration,integer,
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C25372,C25372,Category,string,Interval
2024-12-17,Single Beat QTCF Interval,C117787,C117787,C62085,Electrocardiogram Findings,"QTcF Interval, Single Beat;QTCFSB;Single Beat QTCF Interval",Quantitative,A QT single beat interval corrected for heart rate using Fridericia's formula.,http://loinc.org/,LOINC,76634-5,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C25372,C25372,Category,string,Interval
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C25330,C25330,Duration,integer,
2024-12-17,Single Beat QT Interval,C117788,C117788,C62085,Electrocardiogram Findings,"QT Interval, Single Beat;Single Beat QT Interval;QTSB",Quantitative,An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC),http://loinc.org/,LOINC,8634-8,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C25372,C25372,Category,string,Interval
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C25330,C25330,Duration,integer,
2024-12-17,Aggregate RR Interval,C117791,C117791,C62085,Electrocardiogram Findings,RR Interval Aggregate;RRAG,Quantitative,"An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)",http://loinc.org/,LOINC,8637-1,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C25330,C25330,Duration,integer,
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C82515,C82515,Collection Date Time,datetime,
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,RR Interval Single Measurement,C117792,C117792,C62085,Electrocardiogram Findings,RR Interval Single Measurement;RRSM,Quantitative,"An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)",http://loinc.org/,LOINC,8637-1,C25372,C25372,Category,string,Interval
2024-12-17,ECG Technical Quality,C117807,C117807,C62085,Electrocardiogram Findings,TECHQUAL,Nominal,"A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)",,,,C114120,C114120,ECG Recording Quality,string,Incomplete ECG;Poor Quality ECG;Muscle Tremor Artifact;ECG Waveforms Not Present
2024-12-17,ECG Technical Quality,C117807,C117807,C62085,Electrocardiogram Findings,TECHQUAL,Nominal,"A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,ECG Technical Quality,C117807,C117807,C62085,Electrocardiogram Findings,TECHQUAL,Nominal,"A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)",,,,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,ECG Technical Quality,C117807,C117807,C62085,Electrocardiogram Findings,TECHQUAL,Nominal,"A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)",,,,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,ECG Technical Quality,C117807,C117807,C62085,Electrocardiogram Findings,TECHQUAL,Nominal,"A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)",,,,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Progesterone Receptor Measurement,C117846,C117846,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Progesterone Receptor Measurement,C117846,C117846,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2024-12-17,Progesterone Receptor Measurement,C117846,C117846,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2024-12-17,Progesterone Receptor Measurement,C117846,C117846,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Progesterone Receptor Measurement,C117846,C117846,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Allred Proportion Positive Score;Allred  Staining Intensity Score;Allred Total Score
2024-12-17,Progesterone Receptor Measurement,C117846,C117846,C64430,Oncology Standards;Breast Cancer;Chemistry Test;Protein or Enzyme Type Measurement,PROGESTR;NR3C3;PGR;PR;Progesterone Receptor,Nominal;Quantitative,The determination of the amount of progesterone receptor present in a sample.,,,,C170500,C170500,Result Anatomical Location,string,Breast
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C82515,C82515,Collection Date Time,datetime,
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C25372,C25372,Category,string,Measurement
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C70856,C70856,Observation Result,integer,
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,QRS Axis,C118165,C118165,C62085,Electrocardiogram Findings,,Quantitative,"A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)",http://loinc.org/,LOINC,8632-2,C68667,C68667,Degree Unit of Plane Angle,string,Degree
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C51824,C51824,Evaluator,string,Investigator;CEC Adjudicator
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C82546,C82546,Observation Object,string,Acute Myocardial Infarction
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C25372,C25372,Category,string,
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C70856,C70856,Observation Result,string,Type 1 Myocardial Infraction;Type 2 Myocardial Infraction;Type 3 Myocardial Infraction;Type 4A Myocardial Infraction;Type 4B Myocardial Infraction;Type 4C Myocardial Infraction;Type 5 Myocardial Infraction
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C82535,C82535,Test Method,string,Coronary Angiography;Autopsy
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Acute Myocardial Infarction Type,C118936,C118936,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,ACMITYPE,Ordinal,A classification or description of the acute myocardial infarction.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Coronary Artery Thrombosis Method of Identification,C119229,C119229,C111095,Findings About Cardiovascular Events;Cardiovascular System Finding;Clot Detection,CATMTHID;Coronary Artery Thrombosis Method Ident,Nominal,The method used to detect a coronary artery thrombus.,,,,C82546,C82546,Observation Object,string,
2024-12-16,Coronary Artery Thrombosis Method of Identification,C119229,C119229,C111095,Findings About Cardiovascular Events;Cardiovascular System Finding;Clot Detection,CATMTHID;Coronary Artery Thrombosis Method Ident,Nominal,The method used to detect a coronary artery thrombus.,,,,C25372,C25372,Category,string,
2024-12-16,Coronary Artery Thrombosis Method of Identification,C119229,C119229,C111095,Findings About Cardiovascular Events;Cardiovascular System Finding;Clot Detection,CATMTHID;Coronary Artery Thrombosis Method Ident,Nominal,The method used to detect a coronary artery thrombus.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Coronary Artery Thrombosis Method of Identification,C119229,C119229,C111095,Findings About Cardiovascular Events;Cardiovascular System Finding;Clot Detection,CATMTHID;Coronary Artery Thrombosis Method Ident,Nominal,The method used to detect a coronary artery thrombus.,,,,C70856,C70856,Observation Result,string,Angiography;Autopsy
2024-12-16,Coronary Artery Thrombosis Method of Identification,C119229,C119229,C111095,Findings About Cardiovascular Events;Cardiovascular System Finding;Clot Detection,CATMTHID;Coronary Artery Thrombosis Method Ident,Nominal,The method used to detect a coronary artery thrombus.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Coronary Artery Thrombosis Method of Identification,C119229,C119229,C111095,Findings About Cardiovascular Events;Cardiovascular System Finding;Clot Detection,CATMTHID;Coronary Artery Thrombosis Method Ident,Nominal,The method used to detect a coronary artery thrombus.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Healthcare Encounter Type,C119231,C119231,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,HETYPE;Encounter Type,Nominal,A classification or description of the visit by a patient or study participant to a medical professional.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Healthcare Encounter Type,C119231,C119231,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,HETYPE;Encounter Type,Nominal,A classification or description of the visit by a patient or study participant to a medical professional.,,,,C70856,C70856,Observation Result,string,Heart Failure Hospitalization;Urgent Heart Failure Visit
2024-12-16,Healthcare Encounter Type,C119231,C119231,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,HETYPE;Encounter Type,Nominal,A classification or description of the visit by a patient or study participant to a medical professional.,,,,C82546,C82546,Observation Object,string,
2024-12-16,Healthcare Encounter Type,C119231,C119231,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,HETYPE;Encounter Type,Nominal,A classification or description of the visit by a patient or study participant to a medical professional.,,,,C25372,C25372,Category,string,
2024-12-16,Healthcare Encounter Type,C119231,C119231,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,HETYPE;Encounter Type,Nominal,A classification or description of the visit by a patient or study participant to a medical professional.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Healthcare Encounter Type,C119231,C119231,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,HETYPE;Encounter Type,Nominal,A classification or description of the visit by a patient or study participant to a medical professional.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Lab Findings of New or Worsening Heart Failure,C119232,C119232,C36292,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFLBFNW;Heart Failure New/Worsening Lab Findings,Nominal;Ordinal,"A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.",,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Lab Findings of New or Worsening Heart Failure,C119232,C119232,C36292,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFLBFNW;Heart Failure New/Worsening Lab Findings,Nominal;Ordinal,"A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.",,,,C82546,C82546,Observation Object,string,
2024-12-16,Lab Findings of New or Worsening Heart Failure,C119232,C119232,C36292,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFLBFNW;Heart Failure New/Worsening Lab Findings,Nominal;Ordinal,"A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.",,,,C25372,C25372,Category,string,
2024-12-16,Lab Findings of New or Worsening Heart Failure,C119232,C119232,C36292,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFLBFNW;Heart Failure New/Worsening Lab Findings,Nominal;Ordinal,"A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.",,,,C70856,C70856,Observation Result,string,Increase in Heart Failure Biomarker;Invasive Diagnostic Evidence of Heart Failure;Non-Invasive Diagnostic Evidence of Heart Failure;Radiological Evidence of Pulmonary;Yes;No
2024-12-16,Lab Findings of New or Worsening Heart Failure,C119232,C119232,C36292,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFLBFNW;Heart Failure New/Worsening Lab Findings,Nominal;Ordinal,"A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.",,,,C25692,C25692,Subcategory,string,
2024-12-16,Lab Findings of New or Worsening Heart Failure,C119232,C119232,C36292,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFLBFNW;Heart Failure New/Worsening Lab Findings,Nominal;Ordinal,"A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Physical Examination Findings of New or Worsening Heart Failure,C119233,C119233,C83119,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFPEFNW;Heart Failure New/Worsening PE Findings,Nominal;Ordinal,A description of the physical examination evidence of heart failure that can be classified as new or worsening.,,,,C70856,C70856,Observation Result,string,Clinically Significant or Rapid Weight Gain;Increased Jugular Venous Pressure or Hepato Jugular Reflux;Increasing Abdominal Distention or Ascites;Peripheral Edema;Pulmonary Rales/Crackles/Crepitations;S3 Gallop;Yes;No
2024-12-16,Physical Examination Findings of New or Worsening Heart Failure,C119233,C119233,C83119,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFPEFNW;Heart Failure New/Worsening PE Findings,Nominal;Ordinal,A description of the physical examination evidence of heart failure that can be classified as new or worsening.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Physical Examination Findings of New or Worsening Heart Failure,C119233,C119233,C83119,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFPEFNW;Heart Failure New/Worsening PE Findings,Nominal;Ordinal,A description of the physical examination evidence of heart failure that can be classified as new or worsening.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Physical Examination Findings of New or Worsening Heart Failure,C119233,C119233,C83119,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFPEFNW;Heart Failure New/Worsening PE Findings,Nominal;Ordinal,A description of the physical examination evidence of heart failure that can be classified as new or worsening.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Physical Examination Findings of New or Worsening Heart Failure,C119233,C119233,C83119,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFPEFNW;Heart Failure New/Worsening PE Findings,Nominal;Ordinal,A description of the physical examination evidence of heart failure that can be classified as new or worsening.,,,,C25372,C25372,Category,string,
2024-12-16,Physical Examination Findings of New or Worsening Heart Failure,C119233,C119233,C83119,Findings About Cardiovascular Events;Cardiovascular System Finding;Laboratory Test Result,HFPEFNW;Heart Failure New/Worsening PE Findings,Nominal;Ordinal,A description of the physical examination evidence of heart failure that can be classified as new or worsening.,,,,C82546,C82546,Observation Object,string,
2024-12-16,Heart Failure Therapy Intensification Type,C119234,C119234,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,"HFTHERIN;Heart Failure Therapy, Intensification",Nominal,A classification or description of the therapeutic agent or procedure that is being escalated.,,,,C82546,C82546,Observation Object,string,
2024-12-16,Heart Failure Therapy Intensification Type,C119234,C119234,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,"HFTHERIN;Heart Failure Therapy, Intensification",Nominal,A classification or description of the therapeutic agent or procedure that is being escalated.,,,,C70856,C70856,Observation Result,string,"Augmentation of Oral Diuretic Theraphy;Intravenous Diuretic Inotrope, or Vasodilator Theraphy;Mechanical or Surgical Intervention"
2024-12-16,Heart Failure Therapy Intensification Type,C119234,C119234,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,"HFTHERIN;Heart Failure Therapy, Intensification",Nominal,A classification or description of the therapeutic agent or procedure that is being escalated.,,,,C25372,C25372,Category,string,
2024-12-16,Heart Failure Therapy Intensification Type,C119234,C119234,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,"HFTHERIN;Heart Failure Therapy, Intensification",Nominal,A classification or description of the therapeutic agent or procedure that is being escalated.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Heart Failure Therapy Intensification Type,C119234,C119234,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,"HFTHERIN;Heart Failure Therapy, Intensification",Nominal,A classification or description of the therapeutic agent or procedure that is being escalated.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Heart Failure Therapy Intensification Type,C119234,C119234,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,"HFTHERIN;Heart Failure Therapy, Intensification",Nominal,A classification or description of the therapeutic agent or procedure that is being escalated.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Ischemic Evidence Type,C119236,C119236,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,ISCETYP,Nominal,A classification or description of the evidence of ischemia in the subject.,,,,C82546,C82546,Observation Object,string,
2024-12-16,Ischemic Evidence Type,C119236,C119236,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,ISCETYP,Nominal,A classification or description of the evidence of ischemia in the subject.,,,,C25372,C25372,Category,string,
2024-12-16,Ischemic Evidence Type,C119236,C119236,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,ISCETYP,Nominal,A classification or description of the evidence of ischemia in the subject.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Ischemic Evidence Type,C119236,C119236,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,ISCETYP,Nominal,A classification or description of the evidence of ischemia in the subject.,,,,C70856,C70856,Observation Result,string,Coronary Lesion on Angiography;Coronary Revascularization;Inducible Myocardial Ischemia;Resting ECG Changes
2024-12-16,Ischemic Evidence Type,C119236,C119236,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,ISCETYP,Nominal,A classification or description of the evidence of ischemia in the subject.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Ischemic Evidence Type,C119236,C119236,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,ISCETYP,Nominal,A classification or description of the evidence of ischemia in the subject.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,New or Worsening Symptom,C119238,C119238,C4876,Findings About Cardiovascular Events;Cardiovascular System Finding;Symptom,NWSYMP;New or Worsening Symptoms,Nominal;Ordinal,The subjective evidence of disease perceived by the patient that can be classified as new or worsening,,,,C70856,C70856,Observation Result,string,Decreased Exercise Tolerance;Dyspnea;Fatigue;Volume Overload;Worsened End-Organ Perfusion;Yes;No
2024-12-16,New or Worsening Symptom,C119238,C119238,C4876,Findings About Cardiovascular Events;Cardiovascular System Finding;Symptom,NWSYMP;New or Worsening Symptoms,Nominal;Ordinal,The subjective evidence of disease perceived by the patient that can be classified as new or worsening,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,New or Worsening Symptom,C119238,C119238,C4876,Findings About Cardiovascular Events;Cardiovascular System Finding;Symptom,NWSYMP;New or Worsening Symptoms,Nominal;Ordinal,The subjective evidence of disease perceived by the patient that can be classified as new or worsening,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,New or Worsening Symptom,C119238,C119238,C4876,Findings About Cardiovascular Events;Cardiovascular System Finding;Symptom,NWSYMP;New or Worsening Symptoms,Nominal;Ordinal,The subjective evidence of disease perceived by the patient that can be classified as new or worsening,,,,C25692,C25692,Subcategory,string,
2024-12-16,New or Worsening Symptom,C119238,C119238,C4876,Findings About Cardiovascular Events;Cardiovascular System Finding;Symptom,NWSYMP;New or Worsening Symptoms,Nominal;Ordinal,The subjective evidence of disease perceived by the patient that can be classified as new or worsening,,,,C25372,C25372,Category,string,
2024-12-16,New or Worsening Symptom,C119238,C119238,C4876,Findings About Cardiovascular Events;Cardiovascular System Finding;Symptom,NWSYMP;New or Worsening Symptoms,Nominal;Ordinal,The subjective evidence of disease perceived by the patient that can be classified as new or worsening,,,,C82546,C82546,Observation Object,string,
2024-12-16,Acute Myocardial Infarction From PCI Complication Type,C119239,C119239,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,PCIAAC;PCI Acute Angiographic Complication,Nominal,A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.,,,,C25372,C25372,Category,string,
2024-12-16,Acute Myocardial Infarction From PCI Complication Type,C119239,C119239,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,PCIAAC;PCI Acute Angiographic Complication,Nominal,A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Acute Myocardial Infarction From PCI Complication Type,C119239,C119239,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,PCIAAC;PCI Acute Angiographic Complication,Nominal,A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.,,,,C70856,C70856,Observation Result,string,Loss of a Side Branch;Loss of Major Coronary;Slow-Flow/No-Flow/Embolization
2024-12-16,Acute Myocardial Infarction From PCI Complication Type,C119239,C119239,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,PCIAAC;PCI Acute Angiographic Complication,Nominal,A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Acute Myocardial Infarction From PCI Complication Type,C119239,C119239,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,PCIAAC;PCI Acute Angiographic Complication,Nominal,A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Acute Myocardial Infarction From PCI Complication Type,C119239,C119239,C25284,Findings About Cardiovascular Events;Cardiovascular System Finding,PCIAAC;PCI Acute Angiographic Complication,Nominal,A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Symptom Indicator,C119241,C119241,,Indicator,,,An indication as to whether the subject had symptoms related to the clinical event of interest.,,,,,,,,
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C25372,C25372,Category,string,Measurement
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C70856,C70856,Observation Result,integer,
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C73688,C73688,Count per Minute,string,Beats per Minute
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Mean Heart Rate by Electrocardiogram,C119259,C119259,C62085,Electrocardiogram Findings,ECG Mean Heart Rate;EKG Mean Heart Rate;EGHRMN,Quantitative,"The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.",http://loinc.org/,LOINC,76282-3,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2025-04-01,Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement,C119293,C119293,C82624,Laboratory Tests;Blood Oxygen Levels,Horowitz Index;Carrico index;P/F ratio;Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement;PO2FIO2;PAO2/FIO2;PP Arterial O2/Fraction Inspired O2,Quantitative,The determination of the ratio of the pressure of oxygen dissolved in arterial blood to the percentage oxygen of an inhaled mixture of gasses in a biological specimen.,https://loinc.org,LOINC,50984-4,C70856,C70856,Observation Result,decimal,
2025-04-01,Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement,C119293,C119293,C82624,Laboratory Tests;Blood Oxygen Levels,Horowitz Index;Carrico index;P/F ratio;Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement;PO2FIO2;PAO2/FIO2;PP Arterial O2/Fraction Inspired O2,Quantitative,The determination of the ratio of the pressure of oxygen dissolved in arterial blood to the percentage oxygen of an inhaled mixture of gasses in a biological specimen.,https://loinc.org,LOINC,50984-4,C49669,C49669,Unit of Pressure,string,mmHg
2025-04-01,Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement,C119293,C119293,C82624,Laboratory Tests;Blood Oxygen Levels,Horowitz Index;Carrico index;P/F ratio;Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement;PO2FIO2;PAO2/FIO2;PP Arterial O2/Fraction Inspired O2,Quantitative,The determination of the ratio of the pressure of oxygen dissolved in arterial blood to the percentage oxygen of an inhaled mixture of gasses in a biological specimen.,https://loinc.org,LOINC,50984-4,C70713,C70713,Biospecimen Type,string,Blood;Arterial Blood;Venous Blood;Capillary Blood
2024-12-17,Menstrual Cycle Duration,C119549,C119549,C25330,Reproductive Findings,MENSDUR,Quantitative,"The length of time of the menses cycle, measured from the beginning of one menstrual period to the beginning of the next.",,,,C70856,C70856,Observation Result,integer,
2024-12-17,Menstrual Cycle Duration,C119549,C119549,C25330,Reproductive Findings,MENSDUR,Quantitative,"The length of time of the menses cycle, measured from the beginning of one menstrual period to the beginning of the next.",,,,C42574,C42574,Unit of Time,integer,Days
2024-12-17,Menstrual Cycle Duration,C119549,C119549,C25330,Reproductive Findings,MENSDUR,Quantitative,"The length of time of the menses cycle, measured from the beginning of one menstrual period to the beginning of the next.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Stroke Type,C119579,C119579,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,STROKTYP,Nominal,A classification or description of a stroke.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Stroke Type,C119579,C119579,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,STROKTYP,Nominal,A classification or description of a stroke.,,,,C70856,C70856,Observation Result,string,Hemorrhagic Stroke;Ischemic Stroke;Undetermined Stroke
2024-12-16,Stroke Type,C119579,C119579,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,STROKTYP,Nominal,A classification or description of a stroke.,,,,C82546,C82546,Observation Object,string,Stroke
2024-12-16,Stroke Type,C119579,C119579,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,STROKTYP,Nominal,A classification or description of a stroke.,,,,C25372,C25372,Category,string,
2024-12-16,Stroke Type,C119579,C119579,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,STROKTYP,Nominal,A classification or description of a stroke.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Stroke Type,C119579,C119579,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,STROKTYP,Nominal,A classification or description of a stroke.,,,,C117050,C117050,Record Link Identifier,string,
2025-04-01,T-Score,C120401,C120401,,Musculoskeletal Finding;T-Score,,,"A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.",,,,,,,,
2024-12-17,Mean Diameter,C120716,C120716,,Mean Diameter,,,The arithmetic mean of a range of values that describe the diameter of an entity.,,,,,,,,
2024-12-17,Number of Ectopic Pregnancies,C120832,C120832,C106551,Reproductive Findings,ECTPREGN,Quantitative,A measurement of the total number of ectopic pregnancies experienced by a female subject.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Ectopic Pregnancies,C120832,C120832,C106551,Reproductive Findings,ECTPREGN,Quantitative,A measurement of the total number of ectopic pregnancies experienced by a female subject.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Estimated Date of Conception,C120833,C120833,,Reproductive Findings,EDCDTC,Temporal,An approximate calculated date at which the conception event took place.,,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Estimated Date of Conception,C120833,C120833,,Reproductive Findings,EDCDTC,Temporal,An approximate calculated date at which the conception event took place.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Late Fetal Deaths,C120834,C120834,C25337,Reproductive Findings,FETLDTHN,Quantitative,A measurement of the total number of fetal deaths (in which the fetus is greater than or equal to 20 weeks gestational age) experienced by a female subject.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Late Fetal Deaths,C120834,C120834,C25337,Reproductive Findings,FETLDTHN,Quantitative,A measurement of the total number of fetal deaths (in which the fetus is greater than or equal to 20 weeks gestational age) experienced by a female subject.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Induced Abortions,C120835,C120835,C106550,Reproductive Findings,INABORTN,Quantitative,A measurement of the total number of induced abortions experienced by a female subject.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Induced Abortions,C120835,C120835,C106550,Reproductive Findings,INABORTN,Quantitative,A measurement of the total number of induced abortions experienced by a female subject.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Previous Pregnancies,C120836,C120836,C106551,Reproductive Findings,PRVPREGN,Quantitative,A measurement of the total number of pregnancy events experienced by the female subject prior to the current pregnancy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Previous Pregnancies,C120836,C120836,C106551,Reproductive Findings,PRVPREGN,Quantitative,A measurement of the total number of pregnancy events experienced by the female subject prior to the current pregnancy.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Spontaneous Abortions,C120837,C120837,C106550,Reproductive Findings,SPABORTN,Quantitative,A measurement of the total number of spontaneous abortions (in which the fetus is less than 20 weeks gestational age) experienced by a female subject.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Spontaneous Abortions,C120837,C120837,C106550,Reproductive Findings,SPABORTN,Quantitative,A measurement of the total number of spontaneous abortions (in which the fetus is less than 20 weeks gestational age) experienced by a female subject.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,T-Lymphocyte Count,C122157,C122157,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,T-Cell Lymphocytes;T-Cells;T-Lymphocytes,Quantitative,The determination of the amount of T-lymphocytes in a biological specimen.,,,,C67391,C67391,Unit of Number Concentration,string,10^6/L
2025-04-01,T-Lymphocyte Count,C122157,C122157,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,T-Cell Lymphocytes;T-Cells;T-Lymphocytes,Quantitative,The determination of the amount of T-lymphocytes in a biological specimen.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,T-Lymphocyte Count,C122157,C122157,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,T-Cell Lymphocytes;T-Cells;T-Lymphocytes,Quantitative,The determination of the amount of T-lymphocytes in a biological specimen.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,T-Lymphocyte Count,C122157,C122157,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,T-Cell Lymphocytes;T-Cells;T-Lymphocytes,Quantitative,The determination of the amount of T-lymphocytes in a biological specimen.,,,,C70713,C70713,Biospecimen Type,string,Blood;Bronchial Specimen
2024-12-17,Congenital Abnormality Indicator,C122187,C122187,C93491,Reproductive Findings;Clinical Findings Indicator;Indicator,CABNIND;Abnormal Indicator,Ordinal,Specifies whether any abnormality was present at birth or during the neonatal period.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Congenital Abnormality Indicator,C122187,C122187,C93491,Reproductive Findings;Clinical Findings Indicator;Indicator,CABNIND;Abnormal Indicator,Ordinal,Specifies whether any abnormality was present at birth or during the neonatal period.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Estimated Gestational Age,C122188,C122188,C25150,Reproductive Findings;Age,EGESTAGE,Quantitative,An approximate calculation of the gestational age of the fetus.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Estimated Gestational Age,C122188,C122188,C25150,Reproductive Findings;Age,EGESTAGE,Quantitative,An approximate calculation of the gestational age of the fetus.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Estimated Gestational Age,C122188,C122188,C25150,Reproductive Findings;Age,EGESTAGE,Quantitative,An approximate calculation of the gestational age of the fetus.,,,,C50400,C50400,Age Unit,integer,Weeks;Days
2024-12-17,Number of Early Term Births,C122189,C122189,C25337,Reproductive Findings,ERLYTRMN,Quantitative,A measurement of the total number of birth events at which the gestational age of the neonate is 37 weeks and 0 days through 38 weeks and 6 days.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Early Term Births,C122189,C122189,C25337,Reproductive Findings,ERLYTRMN,Quantitative,A measurement of the total number of birth events at which the gestational age of the neonate is 37 weeks and 0 days through 38 weeks and 6 days.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Full Term Births,C122190,C122190,C19332,Reproductive Findings,FULLTRMN,Quantitative,A measurement of the total number of birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Full Term Births,C122190,C122190,C19332,Reproductive Findings,FULLTRMN,Quantitative,A measurement of the total number of birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Miscarriage Indicator,C122191,C122191,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MSCRGIND,Ordinal,Specifies whether any pregnancies resulted in miscarriages.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Miscarriage Indicator,C122191,C122191,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MSCRGIND,Ordinal,Specifies whether any pregnancies resulted in miscarriages.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Pregnancy Confirmed Indicator,C122192,C122192,C139264,Reproductive Findings;Clinical Findings Indicator;Indicator,PCONFIND,Ordinal,Specifies whether the subject's pregnancy has been confirmed.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Pregnancy Confirmed Indicator,C122192,C122192,C139264,Reproductive Findings;Clinical Findings Indicator;Indicator,PCONFIND,Ordinal,Specifies whether the subject's pregnancy has been confirmed.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Premature Births,C122193,C122193,C19332,Reproductive Findings,PREMBTHN,Quantitative,A measurement of the total number of birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Premature Births,C122193,C122193,C19332,Reproductive Findings,PREMBTHN,Quantitative,A measurement of the total number of birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Stillbirth Indicator,C122194,C122194,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,STILBIND,Ordinal,Specifies whether any pregnancies resulted in stillbirths.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Stillbirth Indicator,C122194,C122194,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,STILBIND,Ordinal,Specifies whether any pregnancies resulted in stillbirths.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Blistering Indicator,C122195,C122195,C119241,Symptom Indicator;Skin Response;Reproductive Findings,BLISTIND,Ordinal,Specifies whether blistering occurred.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Blistering Indicator,C122195,C122195,C119241,Symptom Indicator;Skin Response;Reproductive Findings,BLISTIND,Ordinal,Specifies whether blistering occurred.,,,,C70856,C70856,Observation Result,string,N;U;Y
2024-12-17,Blistering Indicator,C122195,C122195,C119241,Symptom Indicator;Skin Response;Reproductive Findings,BLISTIND,Ordinal,Specifies whether blistering occurred.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Blistering Indicator,C122195,C122195,C119241,Symptom Indicator;Skin Response;Reproductive Findings,BLISTIND,Ordinal,Specifies whether blistering occurred.,,,,C25185,C25185,Laterality,string,
2024-12-17,Blistering Indicator,C122195,C122195,C119241,Symptom Indicator;Skin Response;Reproductive Findings,BLISTIND,Ordinal,Specifies whether blistering occurred.,,,,C82535,C82535,Test Method,string,
2024-12-17,Blistering Indicator,C122195,C122195,C119241,Symptom Indicator;Skin Response;Reproductive Findings,BLISTIND,Ordinal,Specifies whether blistering occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C82535,C82535,Test Method,string,Ruler
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C25185,C25185,Laterality,string,
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C42578,C42578,Unit of Length,string,mm;cm;in
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Induration Longest Diameter,C122196,C122196,C96684,Longest Diameter;Skin Response,IDRLDIAM,Quantitative,The longest diameter of an area of hardness in the skin.,,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Number of Years of Education,C122393,C122393,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status,EDUYRNUM;Education,Quantitative,The number of education years that a subject has competed.,,,,C42574,C42574,Unit of Time,string,Years
2023-12-12,Number of Years of Education,C122393,C122393,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status,EDUYRNUM;Education,Quantitative,The number of education years that a subject has competed.,,,,C127787,C127787,Total Number,decimal,
2024-12-16,Academic Research Council Coronary Stent Thrombosis Timing,C123424,C123424,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,"STCTIMNG;Stent Thrombosis, Coronary, ARC Timing",Nominal,Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Academic Research Council Coronary Stent Thrombosis Timing,C123424,C123424,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,"STCTIMNG;Stent Thrombosis, Coronary, ARC Timing",Nominal,Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).,,,,C117050,C117050,Record Link Identifier,string,
2024-12-16,Academic Research Council Coronary Stent Thrombosis Timing,C123424,C123424,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,"STCTIMNG;Stent Thrombosis, Coronary, ARC Timing",Nominal,Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).,,,,C82546,C82546,Observation Object,string,Coronary Stent Thrombosis
2024-12-16,Academic Research Council Coronary Stent Thrombosis Timing,C123424,C123424,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,"STCTIMNG;Stent Thrombosis, Coronary, ARC Timing",Nominal,Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).,,,,C25372,C25372,Category,string,
2024-12-16,Academic Research Council Coronary Stent Thrombosis Timing,C123424,C123424,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,"STCTIMNG;Stent Thrombosis, Coronary, ARC Timing",Nominal,Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).,,,,C25692,C25692,Subcategory,string,
2024-12-16,Academic Research Council Coronary Stent Thrombosis Timing,C123424,C123424,C35552,Findings About Cardiovascular Events;Cardiovascular System Finding,"STCTIMNG;Stent Thrombosis, Coronary, ARC Timing",Nominal,Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).,,,,C70856,C70856,Observation Result,string,STENT Thrombosis ARC Acute;STENT Thrombosis ARC Late;STENT Thrombosis ARC Subacute;STENT Thrombosis ARC Very Late
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C117050,C117050,Record Link Identifier,string,
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C25692,C25692,Subcategory,string,
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C70856,C70856,Observation Result,string,New Loss of Viable Myocardium;New Regional Wall Motion Abnormality
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C82535,C82535,Test Method,string,Coronary Angiography
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C51824,C51824,Evaluator,string,Investigator;CEC Adjudicator
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C82546,C82546,Observation Object,string,
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C82515,C82515,Collection Date Time,datetime,
2024-04-02,Clinical Change by Non-Invasive Imaging Procedure,C123443,C123443,C77140,Clinical Test Result,NINVIMGC;Non-Invasive Imaging Change,Ordinal,Any clinical change to a subject as determined by a non-invasive imaging procedure.,,,,C25372,C25372,Category,string,
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor tissue
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C70856,C70856,Observation Result,integer,
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C25372,C25372,Category,string,
2025-04-01,Percentage of in situ Carcinoma,C123559,C123559,C35867,Oncology Standards;Disease Response;Tumor Results;Tumor Measurements;Breast Cancer TAUG,PCTISCA,Quantitative,A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Surgical Margins Status,C123560,C123560,C125581,Oncology Standards;Tumor Results;Pathology Results;Breast Cancer TAUG,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Surgical Margins Status,C123560,C123560,C125581,Oncology Standards;Tumor Results;Pathology Results;Breast Cancer TAUG,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Surgical Margins Status,C123560,C123560,C125581,Oncology Standards;Tumor Results;Pathology Results;Breast Cancer TAUG,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C25372,C25372,Category,string,
2025-04-01,Surgical Margins Status,C123560,C123560,C125581,Oncology Standards;Tumor Results;Pathology Results;Breast Cancer TAUG,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Surgical Margins Status,C123560,C123560,C125581,Oncology Standards;Tumor Results;Pathology Results;Breast Cancer TAUG,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Surgical Margins Status,C123560,C123560,C125581,Oncology Standards;Tumor Results;Pathology Results;Breast Cancer TAUG,Margin Status;SGMGSTAT,Ordinal,The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-04-01,Disease Recurrence Indicator,C123621,C123621,C93645,Oncology Standards;Disease Response;Recurrence,DRCRIND,Ordinal,An indication as to whether disease recurrence occurred.,,,,C70856,C70856,Observation Result,string,Present;Absent
2025-04-01,Disease Recurrence Indicator,C123621,C123621,C93645,Oncology Standards;Disease Response;Recurrence,DRCRIND,Ordinal,An indication as to whether disease recurrence occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Disease Recurrence Indicator,C123621,C123621,C93645,Oncology Standards;Disease Response;Recurrence,DRCRIND,Ordinal,An indication as to whether disease recurrence occurred.,,,,C25372,C25372,Category,string,
2025-04-01,Disease Recurrence Indicator,C123621,C123621,C93645,Oncology Standards;Disease Response;Recurrence,DRCRIND,Ordinal,An indication as to whether disease recurrence occurred.,,,,C25692,C25692,Subcategory,string,
2024-06-27,Metabolic Response,C123623,C123623,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,METBRESP,Ordinal,An evaluation of the metabolic response of the disease to the therapy.,,,,C25372,C25372,Category,string,LUGANO CLASSIFICATION
2024-06-27,Metabolic Response,C123623,C123623,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,METBRESP,Ordinal,An evaluation of the metabolic response of the disease to the therapy.,,,,C70856,C70856,Observation Result,string,CR;PR;SD;PD;NE;CMR
2024-06-27,Metabolic Response,C123623,C123623,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,METBRESP,Ordinal,An evaluation of the metabolic response of the disease to the therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Metabolic Response,C123623,C123623,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,METBRESP,Ordinal,An evaluation of the metabolic response of the disease to the therapy.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Metabolic Response,C123623,C123623,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,METBRESP,Ordinal,An evaluation of the metabolic response of the disease to the therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3;Hematologist 1;Hematologist 2
2024-06-27,Radiologic Response,C123627,C123627,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,RDIORESP,Nominal,An evaluation of the radiologic response of the disease to the therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Radiologic Response,C123627,C123627,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,RDIORESP,Nominal,An evaluation of the radiologic response of the disease to the therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Radiologic Response,C123627,C123627,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,RDIORESP,Nominal,An evaluation of the radiologic response of the disease to the therapy.,,,,C117394,C117394,Disease Response Link Group,string,A1;A2;A3
2024-06-27,Radiologic Response,C123627,C123627,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,RDIORESP,Nominal,An evaluation of the radiologic response of the disease to the therapy.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Radiologic Response,C123627,C123627,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,RDIORESP,Nominal,An evaluation of the radiologic response of the disease to the therapy.,,,,C25372,C25372,Category,string,RANO;iRANO
2024-06-27,Radiologic Response,C123627,C123627,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,RDIORESP,Nominal,An evaluation of the radiologic response of the disease to the therapy.,,,,C70856,C70856,Observation Result,string,CR;PR;SD;PD;NE;Psuedoprogression;Psuedoresponse;NED
2024-12-16,Location of Death,C124331,C124331,C25341,Death Diagnosis and Details;Location,LOCDTH;Location of Death,Ordinal,The physical place at which the subject ceased to live.,,,,C70856,C70856,Observation Result,string,Clinic;Home;Hospital
2024-12-16,Location of Death,C124331,C124331,C25341,Death Diagnosis and Details;Location,LOCDTH;Location of Death,Ordinal,The physical place at which the subject ceased to live.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3;Pathologist 1;Pathologist 2
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C70856,C70856,Observation Result,string,Pathological
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C117413,C117413,Tumor Results Link Identifier,string,T01;NT01;NEW01
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C117419,C117419,Tumor Results Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C117411,C117411,Tumor Results Group Identifier,string,Target;Non-target;New
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C117412,C117412,Tumor Results Link Group,string,A1;A2;A3
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Lymph Node State,C124448,C124448,C135508,Oncology Standards;Tumor/Lesion Results;TR,LNSTATE,Nominal,A condition or state of a lymph node at a particular time.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Clinical Interpretation,C125009,C125009,,Clinical Interpretation,,,The determination of the meaning of a clinical result.,,,,,,,,
2025-04-01,Overall Survival,C125201,C125201,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Overall Survival,C125201,C125201,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2025-04-01,Overall Survival,C125201,C125201,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C25372,C25372,Category,string,
2025-04-01,Overall Survival,C125201,C125201,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Overall Survival,C125201,C125201,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Overall Survival Time,Temporal,A measure of the time until death from any cause.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Pathology Result,C125581,C125581,,Laboratory Tests,Pathology Examination Result,,The outcome of a pathologic examination.,,,,,,,,
2025-04-01,Urea Nitrogen Measurement,C125949,C125949,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Urea Nitrogen,Quantitative,The determination of the amount of urea nitrogen present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Urea Nitrogen Measurement,C125949,C125949,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Urea Nitrogen,Quantitative,The determination of the amount of urea nitrogen present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Urea Nitrogen Measurement,C125949,C125949,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Urea Nitrogen,Quantitative,The determination of the amount of urea nitrogen present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;mg/dL;mg/L
2025-04-01,Urea Nitrogen Measurement,C125949,C125949,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Urea Nitrogen,Quantitative,The determination of the amount of urea nitrogen present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol,C127127,C127127,C45398,Laboratory Tests;Nitroso Carcinogens;Carcinogenic Nitrosamines,NNAL;Nicotine-Derived Nitrosamine Alcohol,Quantitative,"The major metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK) that is detected in the urine of subjects exposed to tobacco products. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL) is produced by carbonyl reduction of NNK and may also be a carcinogen.",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol,C127127,C127127,C45398,Laboratory Tests;Nitroso Carcinogens;Carcinogenic Nitrosamines,NNAL;Nicotine-Derived Nitrosamine Alcohol,Quantitative,"The major metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK) that is detected in the urine of subjects exposed to tobacco products. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL) is produced by carbonyl reduction of NNK and may also be a carcinogen.",,,,C70713,C70713,Biospecimen Type,string,Urine
2025-04-01,4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol,C127127,C127127,C45398,Laboratory Tests;Nitroso Carcinogens;Carcinogenic Nitrosamines,NNAL;Nicotine-Derived Nitrosamine Alcohol,Quantitative,"The major metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK) that is detected in the urine of subjects exposed to tobacco products. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL) is produced by carbonyl reduction of NNK and may also be a carcinogen.",,,,C48207,C48207,Unit of Concentration,string,
2024-12-17,Tenderness Indicator,C127775,C127775,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,TNDRIND,Ordinal,An indicator as to whether the subject has symptoms of tenderness.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Tenderness Indicator,C127775,C127775,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,TNDRIND,Ordinal,An indicator as to whether the subject has symptoms of tenderness.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Tenderness Indicator,C127775,C127775,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,TNDRIND,Ordinal,An indicator as to whether the subject has symptoms of tenderness.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Tenderness Indicator,C127775,C127775,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,TNDRIND,Ordinal,An indicator as to whether the subject has symptoms of tenderness.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Total Number,C127787,C127787,,Number,,,The determination of the amount of total number of entities.,,,,,,,,
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Blood
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C25372,C25372,Category,string,
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C25692,C25692,Subcategory,string,
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,PD-L1 Positive,C128554,C128554,C177692,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,B7 Homolog 1 Positive;B7-H Positive;B7H1 Positive;CD274 Antigen Positive;CD274 Molecule Positive;CD274 Positive;Expression of PD-L1;PD-L1 Positive;PD-L1+;PDCD1L1 Positive;PDCD1LG1 Positive;PDL1 Positive;Positive;Programmed Cell Death 1 Ligand 1 Positive,Ordinal,An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.,,,,C82515,C82515,Collection Date Time,datetime,
2023-07-06,Specimen Isolation,C128947,C128947,,Biospecimen Events,Isolating;Isolated,Nominal,The act of separating a sub-component from the original collected specimen.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor Tissue;Blood
2023-07-06,Specimen Isolation,C128947,C128947,,Biospecimen Events,Isolating;Isolated,Nominal,The act of separating a sub-component from the original collected specimen.,,,,C117052,C117052,Accountable Party,string,Site
2023-07-06,Specimen Isolation,C128947,C128947,,Biospecimen Events,Isolating;Isolated,Nominal,The act of separating a sub-component from the original collected specimen.,,,,C25692,C25692,Subcategory,string,
2023-07-06,Specimen Isolation,C128947,C128947,,Biospecimen Events,Isolating;Isolated,Nominal,The act of separating a sub-component from the original collected specimen.,,,,C25372,C25372,Category,string,
2023-07-06,Specimen Isolation,C128947,C128947,,Biospecimen Events,Isolating;Isolated,Nominal,The act of separating a sub-component from the original collected specimen.,,,,C82977,C82977,Dictionary-derived Term,string,Isolating
2023-07-06,Specimen Isolation,C128947,C128947,,Biospecimen Events,Isolating;Isolated,Nominal,The act of separating a sub-component from the original collected specimen.,,,,C82571,C82571,Reported Event Term,string,
2024-12-17,Wheal Diameter Interpretation,C130186,C130186,C125009,Clinical Interpretation;Skin Response,WHLINT,Nominal,"A further, qualitative assessment based on the diameter of a wheal on the skin.",,,,C25185,C25185,Laterality,string,
2024-12-17,Wheal Diameter Interpretation,C130186,C130186,C125009,Clinical Interpretation;Skin Response,WHLINT,Nominal,"A further, qualitative assessment based on the diameter of a wheal on the skin.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Wheal Diameter Interpretation,C130186,C130186,C125009,Clinical Interpretation;Skin Response,WHLINT,Nominal,"A further, qualitative assessment based on the diameter of a wheal on the skin.",,,,C82546,C82546,Observation Object,string,
2024-12-17,Wheal Diameter Interpretation,C130186,C130186,C125009,Clinical Interpretation;Skin Response,WHLINT,Nominal,"A further, qualitative assessment based on the diameter of a wheal on the skin.",,,,C82535,C82535,Test Method,string,
2024-12-17,Wheal Diameter Interpretation,C130186,C130186,C125009,Clinical Interpretation;Skin Response,WHLINT,Nominal,"A further, qualitative assessment based on the diameter of a wheal on the skin.",,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Wheal Diameter Interpretation,C130186,C130186,C125009,Clinical Interpretation;Skin Response,WHLINT,Nominal,"A further, qualitative assessment based on the diameter of a wheal on the skin.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Number of Renal Arteries,C130195,C130195,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Arteries;RNLANUM,Quantitative,The determination of the total number of renal arteries.,,,,C82535,C82535,Test Method,string,
2025-04-01,Number of Renal Arteries,C130195,C130195,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Arteries;RNLANUM,Quantitative,The determination of the total number of renal arteries.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Number of Renal Arteries,C130195,C130195,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Arteries;RNLANUM,Quantitative,The determination of the total number of renal arteries.,,,,C13717,C13717,Anatomic Site,string,Kidney
2025-04-01,Number of Renal Arteries,C130195,C130195,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Arteries;RNLANUM,Quantitative,The determination of the total number of renal arteries.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Number of Renal Arteries,C130195,C130195,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Arteries;RNLANUM,Quantitative,The determination of the total number of renal arteries.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Number of Renal Veins,C130196,C130196,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Veins;RNLVNUM,Quantitative,The determination of the total number of renal veins.,,,,C82535,C82535,Test Method,string,
2025-04-01,Number of Renal Veins,C130196,C130196,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Veins;RNLVNUM,Quantitative,The determination of the total number of renal veins.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Number of Renal Veins,C130196,C130196,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Veins;RNLVNUM,Quantitative,The determination of the total number of renal veins.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Number of Renal Veins,C130196,C130196,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Veins;RNLVNUM,Quantitative,The determination of the total number of renal veins.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Number of Renal Veins,C130196,C130196,C25337,Findings;Clinical Test Result;Urinary System Findings,Number of Renal Veins;RNLVNUM,Quantitative,The determination of the total number of renal veins.,,,,C13717,C13717,Anatomic Site,string,Kidney
2025-04-01,Treponema pallidum Antibody Measurement,C132388,C132388,C210010,Laboratory Tests;Microbiology Tests;Immunology Tests;Antibody Measurements,TPLAB;Treponema pallidum Antibody;Syphilis Antibody,Quantitative;Ordinal,The determination of the amount of Treponema pallidum antibody in a biological sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Blood;Cerebrospinal Fluid;Body Fluid
2025-04-01,Treponema pallidum Antibody Measurement,C132388,C132388,C210010,Laboratory Tests;Microbiology Tests;Immunology Tests;Antibody Measurements,TPLAB;Treponema pallidum Antibody;Syphilis Antibody,Quantitative;Ordinal,The determination of the amount of Treponema pallidum antibody in a biological sample.,,,,C82535,C82535,Test Method,string,Immunofluorescence;Hemagglutination;Enzyme Immunoassay;Chemiluminescence Immunoassay;Immunoblots;Rapid Treponemal Assay
2025-04-01,Treponema pallidum Antibody Measurement,C132388,C132388,C210010,Laboratory Tests;Microbiology Tests;Immunology Tests;Antibody Measurements,TPLAB;Treponema pallidum Antibody;Syphilis Antibody,Quantitative;Ordinal,The determination of the amount of Treponema pallidum antibody in a biological sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Detection
2025-04-01,Treponema pallidum Antibody Measurement,C132388,C132388,C210010,Laboratory Tests;Microbiology Tests;Immunology Tests;Antibody Measurements,TPLAB;Treponema pallidum Antibody;Syphilis Antibody,Quantitative;Ordinal,The determination of the amount of Treponema pallidum antibody in a biological sample.,,,,C70856,C70856,Observation Result,string,
2023-12-12,Eligibility Criteria Met By Subject,C132447,C132447,,Subject Disposition;Protocol Milestones,Eligibility Criteria Met,Nominal,An indication that the subject has fulfilled the criteria needed to continue to the next study period.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Eligibility Criteria Met By Subject,C132447,C132447,,Subject Disposition;Protocol Milestones,Eligibility Criteria Met,Nominal,An indication that the subject has fulfilled the criteria needed to continue to the next study period.,,,,C82977,C82977,Dictionary-derived Term,string,Eligibility Criteria Met
2023-12-12,Eligibility Criteria Met By Subject,C132447,C132447,,Subject Disposition;Protocol Milestones,Eligibility Criteria Met,Nominal,An indication that the subject has fulfilled the criteria needed to continue to the next study period.,,,,C25372,C25372,Category,string,Protocol Milestone
2023-12-12,Eligibility Criteria Met By Subject,C132447,C132447,,Subject Disposition;Protocol Milestones,Eligibility Criteria Met,Nominal,An indication that the subject has fulfilled the criteria needed to continue to the next study period.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Eligibility Criteria Met By Subject,C132447,C132447,,Subject Disposition;Protocol Milestones,Eligibility Criteria Met,Nominal,An indication that the subject has fulfilled the criteria needed to continue to the next study period.,,,,C82517,C82517,Observation Start Date Time,datetime,
2025-04-01,Metastatic Disease Indicator,C132456,C132456,C181043,Oncology Standards;Metastasis,Metastatic Indicator;METSIND,Ordinal,An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.,,,,C25372,C25372,Category,string,
2025-04-01,Metastatic Disease Indicator,C132456,C132456,C181043,Oncology Standards;Metastasis,Metastatic Indicator;METSIND,Ordinal,An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Metastatic Disease Indicator,C132456,C132456,C181043,Oncology Standards;Metastasis,Metastatic Indicator;METSIND,Ordinal,An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Metastatic Disease Indicator,C132456,C132456,C181043,Oncology Standards;Metastasis,Metastatic Indicator;METSIND,Ordinal,An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Metastatic Disease Indicator,C132456,C132456,C181043,Oncology Standards;Metastasis,Metastatic Indicator;METSIND,Ordinal,An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-04-01,Metastatic Disease Indicator,C132456,C132456,C181043,Oncology Standards;Metastasis,Metastatic Indicator;METSIND,Ordinal,An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2024-12-16,Age at Death,C135383,C135383,C25150,Death Diagnosis and Details;Age,AGEDTH;Age At Date of Death,Quantitative,The age at which death occurred.,,,,C50400,C50400,Age Unit,string,Days;Hours;Months;Weeks;Years
2024-12-16,Age at Death,C135383,C135383,C25150,Death Diagnosis and Details;Age,AGEDTH;Age At Date of Death,Quantitative,The age at which death occurred.,,,,C70856,C70856,Observation Result,string,
2024-12-16,Age at Death,C135383,C135383,C25150,Death Diagnosis and Details;Age,AGEDTH;Age At Date of Death,Quantitative,The age at which death occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-04-02,Autopsy Indicator,C135384,C135384,C25180,Indicator,AUTOPIND;Was Autopsy Performed,Ordinal,An indication as to whether an autopsy was performed.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-04-02,Autopsy Indicator,C135384,C135384,C25180,Indicator,AUTOPIND;Was Autopsy Performed,Ordinal,An indication as to whether an autopsy was performed.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Death Certification Indicator,C135385,C135385,C25180,Death Diagnosis and Details;Indicator,DTHCOIND;Death Certificate Obtained Indicator,Ordinal,An indication as to whether a death certificate was obtained.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-16,Death Certification Indicator,C135385,C135385,C25180,Death Diagnosis and Details;Indicator,DTHCOIND;Death Certificate Obtained Indicator,Ordinal,An indication as to whether a death certificate was obtained.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Hospital Medical Record Indicator,C135386,C135386,C25180,Death Diagnosis and Details;Indicator,HMROIND;Hospital Medical Record Obtained Ind;Hospital Medical Record Obtained Indicator,Ordinal,An indication as to whether medical records were obtained from the hospital.,,,,C70856,C70856,Observation Result,string,N;Y;U;NA
2024-12-16,Hospital Medical Record Indicator,C135386,C135386,C25180,Death Diagnosis and Details;Indicator,HMROIND;Hospital Medical Record Obtained Ind;Hospital Medical Record Obtained Indicator,Ordinal,An indication as to whether medical records were obtained from the hospital.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Bone Marrow Disease Involvement Indicator,C135477,C135477,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,BMIVLIND;Bone Marrow Involvement Indicator,Ordinal,An indication as to whether disease is present in the bone marrow.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3;Hematologist 1;Hematologist 2
2024-06-27,Bone Marrow Disease Involvement Indicator,C135477,C135477,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,BMIVLIND;Bone Marrow Involvement Indicator,Ordinal,An indication as to whether disease is present in the bone marrow.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Bone Marrow Disease Involvement Indicator,C135477,C135477,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,BMIVLIND;Bone Marrow Involvement Indicator,Ordinal,An indication as to whether disease is present in the bone marrow.,,,,C70856,C70856,Observation Result,string,N;U;Y
2024-06-27,Bone Marrow Disease Involvement Indicator,C135477,C135477,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,BMIVLIND;Bone Marrow Involvement Indicator,Ordinal,An indication as to whether disease is present in the bone marrow.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Bone Marrow Disease Involvement Indicator,C135477,C135477,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,BMIVLIND;Bone Marrow Involvement Indicator,Ordinal,An indication as to whether disease is present in the bone marrow.,,,,C25372,C25372,Category,string,LUGANO CLASSIFICATION
2024-06-27,Clinical Performance Status,C135478,C135478,C171082,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,CPRFSTAT,Ordinal,"An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.",,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Clinical Performance Status,C135478,C135478,C171082,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,CPRFSTAT,Ordinal,"An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.",,,,C70856,C70856,Observation Result,string,Improved;Stable;Worsened;NE
2024-06-27,Clinical Performance Status,C135478,C135478,C171082,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,CPRFSTAT,Ordinal,"An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.",,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Clinical Performance Status,C135478,C135478,C171082,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,CPRFSTAT,Ordinal,"An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.",,,,C25372,C25372,Category,string,RANO;iRANO
2024-06-27,Clinical Performance Status,C135478,C135478,C171082,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,CPRFSTAT,Ordinal,"An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.",,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Non-Target Enhancing Lesion Response,C135480,C135480,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTERESP;Non-Target Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target enhancing lesion.,,,,C25372,C25372,Category,string,RANO;iRANO
2024-06-27,Non-Target Enhancing Lesion Response,C135480,C135480,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTERESP;Non-Target Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target enhancing lesion.,,,,C70856,C70856,Observation Result,string,CR;SD;PD;NE
2024-06-27,Non-Target Enhancing Lesion Response,C135480,C135480,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTERESP;Non-Target Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target enhancing lesion.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Non-Target Enhancing Lesion Response,C135480,C135480,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTERESP;Non-Target Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target enhancing lesion.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Non-Target Enhancing Lesion Response,C135480,C135480,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTERESP;Non-Target Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target enhancing lesion.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Non-Target Non-Enhancing Lesion Response,C135481,C135481,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTNERESP;Non-Target Non-Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target non-enhancing lesion.,,,,C25372,C25372,Category,string,RANO;iRANO
2024-06-27,Non-Target Non-Enhancing Lesion Response,C135481,C135481,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTNERESP;Non-Target Non-Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target non-enhancing lesion.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Non-Target Non-Enhancing Lesion Response,C135481,C135481,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTNERESP;Non-Target Non-Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target non-enhancing lesion.,,,,C70856,C70856,Observation Result,string,Increased;Decreased;SD;NE
2024-06-27,Non-Target Non-Enhancing Lesion Response,C135481,C135481,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTNERESP;Non-Target Non-Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target non-enhancing lesion.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Non-Target Non-Enhancing Lesion Response,C135481,C135481,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,NTNERESP;Non-Target Non-Enhancing Response,Nominal,An assessment of the response to the therapy of the non-target non-enhancing lesion.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Disease Response in Spleen,C135482,C135482,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION;IWC HALLEK CLL 2018,SPLNRESP;Spleen Response,Ordinal,An assessment of the disease response to therapy within the involved spleen.,,,,C25372,C25372,Category,string,LUGANO CLASSIFICATION;IWC HALLEK CLL 2018
2024-06-27,Disease Response in Spleen,C135482,C135482,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION;IWC HALLEK CLL 2018,SPLNRESP;Spleen Response,Ordinal,An assessment of the disease response to therapy within the involved spleen.,,,,C70856,C70856,Observation Result,string,CR;PR;SD;PD;NE
2024-06-27,Disease Response in Spleen,C135482,C135482,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION;IWC HALLEK CLL 2018,SPLNRESP;Spleen Response,Ordinal,An assessment of the disease response to therapy within the involved spleen.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Disease Response in Spleen,C135482,C135482,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION;IWC HALLEK CLL 2018,SPLNRESP;Spleen Response,Ordinal,An assessment of the disease response to therapy within the involved spleen.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Disease Response in Spleen,C135482,C135482,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION;IWC HALLEK CLL 2018,SPLNRESP;Spleen Response,Ordinal,An assessment of the disease response to therapy within the involved spleen.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Steroid Use Status,C135483,C135483,C83430,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,STRUSTAT,Ordinal,An assessment of steroid usage as a condition of disease response to therapy.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Steroid Use Status,C135483,C135483,C83430,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,STRUSTAT,Ordinal,An assessment of steroid usage as a condition of disease response to therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Steroid Use Status,C135483,C135483,C83430,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,STRUSTAT,Ordinal,An assessment of steroid usage as a condition of disease response to therapy.,,,,C70856,C70856,Observation Result,string,None Beyond Physiologic Replacement Dose;Decreased;Stable;Increased
2024-06-27,Steroid Use Status,C135483,C135483,C83430,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,STRUSTAT,Ordinal,An assessment of steroid usage as a condition of disease response to therapy.,,,,C25372,C25372,Category,string,RANO;iRANO
2024-06-27,Steroid Use Status,C135483,C135483,C83430,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RANO;iRANO,STRUSTAT,Ordinal,An assessment of steroid usage as a condition of disease response to therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2023-07-06,Organ State,C135508,C135508,,Findings;Status;Medical Status,,,A condition or state of an organ at a particular time.,,,,,,,,
2025-04-01,Organ Craniocaudal Length Measurement,C135509,C135509,C25334,Findings;Clinical Test Result;Urinary System Findings,Organ Vertical Length;ORVERLN,Quantitative,The linear extent along the craniocaudal axis from one end of an organ to the other end.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Organ Craniocaudal Length Measurement,C135509,C135509,C25334,Findings;Clinical Test Result;Urinary System Findings,Organ Vertical Length;ORVERLN,Quantitative,The linear extent along the craniocaudal axis from one end of an organ to the other end.,,,,C82535,C82535,Test Method,string,Sonography;Ultrasound
2025-04-01,Organ Craniocaudal Length Measurement,C135509,C135509,C25334,Findings;Clinical Test Result;Urinary System Findings,Organ Vertical Length;ORVERLN,Quantitative,The linear extent along the craniocaudal axis from one end of an organ to the other end.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Organ Craniocaudal Length Measurement,C135509,C135509,C25334,Findings;Clinical Test Result;Urinary System Findings,Organ Vertical Length;ORVERLN,Quantitative,The linear extent along the craniocaudal axis from one end of an organ to the other end.,,,,C13717,C13717,Anatomic Site,string,Kidney;Bladder;Liver
2025-04-01,Organ Craniocaudal Length Measurement,C135509,C135509,C25334,Findings;Clinical Test Result;Urinary System Findings,Organ Vertical Length;ORVERLN,Quantitative,The linear extent along the craniocaudal axis from one end of an organ to the other end.,,,,C42578,C42578,Unit of Length,string,mm;cm;in
2025-04-01,Organ Craniocaudal Length Measurement,C135509,C135509,C25334,Findings;Clinical Test Result;Urinary System Findings,Organ Vertical Length;ORVERLN,Quantitative,The linear extent along the craniocaudal axis from one end of an organ to the other end.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Graft Status,C135522,C135522,C135508,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings;Organ Transplant Status,Graft Status;GRFTSTAT,Nominal,The condition of the donated organ or tissue.,http://loinc.org/,LOINC,44781-3,C70856,C70856,Observation Result,string,Functioning;Non-functioning
2025-04-01,Graft Status,C135522,C135522,C135508,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings;Organ Transplant Status,Graft Status;GRFTSTAT,Nominal,The condition of the donated organ or tissue.,http://loinc.org/,LOINC,44781-3,C13717,C13717,Anatomic Site,string,Kidney
2025-04-01,Graft Status,C135522,C135522,C135508,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings;Organ Transplant Status,Graft Status;GRFTSTAT,Nominal,The condition of the donated organ or tissue.,http://loinc.org/,LOINC,44781-3,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Graft Status,C135522,C135522,C135508,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings;Organ Transplant Status,Graft Status;GRFTSTAT,Nominal,The condition of the donated organ or tissue.,http://loinc.org/,LOINC,44781-3,C82535,C82535,Test Method,string,Needle Biopsy;Creatinine Measurement
2025-04-01,Graft Status,C135522,C135522,C135508,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings;Organ Transplant Status,Graft Status;GRFTSTAT,Nominal,The condition of the donated organ or tissue.,http://loinc.org/,LOINC,44781-3,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Liquid Biopsy,C135727,C135727,C15189,Laboratory Tests;Diagnostic Procedure;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma
2025-04-01,Liquid Biopsy,C135727,C135727,C15189,Laboratory Tests;Diagnostic Procedure;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C25372,C25372,Category,string,
2025-04-01,Liquid Biopsy,C135727,C135727,C15189,Laboratory Tests;Diagnostic Procedure;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C70856,C70856,Observation Result,string,Positive;Negative;Variant Detection
2025-04-01,Liquid Biopsy,C135727,C135727,C15189,Laboratory Tests;Diagnostic Procedure;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Liquid Biopsy,C135727,C135727,C15189,Laboratory Tests;Diagnostic Procedure;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results,Plasma Biopsy,Nominal;Ordinal,"Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Carbon Monoxide Measurement,C139084,C139084,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Monoxide;CO,Quantitative,The determination of the amount of carbon monoxide present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Arterial Blood;Venous Blood;Capillary Blood;Expired Air
2025-04-01,Carbon Monoxide Measurement,C139084,C139084,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Monoxide;CO,Quantitative,The determination of the amount of carbon monoxide present in a sample.,,,,C48207,C48207,Unit of Concentration,string,nmol/L;ug/L;ppm
2025-04-01,Carbon Monoxide Measurement,C139084,C139084,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Monoxide;CO,Quantitative,The determination of the amount of carbon monoxide present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Bone Mineral Density Z-Score,C139217,C139217,C68741,Musculoskeletal Finding;Z-Score,BMDZ,Quantitative,"A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Bone Mineral Density Z-Score,C139217,C139217,C68741,Musculoskeletal Finding;Z-Score,BMDZ,Quantitative,"A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Bone Mineral Density Z-Score,C139217,C139217,C68741,Musculoskeletal Finding;Z-Score,BMDZ,Quantitative,"A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.",,,,C82535,C82535,Test Method,string,DXA SCAN
2025-04-01,Bone Mineral Density Z-Score,C139217,C139217,C68741,Musculoskeletal Finding;Z-Score,BMDZ,Quantitative,"A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.",,,,C170500,C170500,Result Anatomical Location,string,Cervical Spine;Lumbar Spine
2025-04-01,Bone Mineral Density Z-Score,C139217,C139217,C68741,Musculoskeletal Finding;Z-Score,BMDZ,Quantitative,"A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Body Fat Percentage,C139218,C139218,C19332,Musculoskeletal Finding;Personal Attribute,BODYFATP,Quantitative,"The amount of an individual's total body mass that is fat, expressed as a percent.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Body Fat Percentage,C139218,C139218,C19332,Musculoskeletal Finding;Personal Attribute,BODYFATP,Quantitative,"The amount of an individual's total body mass that is fat, expressed as a percent.",,,,C82535,C82535,Test Method,string,
2025-04-01,Body Fat Percentage,C139218,C139218,C19332,Musculoskeletal Finding;Personal Attribute,BODYFATP,Quantitative,"The amount of an individual's total body mass that is fat, expressed as a percent.",,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Body Fat Percentage,C139218,C139218,C19332,Musculoskeletal Finding;Personal Attribute,BODYFATP,Quantitative,"The amount of an individual's total body mass that is fat, expressed as a percent.",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Extension",C139220,C139220,C25338,Musculoskeletal Finding;Score,"BMMTEXT;Brooke mMRC MMT Score, Extension",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Extension",C139220,C139220,C25338,Musculoskeletal Finding;Score,"BMMTEXT;Brooke mMRC MMT Score, Extension",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Extension",C139220,C139220,C25338,Musculoskeletal Finding;Score,"BMMTEXT;Brooke mMRC MMT Score, Extension",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Extension",C139220,C139220,C25338,Musculoskeletal Finding;Score,"BMMTEXT;Brooke mMRC MMT Score, Extension",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Extension",C139220,C139220,C25338,Musculoskeletal Finding;Score,"BMMTEXT;Brooke mMRC MMT Score, Extension",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion",C139221,C139221,C25338,Musculoskeletal Finding;Score,"BMMTPF;Brooke mMRC MMT Score, Plantar Flex;Brooke mMRC MMT Score, Plantar Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion",C139221,C139221,C25338,Musculoskeletal Finding;Score,"BMMTPF;Brooke mMRC MMT Score, Plantar Flex;Brooke mMRC MMT Score, Plantar Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion",C139221,C139221,C25338,Musculoskeletal Finding;Score,"BMMTPF;Brooke mMRC MMT Score, Plantar Flex;Brooke mMRC MMT Score, Plantar Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion",C139221,C139221,C25338,Musculoskeletal Finding;Score,"BMMTPF;Brooke mMRC MMT Score, Plantar Flex;Brooke mMRC MMT Score, Plantar Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion",C139221,C139221,C25338,Musculoskeletal Finding;Score,"BMMTPF;Brooke mMRC MMT Score, Plantar Flex;Brooke mMRC MMT Score, Plantar Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion",C139222,C139222,C25338,Musculoskeletal Finding;Score,"BMMTFLX;Brooke mMRC MMT Score, Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion",C139222,C139222,C25338,Musculoskeletal Finding;Score,"BMMTFLX;Brooke mMRC MMT Score, Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion",C139222,C139222,C25338,Musculoskeletal Finding;Score,"BMMTFLX;Brooke mMRC MMT Score, Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion",C139222,C139222,C25338,Musculoskeletal Finding;Score,"BMMTFLX;Brooke mMRC MMT Score, Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion",C139222,C139222,C25338,Musculoskeletal Finding;Score,"BMMTFLX;Brooke mMRC MMT Score, Flexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction",C139223,C139223,C25338,Musculoskeletal Finding;Score,"BMMTABDT;Brooke mMRC MMT Score, Abduction",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction",C139223,C139223,C25338,Musculoskeletal Finding;Score,"BMMTABDT;Brooke mMRC MMT Score, Abduction",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction",C139223,C139223,C25338,Musculoskeletal Finding;Score,"BMMTABDT;Brooke mMRC MMT Score, Abduction",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction",C139223,C139223,C25338,Musculoskeletal Finding;Score,"BMMTABDT;Brooke mMRC MMT Score, Abduction",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction",C139223,C139223,C25338,Musculoskeletal Finding;Score,"BMMTABDT;Brooke mMRC MMT Score, Abduction",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation",C139224,C139224,C25338,Musculoskeletal Finding;Score,"BMMTLR;Brooke mMRC MMT Score, Lat. Rotat.;Brooke mMRC MMT Score, Lateral Rotation",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation",C139224,C139224,C25338,Musculoskeletal Finding;Score,"BMMTLR;Brooke mMRC MMT Score, Lat. Rotat.;Brooke mMRC MMT Score, Lateral Rotation",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation",C139224,C139224,C25338,Musculoskeletal Finding;Score,"BMMTLR;Brooke mMRC MMT Score, Lat. Rotat.;Brooke mMRC MMT Score, Lateral Rotation",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation",C139224,C139224,C25338,Musculoskeletal Finding;Score,"BMMTLR;Brooke mMRC MMT Score, Lat. Rotat.;Brooke mMRC MMT Score, Lateral Rotation",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation",C139224,C139224,C25338,Musculoskeletal Finding;Score,"BMMTLR;Brooke mMRC MMT Score, Lat. Rotat.;Brooke mMRC MMT Score, Lateral Rotation",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion",C139225,C139225,C25338,Musculoskeletal Finding;Score,"BMMTDORS;Brooke mMRC MMT Score, Dorsiflexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion",C139225,C139225,C25338,Musculoskeletal Finding;Score,"BMMTDORS;Brooke mMRC MMT Score, Dorsiflexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion",C139225,C139225,C25338,Musculoskeletal Finding;Score,"BMMTDORS;Brooke mMRC MMT Score, Dorsiflexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion",C139225,C139225,C25338,Musculoskeletal Finding;Score,"BMMTDORS;Brooke mMRC MMT Score, Dorsiflexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion",C139225,C139225,C25338,Musculoskeletal Finding;Score,"BMMTDORS;Brooke mMRC MMT Score, Dorsiflexion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion",C139226,C139226,C25338,Musculoskeletal Finding;Score,"BMMTINV;Brooke mMRC MMT Score, Inversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion",C139226,C139226,C25338,Musculoskeletal Finding;Score,"BMMTINV;Brooke mMRC MMT Score, Inversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion",C139226,C139226,C25338,Musculoskeletal Finding;Score,"BMMTINV;Brooke mMRC MMT Score, Inversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion",C139226,C139226,C25338,Musculoskeletal Finding;Score,"BMMTINV;Brooke mMRC MMT Score, Inversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion",C139226,C139226,C25338,Musculoskeletal Finding;Score,"BMMTINV;Brooke mMRC MMT Score, Inversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion",C139227,C139227,C25338,Musculoskeletal Finding;Score,"BMMTEVE;Brooke mMRC MMT Score, Eversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C91106,C91106,Clinical or Research Assessment Answer,string,"0 No visible or palpable contraction;1 Visible or palpable contraction without motion;2 Full range of motion, gravity eliminated;3 Full range of motion against gravity;4 Full range of motion against gravity, moderate resistance;5 Full range of motion against gravity, maximal resistance"
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion",C139227,C139227,C25338,Musculoskeletal Finding;Score,"BMMTEVE;Brooke mMRC MMT Score, Eversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C46126,C46126,Ordinal Position,integer,0;1;2;3;4;5
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion",C139227,C139227,C25338,Musculoskeletal Finding;Score,"BMMTEVE;Brooke mMRC MMT Score, Eversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion",C139227,C139227,C25338,Musculoskeletal Finding;Score,"BMMTEVE;Brooke mMRC MMT Score, Eversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,"Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion",C139227,C139227,C25338,Musculoskeletal Finding;Score,"BMMTEVE;Brooke mMRC MMT Score, Eversion",Ordinal,"The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).",,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Failure To Meet Continuation Criteria,C139236,C139236,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Failure To Meet Continuation Criteria,C139236,C139236,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.,,,,C25692,C25692,Subcategory,string,Study Participation
2023-12-12,Failure To Meet Continuation Criteria,C139236,C139236,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Failure To Meet Continuation Criteria,C139236,C139236,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.,,,,C82977,C82977,Dictionary-derived Term,string,Failure to Meet Continuation Criteria
2023-12-12,Failure To Meet Continuation Criteria,C139236,C139236,C74590,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.,,,,C82571,C82571,Reported Event Term,string,
2024-12-17,Pregnancy Indicator,C139264,C139264,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,PREGIND;Pregnant Indicator,Ordinal,An indication as to whether the individual is pregnant.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Pregnancy Indicator,C139264,C139264,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,PREGIND;Pregnant Indicator,Ordinal,An indication as to whether the individual is pregnant.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Full Term Live Births,C139265,C139265,C178141,Reproductive Findings,BRTHFTN;Number Full Term Live Births,Quantitative,A measurement of the total number of live birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Full Term Live Births,C139265,C139265,C178141,Reproductive Findings,BRTHFTN;Number Full Term Live Births,Quantitative,A measurement of the total number of live birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Premature Live Births,C139266,C139266,C178141,Reproductive Findings,BRTHPRN,Quantitative,A measurement of the total number of live birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Premature Live Births,C139266,C139266,C178141,Reproductive Findings,BRTHPRN,Quantitative,A measurement of the total number of live birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Stillbirths,C139267,C139267,C25337,Reproductive Findings,BRTHSTN,Quantitative,"A measurement of the total number of birth events at which the fetus is of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, which is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.",,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Stillbirths,C139267,C139267,C25337,Reproductive Findings,BRTHSTN,Quantitative,"A measurement of the total number of birth events at which the fetus is of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, which is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C25692,C25692,Subcategory,string,
2025-04-01,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C70856,C70856,Observation Result,string,Stage 0;Stage I;Stage II;Stage III;Stage IV
2025-04-01,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Breast Cancer by AJCC v8 Stage,C139532,C139532,C4872,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)",,,,C25372,C25372,Category,string,
2025-04-01,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C70856,C70856,Observation Result,string,Stage 0;Stage I;Stage II;Stage III;Stage IV
2025-04-01,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C25372,C25372,Category,string,
2025-04-01,Breast Cancer by AJCC v8 Anatomic Stage,C139533,C139533,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Anatomic Stage;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)",,,,C25692,C25692,Subcategory,string,
2025-04-01,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C25692,C25692,Subcategory,string,
2025-04-01,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C70856,C70856,Observation Result,string,Stage 0;Stage I;Stage II;Stage III;Stage IV
2025-04-01,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Breast Cancer by AJCC v8 Prognostic Stage,C139554,C139554,C139532,Oncology Standards;Breast Cancer TAUG;Staging,Breast Carcinoma by AJCC v8 Prognostic Stage;Breast Cancer by AJCC v8 Prognostic Stage Group;TNM Staging,Ordinal,"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)",,,,C25372,C25372,Category,string,
2024-06-27,New Lesion Indicator,C142362,C142362,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,NEWLIND,Ordinal,"An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.",,,,C25372,C25372,Category,string,LUGANO CLASSIFICATION;iRECIST;RANO;IRANO 2015
2024-06-27,New Lesion Indicator,C142362,C142362,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,NEWLIND,Ordinal,"An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.",,,,C70856,C70856,Observation Result,string,N;U;Y
2024-06-27,New Lesion Indicator,C142362,C142362,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,NEWLIND,Ordinal,"An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.",,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,New Lesion Indicator,C142362,C142362,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,NEWLIND,Ordinal,"An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.",,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,New Lesion Indicator,C142362,C142362,C181043,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,NEWLIND,Ordinal,"An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.",,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Unblinding,C142742,C142742,,Subject Disposition;Disposition Events;Other Events;Blinding,Unblinded;Unmasking,Nominal,The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Unblinding,C142742,C142742,,Subject Disposition;Disposition Events;Other Events;Blinding,Unblinded;Unmasking,Nominal,The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Unblinding,C142742,C142742,,Subject Disposition;Disposition Events;Other Events;Blinding,Unblinded;Unmasking,Nominal,The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.,,,,C25372,C25372,Category,string,Other Event
2023-12-12,Unblinding,C142742,C142742,,Subject Disposition;Disposition Events;Other Events;Blinding,Unblinded;Unmasking,Nominal,The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.,,,,C82977,C82977,Dictionary-derived Term,string,Treatment Unblinded
2023-12-12,Unblinding,C142742,C142742,,Subject Disposition;Disposition Events;Other Events;Blinding,Unblinded;Unmasking,Nominal,The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.,,,,C82571,C82571,Reported Event Term,string,
2025-04-01,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C25372,C25372,Category,string,
2025-04-01,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Circulating Tumor Cells Positive,C146691,C146691,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,CTC Positive;Circulating Tumor Cells Present,Ordinal,An indication that tumor cells have been detected in a peripheral blood sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C25372,C25372,Category,string,
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,BRCA Mutation Analysis,C146692,C146692,C18302,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Genetic Variation Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA Mutation Status;BRCA Family Gene Mutation Analysis,Ordinal,A procedure to test for the presence of mutations in BRCA family genes.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Choriogonadotropin Measurement,C147128,C147128,,Laboratory Tests;Chemistry Tests;Hormone Measurements;Choriogonadotropin Measurements;HCG Measurements,Choriogonadotropin;Human Chorionic Gonadotropin;HCGND,,The determination of the amount of choriogonadotropin present in a sample.,,,,,,,,
2025-04-01,Carboxyhemoglobin to Total Hemoglobin Ratio Measurement,C147355,C147355,C64848,Laboratory Tests;Chemistry Tests;Hemoglobin Measurements,,Quantitative,The determination of the ratio of carboxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,20563-3,C48570,C48570,Percent Unit,string,%
2025-04-01,Carboxyhemoglobin to Total Hemoglobin Ratio Measurement,C147355,C147355,C64848,Laboratory Tests;Chemistry Tests;Hemoglobin Measurements,,Quantitative,The determination of the ratio of carboxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,20563-3,C70856,C70856,Observation Result,decimal,
2025-04-01,Carboxyhemoglobin to Total Hemoglobin Ratio Measurement,C147355,C147355,C64848,Laboratory Tests;Chemistry Tests;Hemoglobin Measurements,,Quantitative,The determination of the ratio of carboxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,20563-3,C70713,C70713,Biospecimen Type,string,Blood;Arterial Blood;Venous Blood;Capillary Blood
2025-04-01,Macroscopic Blood Measurement,C147390,C147390,C49237,Laboratory Tests;Chemistry Tests,Visible Blood;Macroscopic Blood;MACROBLD,Ordinal,The determination of the amount or presence of macroscopic blood present in a sample.,http://loinc.org/,LOINC,53963-5,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Macroscopic Blood Measurement,C147390,C147390,C49237,Laboratory Tests;Chemistry Tests,Visible Blood;Macroscopic Blood;MACROBLD,Ordinal,The determination of the amount or presence of macroscopic blood present in a sample.,http://loinc.org/,LOINC,53963-5,C70856,C70856,Observation Result,string,
2025-04-01,Macroscopic Blood Measurement,C147390,C147390,C49237,Laboratory Tests;Chemistry Tests,Visible Blood;Macroscopic Blood;MACROBLD,Ordinal,The determination of the amount or presence of macroscopic blood present in a sample.,http://loinc.org/,LOINC,53963-5,C48207,C48207,Unit of Concentration,string,
2025-04-01,Macroscopic Blood Measurement,C147390,C147390,C49237,Laboratory Tests;Chemistry Tests,Visible Blood;Macroscopic Blood;MACROBLD,Ordinal,The determination of the amount or presence of macroscopic blood present in a sample.,http://loinc.org/,LOINC,53963-5,C70713,C70713,Biospecimen Type,string,Urine;Stool
2025-04-01,Nicotine Measurement,C147403,C147403,C75342,Laboratory Tests;Chemistry Tests;Drug Class Measurements;CNS Stimulant Drug Measurements,Nicotine,Quantitative;Ordinal,The determination of the amount of nicotine present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Nicotine Measurement,C147403,C147403,C75342,Laboratory Tests;Chemistry Tests;Drug Class Measurements;CNS Stimulant Drug Measurements,Nicotine,Quantitative;Ordinal,The determination of the amount of nicotine present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/L;ug/L;nmol/L;umol/L
2025-04-01,Nicotine Measurement,C147403,C147403,C75342,Laboratory Tests;Chemistry Tests;Drug Class Measurements;CNS Stimulant Drug Measurements,Nicotine,Quantitative;Ordinal,The determination of the amount of nicotine present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Urine;Hair
2025-04-01,Nornicotine Measurement,C147406,C147406,C49237,Laboratory Tests;Chemistry Tests,Nornicotine,Quantitative,The determination of the amount of nornicotine present in a sample.,http://loinc.org/,LOINC,33917-6,C70856,C70856,Observation Result,decimal,
2025-04-01,Nornicotine Measurement,C147406,C147406,C49237,Laboratory Tests;Chemistry Tests,Nornicotine,Quantitative,The determination of the amount of nornicotine present in a sample.,http://loinc.org/,LOINC,33917-6,C70713,C70713,Biospecimen Type,string,Urine
2025-04-01,Nornicotine Measurement,C147406,C147406,C49237,Laboratory Tests;Chemistry Tests,Nornicotine,Quantitative,The determination of the amount of nornicotine present in a sample.,http://loinc.org/,LOINC,33917-6,C64571,C64571,Unit of Mass Concentration,string,
2025-04-01,Bone Mineral Content,C147472,C147472,C110937,Musculoskeletal Finding,BMC;Bone Mineral Mass;Bone Mass,Quantitative,An assessment of the quantity of minerals within a specific bone.,,,,C42579,C42579,Unit of Mass,string,Kilogram;Gram
2025-04-01,Bone Mineral Content,C147472,C147472,C110937,Musculoskeletal Finding,BMC;Bone Mineral Mass;Bone Mass,Quantitative,An assessment of the quantity of minerals within a specific bone.,,,,C170500,C170500,Result Anatomical Location,string,
2025-04-01,Bone Mineral Content,C147472,C147472,C110937,Musculoskeletal Finding,BMC;Bone Mineral Mass;Bone Mass,Quantitative,An assessment of the quantity of minerals within a specific bone.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Bone Mineral Content,C147472,C147472,C110937,Musculoskeletal Finding,BMC;Bone Mineral Mass;Bone Mass,Quantitative,An assessment of the quantity of minerals within a specific bone.,,,,C82535,C82535,Test Method,string,
2025-04-01,Bone Mineral Content,C147472,C147472,C110937,Musculoskeletal Finding,BMC;Bone Mineral Mass;Bone Mass,Quantitative,An assessment of the quantity of minerals within a specific bone.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Bone Mineral Content,C147472,C147472,C110937,Musculoskeletal Finding,BMC;Bone Mineral Mass;Bone Mass,Quantitative,An assessment of the quantity of minerals within a specific bone.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Bone Mineral Density T-Score,C147473,C147473,C120401,Musculoskeletal Finding;T-Score,BMDT,Quantitative,The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Bone Mineral Density T-Score,C147473,C147473,C120401,Musculoskeletal Finding;T-Score,BMDT,Quantitative,The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Bone Mineral Density T-Score,C147473,C147473,C120401,Musculoskeletal Finding;T-Score,BMDT,Quantitative,The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.,,,,C82535,C82535,Test Method,string,DXA SCAN
2025-04-01,Bone Mineral Density T-Score,C147473,C147473,C120401,Musculoskeletal Finding;T-Score,BMDT,Quantitative,The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.,,,,C170500,C170500,Result Anatomical Location,string,Cervical Spine;Lumbar Spine
2025-04-01,Bone Mineral Density T-Score,C147473,C147473,C120401,Musculoskeletal Finding;T-Score,BMDT,Quantitative,The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Hormone Resistance,C147564,C147564,C36285,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Hormone Resistance,C147564,C147564,C36285,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Hormone Resistance,C147564,C147564,C36285,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C25372,C25372,Category,string,
2025-04-01,Hormone Resistance,C147564,C147564,C36285,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Hormone Resistance,C147564,C147564,C36285,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Hormone Resistance,C147564,C147564,C36285,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,Endocrine Resistance;Hormone Therapy Resistance,Ordinal,A finding indicating decreased tissue sensitivity to a hormone.,,,,C70856,C70856,Observation Result,string,Present;Absent
2025-04-01,Urine Dipstick Test,C147905,C147905,C17241,Laboratory Tests,Urine Test Strip,,Use of a test strip designed to detect one or more specific substances in urine. Results are indicated by a color change and may be qualitative or semi-quantitative.,,,,,,,,
2023-07-06,Non-Protocol Disposition Event,C150824,C150824,,Subject Disposition;Non-Protocol Disposition Events,Other Event,,The group of incidents that are not driven by the protocol but that may occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur.,,,,,,,,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C25185,C25185,Laterality,string,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117511,C117511,Reported Name of Procedure,string,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C25372,C25372,Category,string,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C171435,C171435,Specimen Anatomic Site,string,Liver;Lung;Breast
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Biopsy,C15189,C15189,C18020,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Bx,Nominal,"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.",,,,C54215,C54215,Directionality,string,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C25372,C25372,Category,string,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C171435,C171435,Specimen Anatomic Site,string,Liver;Lung;Breast
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C54215,C54215,Directionality,string,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Needle Biopsy,C15190,C15190,C15189,Diagnostic Procedures;Procedures;Biopsies;Cancer Diagnostic Procedures;Breast Cancer TAUG,Aspiration Biopsy;Needle Biopsy;Puncture Biopsy;needle biopsy,Nominal,"The removal of a tissue sample using a needle, for microscopic examination.",,,,C117511,C117511,Reported Name of Procedure,string,Needle Biopsy
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C25372,C25372,Category,string,
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117511,C117511,Reported Name of Procedure,string,Brachytherapy
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Brachytherapy,C15195,C15195,C15313,Surgeries;Procedures;Breast Cancer Procedures;Radiotherapy;Breast Cancer TAUG,Internal Radiation;Internal Radiation Brachytherapy,Nominal,"A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2024-12-17,Immunodiagnostic Procedure,C15260,C15260,,Immunology Tests;Immunodiagnostic Procedure,,,"Procedures that use immunological methods to diagnose diseases, monitor health, and guide treatment decisions",,,,,,,,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C54215,C54215,Directionality,string,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C13717,C13717,Anatomic Site,string,Axillary Lymph Node
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C25372,C25372,Category,string,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C117511,C117511,Reported Name of Procedure,string,Lymphadenectomy
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Lymphadenectomy,C15275,C15275,,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Lymph Node Dissection;Lymph Node Excision;Excision of the Lymph Node,Nominal,"Surgical removal of lymph nodes, usually done to assess the spread of cancer.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C25372,C25372,Category,string,
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C13717,C13717,Anatomic Site,string,Breast
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117511,C117511,Reported Name of Procedure,string,Mastectomy
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Mastectomy,C15277,C15277,C157802,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Mammectomy;Mastectomy;Partial Mastectomy,Nominal,Surgical removal of the breast.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Breast Conservation Treatment,C15280,C15280,,Surgeries;Procedures;Breast Surgeries;Therapeutic Procedures;Breast Cancer TAUG,,,"Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990)",,,,,,,,
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C25488,C25488,Dose,integer,
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C210652,C210652,Treatment Intent,string,Palliative;Curative
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C124444,C124444,Treatment Environmental Setting,string,Adjuvant;Neo-adjuvant;Metastatic
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C13717,C13717,Anatomic Site,string,Supraclavicular Lymph Node;Breast;Lumbar Vertebra;Axillary Lymph Node
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C18068,C18068,Radiation Dose Unit,string,Gy
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C41184,C41184,Indication,string,Breast Cancer
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C25692,C25692,Subcategory,string,External Beam Radiation Theraphy;Internal Radiation Theraphy
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C25372,C25372,Category,string,Radiation Therapy
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C117512,C117512,Standardized Name of Procedure,string,3D Conformal Radiation Theraphy;Intensity Modulated Radiation Theraphy;Intracavity Brachytheraphy;Interstitial Brachytheraphy
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C117511,C117511,Reported Name of Procedure,string,3D Conformal Radiation Theraphy;Intensity Modulated Radiation Theraphy;Radiosurgery;Stereotactic Body Radiation Thereaphy;Total Body Irritattion;Intracavity Brachytheraphy;Interstitial Brachytheraphy;Radioembolization
2024-12-17,Radiation Therapy,C15313,C15313,C49236,Oncology Standards;Therapeutic Procedure;Radiation Therapy,Cancer Radiotherapy;Radiotherapeutics;RT,Nominal,Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Gram Negative Bacteria Measurement,C154812,C154812,C49188,Laboratory Tests;Microbiology Tests,,,The determination of the gram-negative bacteria present in a sample.,,,,,,,,
2024-12-17,Fundal Height,C154876,C154876,C25347,Reproductive Findings;Height,FUNDHT,Quantitative,A measurement of the distance between the pubic symphysis and the top of the palpable uterus.,,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Fundal Height,C154876,C154876,C25347,Reproductive Findings;Height,FUNDHT,Quantitative,A measurement of the distance between the pubic symphysis and the top of the palpable uterus.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Fundal Height,C154876,C154876,C25347,Reproductive Findings;Height,FUNDHT,Quantitative,A measurement of the distance between the pubic symphysis and the top of the palpable uterus.,,,,C42578,C42578,Unit of Length,decimal,Centimeter;Inch;Millimeter
2024-12-17,Erythema Indicator,C154877,C154877,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ERYTHIND;Redness Indicator,Ordinal,An indication as to whether erythema is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Erythema Indicator,C154877,C154877,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ERYTHIND;Redness Indicator,Ordinal,An indication as to whether erythema is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Erythema Indicator,C154877,C154877,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ERYTHIND;Redness Indicator,Ordinal,An indication as to whether erythema is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Erythema Indicator,C154877,C154877,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ERYTHIND;Redness Indicator,Ordinal,An indication as to whether erythema is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Rash Indicator,C154878,C154878,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,RASHIND,Ordinal,An indication as to whether rash is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Rash Indicator,C154878,C154878,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,RASHIND,Ordinal,An indication as to whether rash is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Rash Indicator,C154878,C154878,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,RASHIND,Ordinal,An indication as to whether rash is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Rash Indicator,C154878,C154878,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,RASHIND,Ordinal,An indication as to whether rash is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Skene's Gland Abnormality Indicator,C154879,C154879,C93491,Reproductive Findings;Clinical Findings Indicator;Indicator,SKGLAIND,Ordinal,An indication as to whether the Skene's gland is abnormal.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Skene's Gland Abnormality Indicator,C154879,C154879,C93491,Reproductive Findings;Clinical Findings Indicator;Indicator,SKGLAIND,Ordinal,An indication as to whether the Skene's gland is abnormal.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Bartholin's Gland Abnormality Indicator,C154880,C154880,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,BTHGLIND;Abnormal Indicator,Ordinal,An indication as to whether the Bartholin's gland is abnormal.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Bartholin's Gland Abnormality Indicator,C154880,C154880,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,BTHGLIND;Abnormal Indicator,Ordinal,An indication as to whether the Bartholin's gland is abnormal.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Ulcer Indicator,C154881,C154881,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ULCERIND;Ulceration Indicator,Ordinal,An indication as to whether an ulcer is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Ulcer Indicator,C154881,C154881,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ULCERIND;Ulceration Indicator,Ordinal,An indication as to whether an ulcer is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Ulcer Indicator,C154881,C154881,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ULCERIND;Ulceration Indicator,Ordinal,An indication as to whether an ulcer is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Ulcer Indicator,C154881,C154881,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ULCERIND;Ulceration Indicator,Ordinal,An indication as to whether an ulcer is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Pustule Indicator,C154882,C154882,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PUSTIND,Ordinal,An indication as to whether a pustule is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Pustule Indicator,C154882,C154882,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PUSTIND,Ordinal,An indication as to whether a pustule is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Pustule Indicator,C154882,C154882,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PUSTIND,Ordinal,An indication as to whether a pustule is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Pustule Indicator,C154882,C154882,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PUSTIND,Ordinal,An indication as to whether a pustule is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Peeling Indicator,C154883,C154883,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PEELIND,Ordinal,An indication as to whether there is the presence of peeling.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Peeling Indicator,C154883,C154883,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PEELIND,Ordinal,An indication as to whether there is the presence of peeling.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Peeling Indicator,C154883,C154883,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PEELIND,Ordinal,An indication as to whether there is the presence of peeling.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Peeling Indicator,C154883,C154883,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,PEELIND,Ordinal,An indication as to whether there is the presence of peeling.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Ecchymosis Indicator,C154884,C154884,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ECCHYIND,Ordinal,An indication as to whether ecchymosis is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Ecchymosis Indicator,C154884,C154884,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ECCHYIND,Ordinal,An indication as to whether ecchymosis is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Ecchymosis Indicator,C154884,C154884,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ECCHYIND,Ordinal,An indication as to whether ecchymosis is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Ecchymosis Indicator,C154884,C154884,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,ECCHYIND,Ordinal,An indication as to whether ecchymosis is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Edema Indicator,C154885,C154885,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,EDEMAIND,Ordinal,An indication as to whether edema is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Edema Indicator,C154885,C154885,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,EDEMAIND,Ordinal,An indication as to whether edema is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Edema Indicator,C154885,C154885,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,EDEMAIND,Ordinal,An indication as to whether edema is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Edema Indicator,C154885,C154885,C119241,Reproductive Findings;Clinical Findings Indicator;Indicator,EDEMAIND,Ordinal,An indication as to whether edema is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Mass Indicator,C154886,C154886,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,MASSIND,Ordinal,An indication as to whether a mass is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Mass Indicator,C154886,C154886,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,MASSIND,Ordinal,An indication as to whether a mass is present.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Mass Indicator,C154886,C154886,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,MASSIND,Ordinal,An indication as to whether a mass is present.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Mass Indicator,C154886,C154886,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,MASSIND,Ordinal,An indication as to whether a mass is present.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Motion Tenderness Indicator,C154887,C154887,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MTENDIND,Ordinal,An indication as to whether there are symptoms of motion tenderness.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Motion Tenderness Indicator,C154887,C154887,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MTENDIND,Ordinal,An indication as to whether there are symptoms of motion tenderness.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Motion Tenderness Indicator,C154887,C154887,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MTENDIND,Ordinal,An indication as to whether there are symptoms of motion tenderness.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Motion Tenderness Indicator,C154887,C154887,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MTENDIND,Ordinal,An indication as to whether there are symptoms of motion tenderness.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Discharge Indicator,C154888,C154888,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,DSCHGIND,Ordinal,An indication as to whether there is the presence of discharge.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Discharge Indicator,C154888,C154888,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,DSCHGIND,Ordinal,An indication as to whether there is the presence of discharge.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Discharge Indicator,C154888,C154888,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,DSCHGIND,Ordinal,An indication as to whether there is the presence of discharge.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Discharge Indicator,C154888,C154888,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,DSCHGIND,Ordinal,An indication as to whether there is the presence of discharge.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Abnormal Bleeding Indicator,C154889,C154889,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,BLEEDIND;Abnormal Indicator,Ordinal,An indication as to whether there is the presence of abnormal bleeding.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Abnormal Bleeding Indicator,C154889,C154889,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,BLEEDIND;Abnormal Indicator,Ordinal,An indication as to whether there is the presence of abnormal bleeding.,,,,C25185,C25185,Laterality,string,Left;Right
2024-12-17,Abnormal Bleeding Indicator,C154889,C154889,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,BLEEDIND;Abnormal Indicator,Ordinal,An indication as to whether there is the presence of abnormal bleeding.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Abnormal Bleeding Indicator,C154889,C154889,C181043,Reproductive Findings;Clinical Findings Indicator;Indicator,BLEEDIND;Abnormal Indicator,Ordinal,An indication as to whether there is the presence of abnormal bleeding.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C25372,C25372,Category,string,Hormone Receptor
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C25692,C25692,Subcategory,string,Nuclear Receptor
2025-04-01,Estrogen Receptor Positive,C15492,C15492,C16150,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,ER Alpha Positive;ER Positive;ER-Alpha Positive;ER +;ERA Positive;Positive Estrogen Receptor;ERS1 Positive,Ordinal,An indication that estrogen receptor alpha expression has been detected in a sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C25372,C25372,Category,string,Hormone Receptor
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C25692,C25692,Subcategory,string,Nuclear Receptor
2025-04-01,Progesterone Receptor Positive,C15496,C15496,C16149,Oncology Standards;Breast Cancer TAUG;Endocrine Tests;Hormone Measurements,PGR Positive;PR Positive,Ordinal,An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2024-06-27,Anatomic Response,C156564,C156564,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,ANATRESP,Ordinal,An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.,,,,C25372,C25372,Category,string,LUGANO CLASSIFICATION
2024-06-27,Anatomic Response,C156564,C156564,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,ANATRESP,Ordinal,An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.,,,,C70856,C70856,Observation Result,string,CR;PR;SD;PD;NE
2024-06-27,Anatomic Response,C156564,C156564,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,ANATRESP,Ordinal,An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Anatomic Response,C156564,C156564,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,ANATRESP,Ordinal,An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Anatomic Response,C156564,C156564,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;LUGANO CLASSIFICATION,ANATRESP,Ordinal,An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Menses Flow Rate Description,C156585,C156585,C117720,Reproductive Findings,MENFRD,Narrative,A subjective description of the menstrual flow rate during a menstrual cycle.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Menses Flow Rate Description,C156585,C156585,C117720,Reproductive Findings,MENFRD,Narrative,A subjective description of the menstrual flow rate during a menstrual cycle.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Menses Duration,C156586,C156586,C117720,Reproductive Findings,MENFDUR;Menses Flow Duration,Quantitative,The number of days during which menses is expelled from the uterus.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Menses Duration,C156586,C156586,C117720,Reproductive Findings,MENFDUR;Menses Flow Duration,Quantitative,The number of days during which menses is expelled from the uterus.,,,,C42574,C42574,Unit of Time,integer,Days;Hours
2024-12-17,Menses Duration,C156586,C156586,C117720,Reproductive Findings,MENFDUR;Menses Flow Duration,Quantitative,The number of days during which menses is expelled from the uterus.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Menstrual Cycle Regularity,C156587,C156587,C117720,Reproductive Findings,MENREG,Narrative,A description of how an individual's menstrual cycle conforms to a consistent temporal pattern.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Menstrual Cycle Regularity,C156587,C156587,C117720,Reproductive Findings,MENREG,Narrative,A description of how an individual's menstrual cycle conforms to a consistent temporal pattern.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Induced Abortion Indicator,C156588,C156588,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,INABOIND,Ordinal,An indication as to whether the female subject has had an induced abortion procedure.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Induced Abortion Indicator,C156588,C156588,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,INABOIND,Ordinal,An indication as to whether the female subject has had an induced abortion procedure.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Live Birth Indicator,C156589,C156589,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,BRTLVIND,Ordinal,An indication as to whether the subject has delivered live-born offspring.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Live Birth Indicator,C156589,C156589,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,BRTLVIND,Ordinal,An indication as to whether the subject has delivered live-born offspring.,,,,C70856,C70856,Observation Result,string,N;Y;U
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83208,C83208,Adverse Event Pattern,string,Intermittent;Continuous;Single Event
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83210,C83210,Adverse Event Relationship to Non Study Treatment,string,Not related;Unlikely Related;Possibly Related;Related
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C41358,C41358,Adverse Event Attribution to Product or Procedure,string,Not related;Unlikely Related;Possibly Related;Related
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83109,C83109,Other Actions taken in Response to Adverse Event,string,Treatment Unblinded;Ptrimary Care Physician Notified
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83013,C83013,Adverse Event Action Taken with Study Treatment,string,Drug Withdrawn;Dose Reduced;Dose Increased;Dose Not Changed;Unknown
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C78541,C78541,Adverse Event Verbatim Description,string,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C49489,C49489,Adverse Event Outcome,string,Fatal;Not Recovered/Not Resolved;Recovered/Resolved With Sequelae;Recovered/Resolved;Recovering/Resolving;Unknown
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83198,C83198,Adverse Event Category,string,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83212,C83212,Adverse Event Subcategory,string,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C87840,C87840,Adverse Event Pre-specified,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83205,C83205,Adverse Event Location,string,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C78605,C78605,Adverse Event Toxicity Grade,string,0;1;2;3;4;5
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83344,C83344,Adverse Event Dictionary Derived Term,string,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C53253,C53253,Severity of Adverse Event,string,Mild;Moderate;Severe
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83053,C83053,Adverse Event Associated with Serious Medical Event,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83201,C83201,Adverse Event End Date Time,datetime,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C53252,C53252,Seriousness of Adverse Event,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83215,C83215,Adverse Event Start Date Time,datetime,
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C84266,C84266,Life Threatening Adverse Event,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83052,C83052,Adverse Event associated with Hospitalization,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C48275,C48275,Death Related to Adverse Event,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C113380,C113380,Disabling Adverse Event,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83117,C83117,Adverse Event Seriousness Due to Congenital Anomaly,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83211,C83211,Adverse Event Involves Cancer,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83199,C83199,Adverse Event Concomitant Treatment,boolean,Y;N
2023-10-03,Anticipated Adverse Event,C156629,C156629,C41331,Events;Reported Events;Adverse Events,Adverse Event;Prespecified Adverse Event,Nominal,An adverse event that is reasonably expected and/or listed in the clinical protocol or other study-related document.,,,,C83214,C83214,Adverse Event Occurred with Overdose,boolean,Y;N
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117511,C117511,Reported Name of Procedure,string,Sentinel Lymph Node Biopsy
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C54215,C54215,Directionality,string,
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C25372,C25372,Category,string,
2025-04-01,Sentinel Lymph Node Biopsy,C15667,C15667,C51900,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,SLNB;SNB;Sentinel Node Biopsy;Sentinel node biopsy alone,Nominal,"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Genetic Testing,C15709,C15709,C19770,Oncology Standards;Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards;Breast Cancer TAUG,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Genetic Testing,C15709,C15709,C19770,Oncology Standards;Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards;Breast Cancer TAUG,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C70856,C70856,Observation Result,string,Positive;Negative;Variant of Unknown Significance
2025-04-01,Genetic Testing,C15709,C15709,C19770,Oncology Standards;Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards;Breast Cancer TAUG,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Genetic Testing,C15709,C15709,C19770,Oncology Standards;Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards;Breast Cancer TAUG,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Blood
2025-04-01,Genetic Testing,C15709,C15709,C19770,Oncology Standards;Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards;Breast Cancer TAUG,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C25372,C25372,Category,string,Genetic Variation;Gene Expression
2025-04-01,Genetic Testing,C15709,C15709,C19770,Oncology Standards;Molecular Analysis;Genetic Variation Analysis;Gene Expression Analysis;Oncology Standards;Breast Cancer TAUG,Genetic Analysis;Genetic Examination,Narrative;Ordinal;Nominal,The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.,,,,C25692,C25692,Subcategory,string,Single Nucleotide Polymorphism;Copy Number Variation
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C70856,C70856,Observation Result,integer,
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C82535,C82535,Test Method,string,Immunohistochemistry
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C25372,C25372,Category,string,
2025-04-01,Ki-67 Labeling Index,C157250,C157250,C28042,Cancer Biomarkers;Oncology Standards;Breast Cancer TAUG;Molecular Measurements,Ki-67;Ki-67Anti-KI67 Labeling Index;Anti-Ki-67 Labeling Index;Anti-MKI67 Labeling Index;Ki-67 Labeling Index;Ki-67 MIB1 Labeling Index;MIB-1 Antibody Labeling Index;MIB-1 Labeling Index;MIB1 Antibody Labeling Index;MIB1 Labeling Index,Quantitative,The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).,,,,C25692,C25692,Subcategory,string,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C54215,C54215,Directionality,string,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C25372,C25372,Category,string,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C13717,C13717,Anatomic Site,string,Breast
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C117511,C117511,Reported Name of Procedure,string,Lumpectomy
2025-04-01,Lumpectomy,C15755,C15755,C15280,Surgeries;Procedures;Breast Cancer Procedures;Breast Cancer TAUG,Lumpectomy;Lumpectomy of Breast;Partial Mastectomy;lumpectomy;partial mastectomy,Nominal,The surgical removal of a discrete mass.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Breast Surgery,C157802,C157802,,Surgeries;Procedures;Breast Surgeries;Therapeutic Procedures;Breast Cancer TAUG,,,A surgical procedure on the breast.,,,,,,,,
2024-12-17,Number of Births,C158275,C158275,C25337,Reproductive Findings,BRTHN,Quantitative,A measurement of the total number of birth events experienced by a female.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Births,C158275,C158275,C25337,Reproductive Findings,BRTHN,Quantitative,A measurement of the total number of birth events experienced by a female.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Estimated Next Menstrual Period Start Date,C158276,C158276,C68616,Reproductive Findings;Start Date,ENMPSDTC;Est Next Menstrual Period Start Date,Temporal,The approximate date of the first day of the next menstrual cycle.,,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Estimated Next Menstrual Period Start Date,C158276,C158276,C68616,Reproductive Findings;Start Date,ENMPSDTC;Est Next Menstrual Period Start Date,Temporal,The approximate date of the first day of the next menstrual cycle.,,,,C82515,C82515,Collection Date Time,datetime,
2023-07-06,Thawed Specimen,C158280,C158280,,Biospecimen Events,Thawing;Thawed,Nominal,A specimen that has changed from a frozen to a liquid or semi-liquid state.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor Tissue;Blood
2023-07-06,Thawed Specimen,C158280,C158280,,Biospecimen Events,Thawing;Thawed,Nominal,A specimen that has changed from a frozen to a liquid or semi-liquid state.,,,,C82571,C82571,Reported Event Term,string,
2023-07-06,Thawed Specimen,C158280,C158280,,Biospecimen Events,Thawing;Thawed,Nominal,A specimen that has changed from a frozen to a liquid or semi-liquid state.,,,,C117052,C117052,Accountable Party,string,Site
2023-07-06,Thawed Specimen,C158280,C158280,,Biospecimen Events,Thawing;Thawed,Nominal,A specimen that has changed from a frozen to a liquid or semi-liquid state.,,,,C25372,C25372,Category,string,Preparation
2023-07-06,Thawed Specimen,C158280,C158280,,Biospecimen Events,Thawing;Thawed,Nominal,A specimen that has changed from a frozen to a liquid or semi-liquid state.,,,,C82977,C82977,Dictionary-derived Term,string,Thawing
2023-07-06,Thawed Specimen,C158280,C158280,,Biospecimen Events,Thawing;Thawed,Nominal,A specimen that has changed from a frozen to a liquid or semi-liquid state.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Physical Property,C158424,C158424,,Laboratory Tests;Physical Property,,,Any of the characteristics that define the nature of matter or forces that act upon it.,,,,,,,,
2025-04-01,Residual Cancer Burden,C160722,C160722,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast;Lymph Node
2025-04-01,Residual Cancer Burden,C160722,C160722,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C25372,C25372,Category,string,
2025-04-01,Residual Cancer Burden,C160722,C160722,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Residual Cancer Burden,C160722,C160722,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Residual Cancer Burden,C160722,C160722,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C70856,C70856,Observation Result,string,0;I;II;III
2025-04-01,Residual Cancer Burden,C160722,C160722,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Residual Cancer Burden Index,C160723,C160723,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Residual Cancer Burden Index,C160723,C160723,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C25372,C25372,Category,string,
2025-04-01,Residual Cancer Burden Index,C160723,C160723,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C171435,C171435,Specimen Anatomic Site,string,Breast;Lymph Node
2025-04-01,Residual Cancer Burden Index,C160723,C160723,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Residual Cancer Burden Index,C160723,C160723,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C70856,C70856,Observation Result,string,RCB-0;RCB-I;RCB-II;RCB-III
2025-04-01,Residual Cancer Burden Index,C160723,C160723,,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Index,Ordinal,"A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Residual Cancer Burden Class,C160724,C160724,C160723,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C25372,C25372,Category,string,
2025-04-01,Residual Cancer Burden Class,C160724,C160724,C160723,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C70856,C70856,Observation Result,string,0;I;II;III
2025-04-01,Residual Cancer Burden Class,C160724,C160724,C160723,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Residual Cancer Burden Class,C160724,C160724,C160723,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Residual Cancer Burden Class,C160724,C160724,C160723,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast;Lymph Node
2025-04-01,Residual Cancer Burden Class,C160724,C160724,C160723,Oncology Standards;Tumor Results;Disease Response;Breast Cancer TAUG,RCB Class,Ordinal,Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Clinical Trial Eligibility Criteria,C16112,C16112,,Eligibility Criteria;Clinical Trial Design,Eligibility Criteria;Study Eligibility Criteria,,"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.",,,,,,,,
2023-12-12,Subject Removed at Sponsor Request,C161410,C161410,,Subject Disposition;Protocol Disposition Events,Sponsor Request,Nominal,An indication that the study subject was removed from the study at the sponsor's request.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Subject Removed at Sponsor Request,C161410,C161410,,Subject Disposition;Protocol Disposition Events,Sponsor Request,Nominal,An indication that the study subject was removed from the study at the sponsor's request.,,,,C82977,C82977,Dictionary-derived Term,string,Sponsor Request
2023-12-12,Subject Removed at Sponsor Request,C161410,C161410,,Subject Disposition;Protocol Disposition Events,Sponsor Request,Nominal,An indication that the study subject was removed from the study at the sponsor's request.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Subject Removed at Sponsor Request,C161410,C161410,,Subject Disposition;Protocol Disposition Events,Sponsor Request,Nominal,An indication that the study subject was removed from the study at the sponsor's request.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Subject Removed at Sponsor Request,C161410,C161410,,Subject Disposition;Protocol Disposition Events,Sponsor Request,Nominal,An indication that the study subject was removed from the study at the sponsor's request.,,,,C82517,C82517,Observation Start Date Time,datetime,
2024-06-27,Non-Target Indicator,C161483,C161483,C25180,Oncology Standards;Tumor/Lesion Identification;TU,NTIND,Nominal,"An indication as to whether a non-target tumor, lesion, or site of disease is present.",,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Non-Target Indicator,C161483,C161483,C25180,Oncology Standards;Tumor/Lesion Identification;TU,NTIND,Nominal,"An indication as to whether a non-target tumor, lesion, or site of disease is present.",,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Non-Target Indicator,C161483,C161483,C25180,Oncology Standards;Tumor/Lesion Identification;TU,NTIND,Nominal,"An indication as to whether a non-target tumor, lesion, or site of disease is present.",,,,C70856,C70856,Observation Result,string,N;Y;U
2024-06-27,Non-Target Indicator,C161483,C161483,C25180,Oncology Standards;Tumor/Lesion Identification;TU,NTIND,Nominal,"An indication as to whether a non-target tumor, lesion, or site of disease is present.",,,,C51824,C51824,Evaluator,string,Investigator
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C25372,C25372,Category,string,
2025-04-01,Progesterone Receptor Status,C16149,C16149,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,PgR Status;Progesterone Receptor,Ordinal,Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards),,,,C25692,C25692,Subcategory,string,
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C25372,C25372,Category,string,
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Estrogen Receptor Status,C16150,C16150,C188928,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,ER Alpha Status;ER Status;ERA Status;ESR Status;ESR1 Status;ESRA Status;Estrogen Receptor 1 Status;Estrogen Receptor Alpha Status;ESTRR Status;NR3A1 Status;Nuclear Receptor Subfamily 3 Group A Member 1 Status,Ordinal,"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a ""late-onset"" form of breast cancer and for an older woman to have an ""early-onset"" variant of the disease.",,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C25372,C25372,Category,string,
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C25692,C25692,Subcategory,string,
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,HER2/Neu Status,C16152,C16152,C94299,Oncology Standards;Breast Cancer TAUG;Molecular Measurements;Endocrine Tests;Hormone Measurements;Gene Expression Analysis,ERBB2 Status;HER2/Her2/Neu Value;HER2/neu,Ordinal,The presence or absence of Her2/Neu on a tissue sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2024-12-17,Products of Conception Examined Indicator,C163557,C163557,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,PRDCEIND;Products of Conception Examined Ind,Ordinal,An indication as to whether the products of conception have been examined.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Products of Conception Examined Indicator,C163557,C163557,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,PRDCEIND;Products of Conception Examined Ind,Ordinal,An indication as to whether the products of conception have been examined.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Pregnancy End Date,C163558,C163558,,Reproductive Findings;End Date,PRGENDTC;Date Pregnancy Ended,Temporal,The date on which the pregnancy ended.,,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Pregnancy End Date,C163558,C163558,,Reproductive Findings;End Date,PRGENDTC;Date Pregnancy Ended,Temporal,The date on which the pregnancy ended.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Body Mass Index,C16358,C16358,,Vital Signs,BMI;Quetelet Index,Quantitative,An individual's weight in kilograms divided by the square of the height in meters.,http://loinc.org/,LOINC,39156-5,C70856,C70856,Observation Result,decimal,
2024-12-16,Body Mass Index,C16358,C16358,,Vital Signs,BMI;Quetelet Index,Quantitative,An individual's weight in kilograms divided by the square of the height in meters.,http://loinc.org/,LOINC,39156-5,C42575,C42575,Unit of Mass Density,string,Kilogram per Square Meter;Pounds per Square Inch
2024-12-16,Body Mass Index,C16358,C16358,,Vital Signs,BMI;Quetelet Index,Quantitative,An individual's weight in kilograms divided by the square of the height in meters.,http://loinc.org/,LOINC,39156-5,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Body Height,C164634,C164634,C25347,Vital Signs,HEIGHT,Quantitative,The vertical measurement or distance from the base to the top of a subject or participant.,http://loinc.org/,LOINC,8302-2,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Body Height,C164634,C164634,C25347,Vital Signs,HEIGHT,Quantitative,The vertical measurement or distance from the base to the top of a subject or participant.,http://loinc.org/,LOINC,8302-2,C168688,C168688,Unit of Height,string,Centimeter;Inch;Millimeter;Meter
2024-12-16,Body Height,C164634,C164634,C25347,Vital Signs,HEIGHT,Quantitative,The vertical measurement or distance from the base to the top of a subject or participant.,http://loinc.org/,LOINC,8302-2,C70856,C70856,Observation Result,decimal,
2023-03-31,Diagnostic Imaging,C16502,C16502,,Diagnostic Imaging;Medical Imaging,Medical Imaging,,Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.,,,,,,,,
2025-04-01,Ethnic Group,C16564,C16564,,Demographic Data;Demographics;Ethnicity,Ethnicity;Ethnic Origin,Nominal,A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.,,,,C16564,C16564,Ethnic Group,string,Hispanic or Latino;Not Hispanic or Latino;Unknown
2025-04-01,Ethnic Group,C16564,C16564,,Demographic Data;Demographics;Ethnicity,Ethnicity;Ethnic Origin,Nominal,A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Immunology Test,C16723,C16723,,Laboratory Tests,,,Laboratory test involving interaction of antigens with specific antibodies.,,,,,,,,
2023-12-12,Informed Consent,C16735,C16735,,Subject Disposition;Protocol Milestones,Informed Consent Obtained,Nominal,Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Informed Consent,C16735,C16735,,Subject Disposition;Protocol Milestones,Informed Consent Obtained,Nominal,Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.,,,,C82977,C82977,Dictionary-derived Term,string,Informed Consent Obtained
2023-12-12,Informed Consent,C16735,C16735,,Subject Disposition;Protocol Milestones,Informed Consent Obtained,Nominal,Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Informed Consent,C16735,C16735,,Subject Disposition;Protocol Milestones,Informed Consent Obtained,Nominal,Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.,,,,C25372,C25372,Category,string,Protocol Milestone
2023-12-12,Informed Consent,C16735,C16735,,Subject Disposition;Protocol Milestones,Informed Consent Obtained,Nominal,Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C25692,C25692,Subcategory,string,
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C117511,C117511,Reported Name of Procedure,string,
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C117512,C117512,Standardized Name of Procedure,string,
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C25372,C25372,Category,string,
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C54215,C54215,Directionality,string,Inner;Outer;Anterior;Dorsal
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C13717,C13717,Anatomic Site,string,Brain;Spine;Bone;Soft Tissue of Joints
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C25185,C25185,Laterality,string,Right;Left;Bilateral
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2023-12-12,Magnetic Resonance Imaging,C16809,C16809,C16502,Diagnostic Imaging;Medical Imaging,Magnetic Resonance;MRI;MRI Scan;NMR;NMR Imaging,Nominal,"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C13717,C13717,Anatomic Site,string,Breast
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C54215,C54215,Directionality,string,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117511,C117511,Reported Name of Procedure,string,Mammography
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C25372,C25372,Category,string,
2025-04-01,Mammography,C16818,C16818,C16502,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,MG,Nominal,"A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117511,C117511,Reported Name of Procedure,string,Positron Emission Tomography
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C25372,C25372,Category,string,
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C13717,C13717,Anatomic Site,string,Brain;Heart;Lung
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Positron Emission Tomography,C17007,C17007,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Medical Imaging;PET;PET SCAN;PET Scan;PET scan;PT;Pet Scan;Positron Emission Tomography Scan;Positron emission tomography (procedure);Positron-Emission Tomography;positron emission tomography scan;proton magnetic resonance spectroscopic imaging,Nominal,"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.",,,,C54215,C54215,Directionality,string,
2025-04-01,Race,C17049,C17049,,Demographic Data;Demographics;Population Group,Racial Group,Nominal,A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Race,C17049,C17049,,Demographic Data;Demographics;Population Group,Racial Group,Nominal,A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.,,,,C17049,C17049,Race,string,Asian;Black or African American;White;American Indian or Alaska Native;Unknown
2024-12-16,Death Witnessed Indicator,C170571,C170571,C25180,Death Diagnosis and Details;Indicator,DTHWIND,Ordinal,An indication as to whether the death event was witnessed by another individual.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-16,Death Witnessed Indicator,C170571,C170571,C25180,Death Diagnosis and Details;Indicator,DTHWIND,Ordinal,An indication as to whether the death event was witnessed by another individual.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Free Thyroxine Index,C170598,C170598,C74786,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T4FRIDX,Quantitative,"A measurement of the thyroid status (function, disease diagnosis, or therapy effectiveness) in a biological specimen. This is calculated by a mathematical formula that takes into account the total thyroxine and unbound thyroxine binding globulins.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Free Thyroxine Index,C170598,C170598,C74786,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T4FRIDX,Quantitative,"A measurement of the thyroid status (function, disease diagnosis, or therapy effectiveness) in a biological specimen. This is calculated by a mathematical formula that takes into account the total thyroxine and unbound thyroxine binding globulins.",,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-04-01,Free Thyroxine Index,C170598,C170598,C74786,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T4FRIDX,Quantitative,"A measurement of the thyroid status (function, disease diagnosis, or therapy effectiveness) in a biological specimen. This is calculated by a mathematical formula that takes into account the total thyroxine and unbound thyroxine binding globulins.",,,,C70856,C70856,Observation Result,decimal,
2023-12-12,Withdrawal of Consent From Protocol-Specified Activity,C170610,C170610,,Subject Disposition;Disposition Events;Other Events;Consent;Withdrawal,,Nominal,"The subject or parent/guardian withdraws their consent for the subject to participate in certain protocol-specified study activities, but does not withdraw consent from participation in the study as a whole.",,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Withdrawal of Consent From Protocol-Specified Activity,C170610,C170610,,Subject Disposition;Disposition Events;Other Events;Consent;Withdrawal,,Nominal,"The subject or parent/guardian withdraws their consent for the subject to participate in certain protocol-specified study activities, but does not withdraw consent from participation in the study as a whole.",,,,C25692,C25692,Subcategory,string,
2023-12-12,Withdrawal of Consent From Protocol-Specified Activity,C170610,C170610,,Subject Disposition;Disposition Events;Other Events;Consent;Withdrawal,,Nominal,"The subject or parent/guardian withdraws their consent for the subject to participate in certain protocol-specified study activities, but does not withdraw consent from participation in the study as a whole.",,,,C25372,C25372,Category,string,Other Event
2023-12-12,Withdrawal of Consent From Protocol-Specified Activity,C170610,C170610,,Subject Disposition;Disposition Events;Other Events;Consent;Withdrawal,,Nominal,"The subject or parent/guardian withdraws their consent for the subject to participate in certain protocol-specified study activities, but does not withdraw consent from participation in the study as a whole.",,,,C82977,C82977,Dictionary-derived Term,string,Withdrawal of Consent from Protocol-Specified Activity
2023-12-12,Withdrawal of Consent From Protocol-Specified Activity,C170610,C170610,,Subject Disposition;Disposition Events;Other Events;Consent;Withdrawal,,Nominal,"The subject or parent/guardian withdraws their consent for the subject to participate in certain protocol-specified study activities, but does not withdraw consent from participation in the study as a whole.",,,,C82571,C82571,Reported Event Term,string,
2024-06-27,Medical Status,C171082,C171082,,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS,,,The status of a patient or subject with regard to their health or a medical procedure.,,,,,,,,
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Measurement,C171439,C171439,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARS-CoV-2 Antibody Detection;SARS-CoV-2 Antibody Test;COVID-19 Antibody Test;COVID-19 Antibody Detection;SAR2AB,Quantitative;Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 antibody in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Detection;Antibody Titer
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Measurement,C171439,C171439,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARS-CoV-2 Antibody Detection;SARS-CoV-2 Antibody Test;COVID-19 Antibody Test;COVID-19 Antibody Detection;SAR2AB,Quantitative;Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 antibody in a sample.,,,,C82535,C82535,Test Method,string,Immunofluorescence
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Measurement,C171439,C171439,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARS-CoV-2 Antibody Detection;SARS-CoV-2 Antibody Test;COVID-19 Antibody Test;COVID-19 Antibody Detection;SAR2AB,Quantitative;Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 antibody in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Measurement,C171439,C171439,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARS-CoV-2 Antibody Detection;SARS-CoV-2 Antibody Test;COVID-19 Antibody Test;COVID-19 Antibody Detection;SAR2AB,Quantitative;Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 antibody in a sample.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Coronaviridae Measurement,C171456,C171456,C49188,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,,,The determination of the amount of coronaviridae in a sample.,,,,,,,,
2024-12-16,Pneumonia Indicator,C171521,C171521,C181043,Clinical Findings Indicators;Respiratory Findings,PNEUMIND,Nominal,An indication as to whether pneumonia has occurred.,,,,C82535,C82535,Test Method,string,X-Ray;CT Scan
2024-12-16,Pneumonia Indicator,C171521,C171521,C181043,Clinical Findings Indicators;Respiratory Findings,PNEUMIND,Nominal,An indication as to whether pneumonia has occurred.,,,,C70856,C70856,Observation Result,string,Y;N;Unknown
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C82535,C82535,Test Method,string,Quantitative Reverse Transcriptase Polymerase Chain Reaction
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C70713,C70713,Biospecimen Type,string,Endotrachial Fluid;Swabbed Material;Lavage Fluid;Blood;Serum;Sputum
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C70700,C70700,Biospecimen Collection Method,string,Swab;Lavage
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Viral Load;Quantification Cycle Number
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C67391,C67391,Unit of Number Concentration,string,log 10 copies/ml
2025-04-01,SARS-CoV-2 RNA Measurement,C171531,C171531,C171532,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SAR2RNA;SARS-CoV-2 RNA,Quantitative,The determination of the amount of SARS-CoV-2 RNA in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,Nasopharynx;Throat;Alveolus
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Measurement,C171532,C171532,C171456,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARSCOV2;SARS-CoV-2 Infection;COVID-19 Infection,Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Detection
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Measurement,C171532,C171532,C171456,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARSCOV2;SARS-CoV-2 Infection;COVID-19 Infection,Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Measurement,C171532,C171532,C171456,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARSCOV2;SARS-CoV-2 Infection;COVID-19 Infection,Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.,,,,C82535,C82535,Test Method,string,Quantitative Reverse Transcriptase Polymerase Chain Reaction
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Measurement,C171532,C171532,C171456,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARSCOV2;SARS-CoV-2 Infection;COVID-19 Infection,Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.,,,,C70713,C70713,Biospecimen Type,string,Endotrachial Fluid;Swabbed Material;Lavage Fluid;Blood;Serum;Sputum
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Measurement,C171532,C171532,C171456,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARSCOV2;SARS-CoV-2 Infection;COVID-19 Infection,Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.,,,,C70700,C70700,Biospecimen Collection Method,string,Swab;Lavage
2025-04-01,Severe Acute Respiratory Syndrome Coronavirus 2 Measurement,C171532,C171532,C171456,Laboratory Tests;Microbiology Tests;Virology Tests;COVID-19 Tests;SARS-CoV-2 Tests,SARSCOV2;SARS-CoV-2 Infection;COVID-19 Infection,Ordinal,The determination of the amount of severe acute respiratory syndrome coronavirus 2 in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,Nasopharynx;Throat;Alveolus
2023-07-06,Tissue Culture,C17201,C17201,,Biospecimen Events,Culturing;Cultured,Nominal,"Originally the maintenance and growth of pieces of explanted tissue (plant or animal) in culture away from the source organism. Now usually refers to the (much more frequently used) technique of cell culture, using cells dispersed from tissues or distant descendants of such cells.",,,,C82977,C82977,Dictionary-derived Term,string,Culturing
2023-07-06,Tissue Culture,C17201,C17201,,Biospecimen Events,Culturing;Cultured,Nominal,"Originally the maintenance and growth of pieces of explanted tissue (plant or animal) in culture away from the source organism. Now usually refers to the (much more frequently used) technique of cell culture, using cells dispersed from tissues or distant descendants of such cells.",,,,C25372,C25372,Category,string,
2023-07-06,Tissue Culture,C17201,C17201,,Biospecimen Events,Culturing;Cultured,Nominal,"Originally the maintenance and growth of pieces of explanted tissue (plant or animal) in culture away from the source organism. Now usually refers to the (much more frequently used) technique of cell culture, using cells dispersed from tissues or distant descendants of such cells.",,,,C25692,C25692,Subcategory,string,
2023-07-06,Tissue Culture,C17201,C17201,,Biospecimen Events,Culturing;Cultured,Nominal,"Originally the maintenance and growth of pieces of explanted tissue (plant or animal) in culture away from the source organism. Now usually refers to the (much more frequently used) technique of cell culture, using cells dispersed from tissues or distant descendants of such cells.",,,,C117052,C117052,Accountable Party,string,Lab
2023-07-06,Tissue Culture,C17201,C17201,,Biospecimen Events,Culturing;Cultured,Nominal,"Originally the maintenance and growth of pieces of explanted tissue (plant or animal) in culture away from the source organism. Now usually refers to the (much more frequently used) technique of cell culture, using cells dispersed from tissues or distant descendants of such cells.",,,,C70713,C70713,Biospecimen Type,string,Blood;Sputum;Tissue
2023-07-06,Tissue Culture,C17201,C17201,,Biospecimen Events,Culturing;Cultured,Nominal,"Originally the maintenance and growth of pieces of explanted tissue (plant or animal) in culture away from the source organism. Now usually refers to the (much more frequently used) technique of cell culture, using cells dispersed from tissues or distant descendants of such cells.",,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C117511,C117511,Reported Name of Procedure,string,
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C117512,C117512,Standardized Name of Procedure,string,
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C54215,C54215,Directionality,string,Inner;Outer;Anterior;Dorsal
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C25185,C25185,Laterality,string,Right;Left;Bilateral
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C13717,C13717,Anatomic Site,string,Chest
2023-12-12,Computed Tomography,C17204,C17204,C16502,Diagnostic Imaging;Medical Imaging,CAT Scan;Computed Axial Tomography;Computed Tomography;Computerized Tomography;CT,Nominal,A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.,,,,C25372,C25372,Category,string,
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C117060,C117060,Sponsor Device Identifier,string,ACME GenePanel 250
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Fragment Count;Genetic Transcription Indicator;Normalized Level;Percentile Rank
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C25709,C25709,Unit of Measure,string,%;Per Megabase Pair;Ratio
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C43568,C43568,Gene Symbol,string,ACTB;GAPDH
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C164811,C164811,Genetic Reference Sequence Identifier,string,
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C82535,C82535,Test Method,string,Targeted Transcriptome Sequencing
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C117039,C117039,Analysis Method,string,Fragments Per Kilobase Million Formula;Transcripts Per Million Formula;Counts Per Million Forumula;Differences of Log2 Intensities Formula
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C93423,C93423,Reference Result,string,
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C70713,C70713,Biospecimen Type,string,RNA
2025-04-01,Transcription,C17208,C17208,C28614,Genomic Findings;Gene Expression Process;Transcription Process,TRNSCPTN;RNA Expression;Genetic Transcription;Transcriptional,Quantitative;Ordinal,"A genetic process in which single-stranded RNA with base sequence complementary to a region of plus strand DNA is synthesized by DNA-dependent RNA polymerases. Following the binding of RNA polymerase on DNA promoter regions, the RNA product is synthesized in a 5' to 3' direction, elongating RNA along the DNA strand as the polymerase proceeds, accompanied by unwinding and rewinding of the DNA template.",,,,C164815,C164815,Reference Genome Assembly Version,string,
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C54215,C54215,Directionality,string,
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C13717,C13717,Anatomic Site,string,Abdomen;Pelvis;Heart;Breast
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C25372,C25372,Category,string,
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117511,C117511,Reported Name of Procedure,string,Ultrasound
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Ultrasound Imaging,C17230,C17230,C17369,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Ultrasonography;2-Dimensional Ultrasound Imaging;Ultrasound;Ultrasound Test;US,Nominal,The use of high-frequency sound waves to generate images of the body.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Urinalysis,C17241,C17241,C49237,Laboratory Tests,Urine Test;UA,,"Laboratory analysis of urine, commonly used to aid in the diagnosis of disease or to detect the presence of a specific substance. It involves examination of the urine by physical or chemical means as well as microscopic examination that helps to screen for urinary tract infections, renal disease, and diseases of other organs, that result in abnormal metabolites (break-down products) appearing in the urine.",,,,,,,,
2025-04-01,Genetic Variation,C17248,C17248,,Genomics Findings;Genetic Variation,Genetic Diversity;Sequence Variant;Sequence Variation;Variant Classification,,"Genetic Variation consists of deviation(s) in the nucleotide sequence of the genetic material of an individual from that typical of the group to which the individual belongs, or deviation(s) in the nucleotide sequence of the genetic material of offspring from that of its parents.",,,,,,,,
2025-04-01,Imaging Procedure,C17369,C17369,,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,,,"Any technology or method that aids in the visualization of any biological process, cell, tissue or organ for use in screening, diagnosis, surgical procedures or therapy.",,,,,,,,
2024-12-16,Sudden Death Indicator,C174284,C174284,C93546,Death Diagnosis and Details;Death Indicator,SDTHIND,Ordinal,An indication as to whether death was unexpected or occurred without warning.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Sudden Death Indicator,C174284,C174284,C93546,Death Diagnosis and Details;Death Indicator,SDTHIND,Ordinal,An indication as to whether death was unexpected or occurred without warning.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C25372,C25372,Category,string,Interval
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C82515,C82515,Collection Date Time,datetime,
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C25330,C25330,Duration,integer,
2024-12-17,"QTc Correction Method Unspecified, Aggregate",C174285,C174285,C62085,Electrocardiogram Findings,QTCUNSAG,Quantitative,"A QT aggregate interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods.",http://loinc.org/,LOINC,8636-3,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C82515,C82515,Collection Date Time,datetime,
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C25372,C25372,Category,string,Interval
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C82516,C82516,Observation End Date Time,datetime,
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C50282,C50282,Lead Device,string,Lead 1;Lead 2
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C25330,C25330,Duration,integer,
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C42574,C42574,Unit of Time,string,Milliseconds;Seconds
2024-12-17,"QTc Correction Method Unspecified, Single Beat",C174286,C174286,C62085,Electrocardiogram Findings,"QTc Corr Method Unspecified, Single Beat;QTc Correction Method Unspecified, Single Beat;QTCUNSSB",Quantitative,"A QT interval that is corrected for heart rate by unspecified correction method, or by non-standard correction methods, based on a QT interval measured on a single beat utilizing one or more ECG leads.",http://loinc.org/,LOINC,8636-3,C62164,C62164,Body Position,string,Supine;Sitting
2025-04-01,B-Lymphocyte Count,C174314,C174314,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,B-Cell Lymphocytes;B-Cells;B-Lymphocytes,Quantitative,A measurement of the B-lymphocyte count in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,B-Lymphocyte Count,C174314,C174314,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,B-Cell Lymphocytes;B-Cells;B-Lymphocytes,Quantitative,A measurement of the B-lymphocyte count in a sample.,,,,C67391,C67391,Unit of Number Concentration,string,10^6/L
2025-04-01,B-Lymphocyte Count,C174314,C174314,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,B-Cell Lymphocytes;B-Cells;B-Lymphocytes,Quantitative,A measurement of the B-lymphocyte count in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,B-Lymphocyte Count,C174314,C174314,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,B-Cell Lymphocytes;B-Cells;B-Lymphocytes,Quantitative,A measurement of the B-lymphocyte count in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2024-12-16,Body Temperature,C174446,C174446,,Vital Signs,Temperature,Quantitative,A measurement of the temperature of the body.,http://loinc.org/,LOINC,8310-5,C44276,C44276,Unit of Temperature,string,Fahrenheit;Celsius;Kelvin
2024-12-16,Body Temperature,C174446,C174446,,Vital Signs,Temperature,Quantitative,A measurement of the temperature of the body.,http://loinc.org/,LOINC,8310-5,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Body Temperature,C174446,C174446,,Vital Signs,Temperature,Quantitative,A measurement of the temperature of the body.,http://loinc.org/,LOINC,8310-5,C70856,C70856,Observation Result,decimal,
2024-12-16,Body Temperature,C174446,C174446,,Vital Signs,Temperature,Quantitative,A measurement of the temperature of the body.,http://loinc.org/,LOINC,8310-5,C13717,C13717,Anatomic Site,string,Axilla;Ear;Forehead;Oral Cavity;Rectum
2023-12-12,Socioeconomic Factors,C17468,C17468,,Subject Characteristics;Social Circumstances,Socioeconomic Status,,"Characteristics of a person such as education and occupation, used to describe the person's position in stratification systems, access to services, etc.",,,,,,,,
2024-12-16,Information Source for Cause of Death,C176287,C176287,C25683,Death Diagnosis and Details;Source,INFOSCOD;cause of death source,Nominal,The authoritative source that provided the cause of death information.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Information Source for Cause of Death,C176287,C176287,C25683,Death Diagnosis and Details;Source,INFOSCOD;cause of death source,Nominal,The authoritative source that provided the cause of death information.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Vaginal Bleeding and/or Spotting Frequency Description,C176359,C176359,,Reproductive Findings,VBSFRQD;Vaginal Bleeding/Spotting Freq Desc;Vaginal Bleeding/Spotting Frequency Description,Narrative,A description of the frequency at which vaginal bleeding and/or spotting has occurred.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Vaginal Bleeding and/or Spotting Frequency Description,C176359,C176359,,Reproductive Findings,VBSFRQD;Vaginal Bleeding/Spotting Freq Desc;Vaginal Bleeding/Spotting Frequency Description,Narrative,A description of the frequency at which vaginal bleeding and/or spotting has occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Hospitalized Due to Pregnancy Complication Indicator,C176360,C176360,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,HSPGCIND;Hosp Due to Pregnancy Complication Ind,Ordinal,An indication as to whether the individual was hospitalized due to a pregnancy complication.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Hospitalized Due to Pregnancy Complication Indicator,C176360,C176360,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,HSPGCIND;Hosp Due to Pregnancy Complication Ind,Ordinal,An indication as to whether the individual was hospitalized due to a pregnancy complication.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Term Pregnancy Category,C176361,C176361,C92720,Reproductive Findings,TRMPGCAT,Nominal,A classification of the gestation duration of the pregnancy at the time of infant birth.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Term Pregnancy Category,C176361,C176361,C92720,Reproductive Findings,TRMPGCAT,Nominal,A classification of the gestation duration of the pregnancy at the time of infant birth.,,,,C70856,C70856,Observation Result,string,Early Term;Full Term;Late Term;Postterm
2025-04-01,Locally Recurrent Disease,C176551,C176551,C38155,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C70856,C70856,Observation Result,string,Positive;Negative;Absent Present
2025-04-01,Locally Recurrent Disease,C176551,C176551,C38155,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Locally Recurrent Disease,C176551,C176551,C38155,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C25372,C25372,Category,string,
2025-04-01,Locally Recurrent Disease,C176551,C176551,C38155,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Local Recurrence,Ordinal,The return of a disease after a period of remission at the site in which it initially manifested or adjacent to it.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Disease-Free Survival,C17751,C17751,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Disease-Free Survival,C17751,C17751,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2025-04-01,Disease-Free Survival,C17751,C17751,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Disease-Free Survival,C17751,C17751,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Disease-Free Survival,C17751,C17751,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,Disease Free;Disease-Free Survival;DFS,Temporal,The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.,,,,C25372,C25372,Category,string,
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C25372,C25372,Category,string,
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C70713,C70713,Biospecimen Type,string,Tissue;Blood
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Expression Positive,C177692,C177692,,Oncology Standards;Laboratory Tests;Immunology Tests;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Breast Cancer TAUG,,,"An indication that the expression of a gene, transcript or protein has been detected in a sample.",,,,C25692,C25692,Subcategory,string,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83288,C83288,Exposure Start Date Time,datetime,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83091,C83091,Exposure Reported Name of Treatment,string,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83282,C83282,Exposure End Date Time,datetime,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83039,C83039,Exposure Dose,decimal,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83279,C83279,Exposure Dose Description,string,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83035,C83035,Exposure Dose Unit,string,
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83111,C83111,Exposure Dose Form,string,Tablet;Capsure;Lotion
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C113358,C113358,Exposure Reference Identifier,string,Kit number;Bottle label;Vial identifier
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83277,C83277,Exposure Intended Dose Regimen,string,Two weeks on;Two weeks off
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83121,C83121,Exposure Route of Administration,string,Oral;Intravenous
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C13717,C13717,Anatomic Site,string,Forearm;Abdomen
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C25185,C25185,Laterality,string,Left;Right
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C54215,C54215,Directionality,string,Upper;Lower
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C93566,C93566,Fasting Status Indicator,boolean,Y;N
2023-12-12,Study Product Administration,C177924,C177924,,Exposure Reported Name of Treatment,Exposure;Study Treatment Administration,Nominal,"The act of the dispensing, applying, or tendering a study product to the participant.",,,,C83043,C83043,Exposure Dose Frequency,string,QD;BID
2025-04-01,Appendicular Skeletal Muscle Mass,C178018,C178018,C112025,Musculoskeletal Finding;Mass Measurement,ASMM;ASMMASS,Quantitative,A measurement of the mass of the muscles of the arms and legs.,,,,C42579,C42579,Unit of Mass,string,Kilogram;Gram;Pound;Ounce
2025-04-01,Appendicular Skeletal Muscle Mass,C178018,C178018,C112025,Musculoskeletal Finding;Mass Measurement,ASMM;ASMMASS,Quantitative,A measurement of the mass of the muscles of the arms and legs.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Appendicular Skeletal Muscle Mass,C178018,C178018,C112025,Musculoskeletal Finding;Mass Measurement,ASMM;ASMMASS,Quantitative,A measurement of the mass of the muscles of the arms and legs.,,,,C25185,C25185,Laterality,string,
2025-04-01,Appendicular Skeletal Muscle Mass,C178018,C178018,C112025,Musculoskeletal Finding;Mass Measurement,ASMM;ASMMASS,Quantitative,A measurement of the mass of the muscles of the arms and legs.,,,,C82535,C82535,Test Method,string,DXA SCAN;Bioimpedance Spectroscopy
2025-04-01,Appendicular Skeletal Muscle Mass,C178018,C178018,C112025,Musculoskeletal Finding;Mass Measurement,ASMM;ASMMASS,Quantitative,A measurement of the mass of the muscles of the arms and legs.,,,,C170500,C170500,Result Anatomical Location,string,
2025-04-01,Appendicular Skeletal Muscle Mass,C178018,C178018,C112025,Musculoskeletal Finding;Mass Measurement,ASMM;ASMMASS,Quantitative,A measurement of the mass of the muscles of the arms and legs.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Actual Date of Delivery,C178050,C178050,,Reproductive Findings,ADLVRDTC,Temporal,The date on which the delivery event occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Actual Date of Delivery,C178050,C178050,,Reproductive Findings,ADLVRDTC,Temporal,The date on which the delivery event occurred.,,,,C70856,C70856,Observation Result,datetime,
2024-06-27,Target Indicator,C178053,C178053,C25180,Oncology Standards;Tumor/Lesion Identification;TU,TIND,Nominal,"An indication as to whether a target tumor, lesion, or site of disease is present.",,,,C70856,C70856,Observation Result,string,N;Y;U
2024-06-27,Target Indicator,C178053,C178053,C25180,Oncology Standards;Tumor/Lesion Identification;TU,TIND,Nominal,"An indication as to whether a target tumor, lesion, or site of disease is present.",,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Target Indicator,C178053,C178053,C25180,Oncology Standards;Tumor/Lesion Identification;TU,TIND,Nominal,"An indication as to whether a target tumor, lesion, or site of disease is present.",,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Target Indicator,C178053,C178053,C25180,Oncology Standards;Tumor/Lesion Identification;TU,TIND,Nominal,"An indication as to whether a target tumor, lesion, or site of disease is present.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Live Births,C178141,C178141,C19332,Reproductive Findings,BRTHLVN;Live Birth Count,Quantitative,A measurement of the total number of live-born offspring a female has delivered.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Live Births,C178141,C178141,C19332,Reproductive Findings,BRTHLVN;Live Birth Count,Quantitative,A measurement of the total number of live-born offspring a female has delivered.,,,,C70856,C70856,Observation Result,integer,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C49489,C49489,Adverse Event Outcome,string,Fatal;Not Recovered/Not Resolved;Recovered/Resolved With Sequelae;Recovered/Resolved;Recovering/Resolving;Unknown
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83201,C83201,Adverse Event End Date Time,datetime,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83215,C83215,Adverse Event Start Date Time,datetime,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83199,C83199,Adverse Event Concomitant Treatment,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83053,C83053,Adverse Event Associated with Serious Medical Event,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83214,C83214,Adverse Event Occurred with Overdose,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83052,C83052,Adverse Event associated with Hospitalization,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C48275,C48275,Death Related to Adverse Event,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C113380,C113380,Disabling Adverse Event,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83117,C83117,Adverse Event Seriousness Due to Congenital Anomaly,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83211,C83211,Adverse Event Involves Cancer,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83208,C83208,Adverse Event Pattern,string,Intermittent;Continuous;Single Event
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C84266,C84266,Life Threatening Adverse Event,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C41358,C41358,Adverse Event Attribution to Product or Procedure,string,Not related;Unlikely Related;Possibly Related;Related
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83210,C83210,Adverse Event Relationship to Non Study Treatment,string,Not related;Unlikely Related;Possibly Related;Related
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C78541,C78541,Adverse Event Verbatim Description,string,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83344,C83344,Adverse Event Dictionary Derived Term,string,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83198,C83198,Adverse Event Category,string,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C87840,C87840,Adverse Event Pre-specified,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83205,C83205,Adverse Event Location,string,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83212,C83212,Adverse Event Subcategory,string,
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C53252,C53252,Seriousness of Adverse Event,boolean,Y;N
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C78605,C78605,Adverse Event Toxicity Grade,string,0;1;2;3;4;5
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83013,C83013,Adverse Event Action Taken with Study Treatment,string,Drug Withdrawn;Dose Reduced;Dose Increased;Dose Not Changed;Unknown
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83109,C83109,Other Actions taken in Response to Adverse Event,string,Treatment Unblinded;Ptrimary Care Physician Notified
2023-10-03,Solicited Adverse Event,C179175,C179175,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C53253,C53253,Severity of Adverse Event,string,Mild;Moderate;Severe
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83208,C83208,Adverse Event Pattern,string,Intermittent;Continuous;Single Event
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C78605,C78605,Adverse Event Toxicity Grade,string,0;1;2;3;4;5
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83210,C83210,Adverse Event Relationship to Non Study Treatment,string,Not related;Unlikely Related;Possibly Related;Related
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C41358,C41358,Adverse Event Attribution to Product or Procedure,string,Not related;Unlikely Related;Possibly Related;Related
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83013,C83013,Adverse Event Action Taken with Study Treatment,string,Drug Withdrawn;Dose Reduced;Dose Increased;Dose Not Changed;Unknown
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C53252,C53252,Seriousness of Adverse Event,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C78541,C78541,Adverse Event Verbatim Description,string,
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83205,C83205,Adverse Event Location,string,
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83212,C83212,Adverse Event Subcategory,string,
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83198,C83198,Adverse Event Category,string,
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83344,C83344,Adverse Event Dictionary Derived Term,string,
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C49489,C49489,Adverse Event Outcome,string,Fatal;Not Recovered/Not Resolved;Recovered/Resolved With Sequelae;Recovered/Resolved;Recovering/Resolving;Unknown
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C53253,C53253,Severity of Adverse Event,string,Mild;Moderate;Severe
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83211,C83211,Adverse Event Involves Cancer,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83109,C83109,Other Actions taken in Response to Adverse Event,string,Treatment Unblinded;Ptrimary Care Physician Notified
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C113380,C113380,Disabling Adverse Event,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C48275,C48275,Death Related to Adverse Event,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83052,C83052,Adverse Event associated with Hospitalization,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C84266,C84266,Life Threatening Adverse Event,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83117,C83117,Adverse Event Seriousness Due to Congenital Anomaly,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83214,C83214,Adverse Event Occurred with Overdose,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83053,C83053,Adverse Event Associated with Serious Medical Event,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83199,C83199,Adverse Event Concomitant Treatment,boolean,Y;N
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83215,C83215,Adverse Event Start Date Time,datetime,
2023-10-03,Unsolicited Adverse Event,C179176,C179176,C41331,Events;Reported Events;Adverse Events,Adverse Event,Nominal,"An adverse event that is voluntarily reported by a healthcare professional, consumer, or patient outside of an organized data collection system.",,,,C83201,C83201,Adverse Event End Date Time,datetime,
2023-12-12,Education Level,C17953,C17953,C17468,Subject Characteristics;Socioeconomic Factors;Socioeconomic Status,EDULEVEL;Education Level Completed;Education,Nominal,"An indication of the years of schooling completed in graded public, private, or parochial schools, and in colleges, universities, or professional schools.",,,,C25554,C25554,Level,string,8th Grade Completion;High School Completion;College Completion;Bachelor's Degree Completion;Master's Degree Completion
2023-07-06,Biospecimen Shipping,C179747,C179747,,Biospecimen Events,Biological Sample Shipment;Biological Sample Shipping;Biological Sample Transport;Specimen Ship;Shipped,Nominal,The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.,,,,C82571,C82571,Reported Event Term,string,
2023-07-06,Biospecimen Shipping,C179747,C179747,,Biospecimen Events,Biological Sample Shipment;Biological Sample Shipping;Biological Sample Transport;Specimen Ship;Shipped,Nominal,The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.,,,,C82977,C82977,Dictionary-derived Term,string,Shipping
2023-07-06,Biospecimen Shipping,C179747,C179747,,Biospecimen Events,Biological Sample Shipment;Biological Sample Shipping;Biological Sample Transport;Specimen Ship;Shipped,Nominal,The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.,,,,C25372,C25372,Category,string,Transport
2023-07-06,Biospecimen Shipping,C179747,C179747,,Biospecimen Events,Biological Sample Shipment;Biological Sample Shipping;Biological Sample Transport;Specimen Ship;Shipped,Nominal,The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.,,,,C25692,C25692,Subcategory,string,
2023-07-06,Biospecimen Shipping,C179747,C179747,,Biospecimen Events,Biological Sample Shipment;Biological Sample Shipping;Biological Sample Transport;Specimen Ship;Shipped,Nominal,The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.,,,,C117052,C117052,Accountable Party,string,Lab
2023-07-06,Biospecimen Shipping,C179747,C179747,,Biospecimen Events,Biological Sample Shipment;Biological Sample Shipping;Biological Sample Transport;Specimen Ship;Shipped,Nominal,The act or process of the logistical considerations for transporting a biological sample from the sender to the receiver.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor Tissue;Blood
2023-07-06,Biospecimen Storage,C179748,C179748,,Biospecimen Events,Biological Sample Storage;Storing,Nominal,"The act, process and logistical considerations of the physical or environmental conditions under which the biological sample is maintained.",,,,C82571,C82571,Reported Event Term,string,
2023-07-06,Biospecimen Storage,C179748,C179748,,Biospecimen Events,Biological Sample Storage;Storing,Nominal,"The act, process and logistical considerations of the physical or environmental conditions under which the biological sample is maintained.",,,,C82977,C82977,Dictionary-derived Term,string,Storing
2023-07-06,Biospecimen Storage,C179748,C179748,,Biospecimen Events,Biological Sample Storage;Storing,Nominal,"The act, process and logistical considerations of the physical or environmental conditions under which the biological sample is maintained.",,,,C25372,C25372,Category,string,Storing
2023-07-06,Biospecimen Storage,C179748,C179748,,Biospecimen Events,Biological Sample Storage;Storing,Nominal,"The act, process and logistical considerations of the physical or environmental conditions under which the biological sample is maintained.",,,,C25692,C25692,Subcategory,string,
2023-07-06,Biospecimen Storage,C179748,C179748,,Biospecimen Events,Biological Sample Storage;Storing,Nominal,"The act, process and logistical considerations of the physical or environmental conditions under which the biological sample is maintained.",,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor Tissue;Blood
2023-07-06,Biospecimen Storage,C179748,C179748,,Biospecimen Events,Biological Sample Storage;Storing,Nominal,"The act, process and logistical considerations of the physical or environmental conditions under which the biological sample is maintained.",,,,C117052,C117052,Accountable Party,string,Site
2024-12-17,Reaction Grade,C179819,C179819,C48309,Grade;Skin Response,REACTGR,Nominal,The position on a scale to assess the response to some kind of stimulus.,,,,C82546,C82546,Observation Object,string,
2024-12-17,Reaction Grade,C179819,C179819,C48309,Grade;Skin Response,REACTGR,Nominal,The position on a scale to assess the response to some kind of stimulus.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Reaction Grade,C179819,C179819,C48309,Grade;Skin Response,REACTGR,Nominal,The position on a scale to assess the response to some kind of stimulus.,,,,C13717,C13717,Anatomic Site,string,
2024-12-17,Reaction Grade,C179819,C179819,C48309,Grade;Skin Response,REACTGR,Nominal,The position on a scale to assess the response to some kind of stimulus.,,,,C25185,C25185,Laterality,string,
2024-12-17,Reaction Grade,C179819,C179819,C48309,Grade;Skin Response,REACTGR,Nominal,The position on a scale to assess the response to some kind of stimulus.,,,,C82535,C82535,Test Method,string,
2024-12-17,Reaction Grade,C179819,C179819,C48309,Grade;Skin Response,REACTGR,Nominal,The position on a scale to assess the response to some kind of stimulus.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Hematoma Indicator,C179823,C179823,C181043,Clinical Findings Indicator;Indicator;Urinary System Findings,HEMAIND,Ordinal,An indication as to whether a hematoma is present.,,,,C25185,C25185,Laterality,string,Left;Right
2025-04-01,Hematoma Indicator,C179823,C179823,C181043,Clinical Findings Indicator;Indicator;Urinary System Findings,HEMAIND,Ordinal,An indication as to whether a hematoma is present.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Hematoma Indicator,C179823,C179823,C181043,Clinical Findings Indicator;Indicator;Urinary System Findings,HEMAIND,Ordinal,An indication as to whether a hematoma is present.,,,,C13717,C13717,Anatomic Site,string,
2025-04-01,Hematoma Indicator,C179823,C179823,C181043,Clinical Findings Indicator;Indicator;Urinary System Findings,HEMAIND,Ordinal,An indication as to whether a hematoma is present.,,,,C54215,C54215,Directionality,string,Inner;Outer;Anterior;Dorsal;Superior
2025-04-01,Hematoma Indicator,C179823,C179823,C181043,Clinical Findings Indicator;Indicator;Urinary System Findings,HEMAIND,Ordinal,An indication as to whether a hematoma is present.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Hematoma Indicator,C179823,C179823,C181043,Clinical Findings Indicator;Indicator;Urinary System Findings,HEMAIND,Ordinal,An indication as to whether a hematoma is present.,,,,C82535,C82535,Test Method,string,X-Ray;CT Scan
2025-04-01,Surgical Damage Indicator,C179824,C179824,C25180,Clinical Findings Indicator;Indicator;Urinary System Findings,SGDMGIND;Surgical Damage Indicator,Ordinal,An indication as to whether damage occurred related to a surgical procedure.,,,,C54215,C54215,Directionality,string,Inner;Outer;Anterior;Dorsal;Superior
2025-04-01,Surgical Damage Indicator,C179824,C179824,C25180,Clinical Findings Indicator;Indicator;Urinary System Findings,SGDMGIND;Surgical Damage Indicator,Ordinal,An indication as to whether damage occurred related to a surgical procedure.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Surgical Damage Indicator,C179824,C179824,C25180,Clinical Findings Indicator;Indicator;Urinary System Findings,SGDMGIND;Surgical Damage Indicator,Ordinal,An indication as to whether damage occurred related to a surgical procedure.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Surgical Damage Indicator,C179824,C179824,C25180,Clinical Findings Indicator;Indicator;Urinary System Findings,SGDMGIND;Surgical Damage Indicator,Ordinal,An indication as to whether damage occurred related to a surgical procedure.,,,,C13717,C13717,Anatomic Site,string,Kidney
2025-04-01,Surgical Damage Indicator,C179824,C179824,C25180,Clinical Findings Indicator;Indicator;Urinary System Findings,SGDMGIND;Surgical Damage Indicator,Ordinal,An indication as to whether damage occurred related to a surgical procedure.,,,,C25185,C25185,Laterality,string,Left;Right
2025-04-01,Surgical Damage Indicator,C179824,C179824,C25180,Clinical Findings Indicator;Indicator;Urinary System Findings,SGDMGIND;Surgical Damage Indicator,Ordinal,An indication as to whether damage occurred related to a surgical procedure.,,,,C82535,C82535,Test Method,string,X-Ray;CT Scan
2023-03-31,Diagnostic Procedure,C18020,C18020,,Procedures,Diagnostic Tests,,Any procedure or test to diagnose a disease or disorder.,,,,,,,,
2024-06-27,Clinical Findings Indicator,C181043,C181043,,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS,,,Specifies whether a clinical finding was observed.,,,,,,,,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C164528,C164528,Genetic Location,string,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C164811,C164811,Genetic Reference Sequence Identifier,string,ENST00000579755.1
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C82535,C82535,Test Method,string,Targeted Genome Sequencing;Karyotyping;Microarray
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C43568,C43568,Gene Symbol,string,CDKN2A
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C164813,C164813,Genetic Variation Identifier,string,COSM12473
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C70713,C70713,Biospecimen Type,string,DNA
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C204091,C204091,Genomic Inheritability Type,string,Somatic Variation
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C93423,C93423,Reference Result,string,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Copy Number Alteration Interpretation;Copy Number Ratio;Number of Altered Exons;Number of Gene Copies
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C117060,C117060,Sponsor Device Identifier,string,ACME GenePanel 500
2025-04-01,Copy Number Variation Assessment,C181330,C181330,C18302,Genomics Findings;Genetic Variation Analysis,CPNUMVAR;Gene Copy Number Variation;Copy Number Variation Assessment,Quantitative;Ordinal,An assessment of the variability in the number of replicas of a gene within the genome.,,,,C164815,C164815,Reference Genome Assembly Version,string,GRCh37.75
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C164811,C164811,Genetic Reference Sequence Identifier,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C164528,C164528,Genetic Location,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C164813,C164813,Genetic Variation Identifier,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C82535,C82535,Test Method,string,Microarray;Targeted Genome Sequencing;Real-Time Polymerase Chain Reaction
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C70713,C70713,Biospecimen Type,string,DNA
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C43568,C43568,Gene Symbol,string,CYP2C19
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C117039,C117039,Analysis Method,string,ADME Variant Profile
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C204090,C204090,Copy Identifier,string,1;2
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C164815,C164815,Reference Genome Assembly Version,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C204091,C204091,Genomic Inheritability Type,string,Somatic Variation;Germline Variation
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C93423,C93423,Reference Result,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Allele Sequence;Genotype;Predicted Amino Acid Change;Predicted Coding Sequence Change;Read Depth;Variant Impact Classification;Variant Read Depth;Variant Read Depth/Read Depth
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C117060,C117060,Sponsor Device Identifier,string,ACME GenePanel 500;DMET Plus
2025-04-01,Single Nucleotide Variation Assessment,C181331,C181331,C18302,Genomics Findings;Genetic Variation Analysis,SNV;Single Nucleotide Variation,Quantitative;Nominal,"An assessment of the variability in a nucleotide found within a specified position of the genome, when compared to a reference nucleotide.",,,,C25709,C25709,Unit of Measure,string,%;Ratio
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C117039,C117039,Analysis Method,string,
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C82535,C82535,Test Method,string,Capillary Electrophoresis
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C70713,C70713,Biospecimen Type,string,DNA
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C164528,C164528,Genetic Location,string,
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Detection;Microsatallite Instability Overall Status
2025-04-01,Microsatellite Instability Length Assessment,C181332,C181332,C63331,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,MICRISTB;Microsatellite Instability,Quantitative;Ordinal,An assessment of the variability in length of microsatellite sequences.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C43568,C43568,Gene Symbol,string,ACTB
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C164815,C164815,Reference Genome Assembly Version,string,GRCh38.p12
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C204091,C204091,Genomic Inheritability Type,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C164528,C164528,Genetic Location,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C93423,C93423,Reference Result,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C164811,C164811,Genetic Reference Sequence Identifier,string,NM_001101.5
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Genetic Transcription Interpretation;Score
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C117039,C117039,Analysis Method,string,IFN-1 Gene Signature
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C82535,C82535,Test Method,string,Targeted Transcriptome Sequencing
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C70713,C70713,Biospecimen Type,string,RNA
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C164813,C164813,Genetic Variation Identifier,string,
2025-04-01,Gene Signature Assessment,C181333,C181333,C63479,Genomic Findings;Gene Expression Analysis,GENESIG;Gene Expression Profile;Gene Expression Signature,Quantitative;Ordinal,An assessment of the unique pattern of gene expression of one to many genes associated with a normal or abnormal biological process.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C164815,C164815,Reference Genome Assembly Version,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C164528,C164528,Genetic Location,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C164813,C164813,Genetic Variation Identifier,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C70713,C70713,Biospecimen Type,string,DNA
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C82535,C82535,Test Method,string,Targeted Genome Sequencing
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C43568,C43568,Gene Symbol,string,BAP1;CYP2D6
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Genotype;Predicted Amino Acid Change;Predicted Coding Sequence Change;Read Depth;Variant Impact Classification;Variant Read Depth;Variant Read Depth/Read Depth
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C93423,C93423,Reference Result,string,
2025-04-01,Short Variation Assessment,C181334,C181334,C18302,Genomics Findings;Genetic Variation Analysis,SHRTVAR;Short Variation,Quantitative;Nominal,"An assessment of the variability in a short sequence of nucleotides (generally defined as 50 base pairs or less), when compared to a reference sequence.",,,,C25709,C25709,Unit of Measure,string,%;Ratio
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C70713,C70713,Biospecimen Type,string,DNA;ctDNA
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C117039,C117039,Analysis Method,string,
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C164815,C164815,Reference Genome Assembly Version,string,GRCh37.75
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C82535,C82535,Test Method,string,Whole Exome Sequencing;Next Generation Targeted Sequencing
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C93423,C93423,Reference Result,string,
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C25709,C25709,Unit of Measure,string,Per Megabase Pair
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C117060,C117060,Sponsor Device Identifier,string,ACME GenePanel 500
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Number of Sequence Variants;Normalized Number of Sequence Variants;Variant Sequence Burden Interpretation
2025-04-01,Tumor Mutation Burden Assessment,C181335,C181335,C18302,Genomics Findings;Genetic Variation Analysis,TMB;Tumor Mutational Burden;Tumor Mutation Burden,Quantitative;Nominal,"A quantitative or qualitative assessment of the number of genomic alterations found in genetic material from tumor cells, when compared to a reference sequence.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Muscle Endurance Measurement,C181501,C181501,C87802,Musculoskeletal Finding;Physical Strength,ENDURM;Muscle Endurance,Quantitative,A measurement of a muscle's ability to perform repetitive contractions against a force.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Muscle Endurance Measurement,C181501,C181501,C87802,Musculoskeletal Finding;Physical Strength,ENDURM;Muscle Endurance,Quantitative,A measurement of a muscle's ability to perform repetitive contractions against a force.,,,,C42574,C42574,Unit of Time,string,Seconds
2025-04-01,Muscle Endurance Measurement,C181501,C181501,C87802,Musculoskeletal Finding;Physical Strength,ENDURM;Muscle Endurance,Quantitative,A measurement of a muscle's ability to perform repetitive contractions against a force.,,,,C170500,C170500,Result Anatomical Location,string,
2025-04-01,Muscle Endurance Measurement,C181501,C181501,C87802,Musculoskeletal Finding;Physical Strength,ENDURM;Muscle Endurance,Quantitative,A measurement of a muscle's ability to perform repetitive contractions against a force.,,,,C82535,C82535,Test Method,string,
2025-04-01,Muscle Endurance Measurement,C181501,C181501,C87802,Musculoskeletal Finding;Physical Strength,ENDURM;Muscle Endurance,Quantitative,A measurement of a muscle's ability to perform repetitive contractions against a force.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Muscle Endurance Measurement,C181501,C181501,C87802,Musculoskeletal Finding;Physical Strength,ENDURM;Muscle Endurance,Quantitative,A measurement of a muscle's ability to perform repetitive contractions against a force.,,,,C25185,C25185,Laterality,string,
2024-12-17,Date of Last Sexual Intercourse,C181524,C181524,,Reproductive Findings,MRSXIDTC;Date of Most Recent Sexual Intercourse,Temporal,The date on which the most recent sexual intercourse occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Date of Last Sexual Intercourse,C181524,C181524,,Reproductive Findings,MRSXIDTC;Date of Most Recent Sexual Intercourse,Temporal,The date on which the most recent sexual intercourse occurred.,,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Total Number of Sexual Partners,C181525,C181525,C127787,Reproductive Findings,TSXPARTN,Quantitative,The total count of all sexual partners.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Total Number of Sexual Partners,C181525,C181525,C127787,Reproductive Findings,TSXPARTN,Quantitative,The total count of all sexual partners.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Condom Use for Most Recent Sexual Intercourse Indicator,C181526,C181526,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,CNDMIND;Condom Use Most Recent Sex Interc Ind,Ordinal,An indication as to whether a condom was used during the most recent occurrence of sexual intercourse.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Condom Use for Most Recent Sexual Intercourse Indicator,C181526,C181526,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,CNDMIND;Condom Use Most Recent Sex Interc Ind,Ordinal,An indication as to whether a condom was used during the most recent occurrence of sexual intercourse.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Condom Use Frequency,C181527,C181527,,Reproductive Findings,CNDUFRQD;Condom Use Frequency Desc;Condom Use Frequency Description,Narrative,The reported frequency of condom use.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Condom Use Frequency,C181527,C181527,,Reproductive Findings,CNDUFRQD;Condom Use Frequency Desc;Condom Use Frequency Description,Narrative,The reported frequency of condom use.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Number of Continuous Days of Menstrual Bleeding and/or Spotting,C181528,C181528,C25337,Reproductive Findings,BLDSPNUM;Number of Continuous Days of Bleed/Spot,Quantitative,The number of days one has experienced continuous menstrual bleeding and/or spotting.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Continuous Days of Menstrual Bleeding and/or Spotting,C181528,C181528,C25337,Reproductive Findings,BLDSPNUM;Number of Continuous Days of Bleed/Spot,Quantitative,The number of days one has experienced continuous menstrual bleeding and/or spotting.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C82535,C82535,Test Method,string,12 Lead Standard;12 Lead Continuous ECG;10 Lead Standard;6 Lead Standard
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C125009,C125009,Clinical Interpretation,string,Normal;Abnormal
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C51824,C51824,Evaluator,string,Investigator;Vendor;Adjudication Committee
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C25372,C25372,Category,string,Interval;Measurement;Finding
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C62164,C62164,Body Position,string,Supine;Sitting
2024-12-17,Electrocardiogram Analysis,C181655,C181655,C25391,Electrocardiogram Findings,ECG Analysis;EKG Analysis;Electrocardiogram Interpretation;ECG Interpretation;EKG Interpretation,Nominal,The examination and interpretation of electrocardiogram data.,http://loinc.org/,LOINC,8601-7,C93532,C93532,Clinically Significant Indicator,string,Y;N;Unknown
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C25692,C25692,Subcategory,string,
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83092,C83092,Substance Use Reported Name,string,Cigarette;Cigar;Pipe;Smokeless Tobacco;Electronic Cigarette
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83044,C83044,Substance Use Dose Frequency,string,Daily;Weekly
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83041,C83041,Substance Use Dose Description,string,
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83038,C83038,Substance Use Dose Unit,string,Cigarette;Cigar;Pipe;Gram;Milligram
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83431,C83431,Substance Use Start Date Time,datetime,
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83419,C83419,Substance Use End Date Time,datetime,
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C162330,C162330,Ongoing Substance Use,boolean,Y;N
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C82520,C82520,Substance Use Duration,string,
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83162,C83162,Substance Use Duration Units,string,Year
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C25372,C25372,Category,string,Tobacco
2023-12-12,History of Tobacco Use,C181760,C181760,,Substance Use;Personal Medical History;Medical History,Tobacco Use;Tobacco Use History,Nominal,A description of an individual's current or previous use of tobacco.,,,,C83416,C83416,Substance Use Dose,integer,
2025-04-01,Molecular Diagnostic Method,C18194,C18194,,Oncology Standards;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures,,,Methods for diagnosis or monitoring of disease predisposition by translation and validation of molecular discoveries in medicine into the clinical diagnostic setting.,,,,,,,,
2025-04-01,Genetic Variation Analysis,C18302,C18302,,Genomics Findings;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Laboratory Procedures,Mutation Analysis,,The identification of genetic variation in a biological sample.,,,,,,,,
2025-04-01,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-04-01,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C25372,C25372,Category,string,
2025-04-01,Circulating Tumor-Derived DNA Positive,C183130,C183130,,Diagnostic Procedures;Genetic Testing;Laboratory Tests;Blood Cell Counts;Oncology Standards;Breast Cancer TAUG;Tumor Results,Cell-Free Circulating Tumor DNA;Circulating Tumor DNA;Circulating Tumor-Derived DNA;ctDNA;ctdDNA,Ordinal,An indication that circulating tumor-derived DNA has been detected in a sample.,,,,C25692,C25692,Subcategory,string,
2024-12-16,Death Expected Indicator,C184505,C184505,C93565,Death Diagnosis and Details;Expected Indicator,DTHEXIND,Ordinal,An indication as to whether the death was expected.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-16,Death Expected Indicator,C184505,C184505,C93565,Death Diagnosis and Details;Expected Indicator,DTHEXIND,Ordinal,An indication as to whether the death was expected.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Treponema pallidum Measurement,C184647,C184647,C154812,Laboratory Tests;Microbiology Tests;Serology Tests;Gram Negative Bacteria Measurements,TPA,Ordinal,The determination of the amount of Treponema pallidum in a biological sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Detection
2025-04-01,Treponema pallidum Measurement,C184647,C184647,C154812,Laboratory Tests;Microbiology Tests;Serology Tests;Gram Negative Bacteria Measurements,TPA,Ordinal,The determination of the amount of Treponema pallidum in a biological sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Treponema pallidum Measurement,C184647,C184647,C154812,Laboratory Tests;Microbiology Tests;Serology Tests;Gram Negative Bacteria Measurements,TPA,Ordinal,The determination of the amount of Treponema pallidum in a biological sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Serum;Urine;Cerebrospinal Fluid;Body Fluid;Swabbed Material
2025-04-01,Treponema pallidum Measurement,C184647,C184647,C154812,Laboratory Tests;Microbiology Tests;Serology Tests;Gram Negative Bacteria Measurements,TPA,Ordinal,The determination of the amount of Treponema pallidum in a biological sample.,,,,C82535,C82535,Test Method,string,Immunofluorescence
2024-12-17,Has Menstrual Periods Indicator,C184708,C184708,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,HMPIND,Ordinal,An indication as to whether the subject experiences menstrual cycles.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Has Menstrual Periods Indicator,C184708,C184708,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,HMPIND,Ordinal,An indication as to whether the subject experiences menstrual cycles.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C70856,C70856,Observation Result,string,
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C25372,C25372,Category,string,
2025-04-01,Microarray Analysis,C18477,C18477,C19770,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,Gene Expression Profiling;Gene Expression Profile,Ordinal;Narrative,"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).",,,,C25692,C25692,Subcategory,string,
2023-12-12,Study Site Transfer,C186208,C186208,C150824,Subject Disposition;Disposition Events;Non-Protocol Disposition Events;Other Events,Site Transfer;Study Subject Site Transfer,Nominal,The study subject has been assigned to a different study site.,,,,C82977,C82977,Dictionary-derived Term,string,Site Transfer
2023-12-12,Study Site Transfer,C186208,C186208,C150824,Subject Disposition;Disposition Events;Non-Protocol Disposition Events;Other Events,Site Transfer;Study Subject Site Transfer,Nominal,The study subject has been assigned to a different study site.,,,,C25372,C25372,Category,string,Other Event
2023-12-12,Study Site Transfer,C186208,C186208,C150824,Subject Disposition;Disposition Events;Non-Protocol Disposition Events;Other Events,Site Transfer;Study Subject Site Transfer,Nominal,The study subject has been assigned to a different study site.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Study Site Transfer,C186208,C186208,C150824,Subject Disposition;Disposition Events;Non-Protocol Disposition Events;Other Events,Site Transfer;Study Subject Site Transfer,Nominal,The study subject has been assigned to a different study site.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Study Site Transfer,C186208,C186208,C150824,Subject Disposition;Disposition Events;Non-Protocol Disposition Events;Other Events,Site Transfer;Study Subject Site Transfer,Nominal,The study subject has been assigned to a different study site.,,,,C82571,C82571,Reported Event Term,string,
2024-12-17,Pregnancy Suspected Indicator,C186213,C186213,C139264,Reproductive Findings;Clinical Findings Indicator;Indicator,PSUSPIND,Ordinal,An indication that the subject is believed likely to be pregnant.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Pregnancy Suspected Indicator,C186213,C186213,C139264,Reproductive Findings;Clinical Findings Indicator;Indicator,PSUSPIND,Ordinal,An indication that the subject is believed likely to be pregnant.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117511,C117511,Reported Name of Procedure,string,Automated Breast Ultrasound
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C54215,C54215,Directionality,string,
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C13717,C13717,Anatomic Site,string,Breast
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C25372,C25372,Category,string,
2025-04-01,Automated Breast Ultrasound,C186741,C186741,C19337,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Automated Ultrasound;Diagnostic Ulatrasound;Ultrasound,Nominal,"A method of ultrasonography for secondary breast cancer screening in asymptomatic women with dense breasts. It uses an ultrasound scanner and a transducer device which moves automatically in a scan box. The patient lies in a supine position and automated breast ultrasound is performed in anteroposterior, medial, and lateral views routinely, and in the superior or inferior view additionally in cases of large breasts. The image series is used for 3-dimensional image reconstruction and tumor detection.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C25372,C25372,Category,string,Breast Cancer;Prostate Cancer
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C25692,C25692,Subcategory,string,Estrogen Receptor;Progesterone Receptor
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Hormone Receptor Status,C188928,C188928,C94299,Oncology Standards;Breast Cancer TAUG;Hormone Measurements;Endocrine Tests;Chemistry Test;Protein or Enzyme Type Measurement,HR Status,Ordinal;Quantitative,An indication of the presence or absence of detection of hormone receptor expression in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Bleeding or Spotting Between Menstrual Periods Indicator,C189352,C189352,C154889,Reproductive Findings;Clinical Findings Indicator;Indicator,BSBMPIND;Bleed/Spot Between Menstrual Periods Ind,Ordinal,An indication as to whether the individual has experienced bleeding or spotting between menstrual periods.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Bleeding or Spotting Between Menstrual Periods Indicator,C189352,C189352,C154889,Reproductive Findings;Clinical Findings Indicator;Indicator,BSBMPIND;Bleed/Spot Between Menstrual Periods Ind,Ordinal,An indication as to whether the individual has experienced bleeding or spotting between menstrual periods.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Irregular Menstrual Periods Indicator,C189353,C189353,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,IRRMPIND,Ordinal,An indication as to whether the individual has experienced irregular menstrual periods.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Irregular Menstrual Periods Indicator,C189353,C189353,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,IRRMPIND,Ordinal,An indication as to whether the individual has experienced irregular menstrual periods.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Average Menstrual Cycle Duration,C189354,C189354,C119549,Reproductive Findings,MENSDURA;Average Menstrual Cycle Length,Quantitative,The average length of time of the menses cycle.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Average Menstrual Cycle Duration,C189354,C189354,C119549,Reproductive Findings,MENSDURA;Average Menstrual Cycle Length,Quantitative,The average length of time of the menses cycle.,,,,C42574,C42574,Unit of Time,integer,Days
2024-12-17,Average Menstrual Cycle Duration,C189354,C189354,C119549,Reproductive Findings,MENSDURA;Average Menstrual Cycle Length,Quantitative,The average length of time of the menses cycle.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Individual Surgically Sterile Indicator,C189355,C189355,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,SRGSTIND;Surgically Sterile Indicator,Ordinal,An indication as to whether the individual has been surgically sterilized.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Individual Surgically Sterile Indicator,C189355,C189355,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,SRGSTIND;Surgically Sterile Indicator,Ordinal,An indication as to whether the individual has been surgically sterilized.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Infertility Indicator,C189356,C189356,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,INFRTIND,Ordinal,An indication as to whether the individual has experienced infertility.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Infertility Indicator,C189356,C189356,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,INFRTIND,Ordinal,An indication as to whether the individual has experienced infertility.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Duration of Sexual Abstinence,C189357,C189357,C25330,Reproductive Findings,SEXABDUR,Quantitative,The length of time during which the individual abstained from sexual activity.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Duration of Sexual Abstinence,C189357,C189357,C25330,Reproductive Findings,SEXABDUR,Quantitative,The length of time during which the individual abstained from sexual activity.,,,,C42574,C42574,Unit of Time,integer,Days
2024-12-17,Duration of Sexual Abstinence,C189357,C189357,C25330,Reproductive Findings,SEXABDUR,Quantitative,The length of time during which the individual abstained from sexual activity.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Cesarean Sections,C189358,C189358,C25337,Reproductive Findings,CSRSCTN;Number of C-Sections,Quantitative,The total number of cesarean section delivery events experienced by the individual.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Cesarean Sections,C189358,C189358,C25337,Reproductive Findings,CSRSCTN;Number of C-Sections,Quantitative,The total number of cesarean section delivery events experienced by the individual.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Vaginal Deliveries,C189359,C189359,C25337,Reproductive Findings,VAGDLVN,Quantitative,The total number of vaginal delivery events experienced by the individual.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Vaginal Deliveries,C189359,C189359,C25337,Reproductive Findings,VAGDLVN,Quantitative,The total number of vaginal delivery events experienced by the individual.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Subject Currently Breastfeeding a Child Indicator,C189360,C189360,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,SCBFCIND;Subj Currently Breastfeeding a Child Ind,Ordinal,An indication as to whether the individual is currently breastfeeding a child.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Subject Currently Breastfeeding a Child Indicator,C189360,C189360,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,SCBFCIND;Subj Currently Breastfeeding a Child Ind,Ordinal,An indication as to whether the individual is currently breastfeeding a child.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Thelarche Age,C189361,C189361,C69217,Reproductive Findings;Age,THLARAGE,Quantitative,The age at onset of breast development.,,,,C50400,C50400,Age Unit,integer,Years
2024-12-17,Thelarche Age,C189361,C189361,C69217,Reproductive Findings;Age,THLARAGE,Quantitative,The age at onset of breast development.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Thelarche Age,C189361,C189361,C69217,Reproductive Findings;Age,THLARAGE,Quantitative,The age at onset of breast development.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Adrenarche Age,C189362,C189362,C69217,Reproductive Findings;Age,ADRNRAGE,Quantitative,The age at onset of adrenal androgen-mediated secondary sexual characteristics.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Adrenarche Age,C189362,C189362,C69217,Reproductive Findings;Age,ADRNRAGE,Quantitative,The age at onset of adrenal androgen-mediated secondary sexual characteristics.,,,,C50400,C50400,Age Unit,integer,Years
2024-12-17,Adrenarche Age,C189362,C189362,C69217,Reproductive Findings;Age,ADRNRAGE,Quantitative,The age at onset of adrenal androgen-mediated secondary sexual characteristics.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Breastfeeding Start Date,C189363,C189363,C68616,Reproductive Findings;Start Date,BRFSTDTC,Temporal,The date on which breastfeeding started.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Breastfeeding Start Date,C189363,C189363,C68616,Reproductive Findings;Start Date,BRFSTDTC,Temporal,The date on which breastfeeding started.,,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Breastfeeding End Date,C189364,C189364,C68617,Reproductive Findings;End Date,BRFENDTC,Temporal,The date on which breastfeeding ended.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Breastfeeding End Date,C189364,C189364,C68617,Reproductive Findings;End Date,BRFENDTC,Temporal,The date on which breastfeeding ended.,,,,C70856,C70856,Observation Result,datetime,
2025-04-01,Proton Density Fat Fraction,C189437,C189437,C96648,Findings;Clinical Test Result;Fat Quantification;Liver Findings;Urinary System Findings,Fat Fraction by Proton Density;PDFF;Proton Density Fat Fraction,Quantitative,An estimated measurement of the fat in a targeted tissue through proton density assessments via magnetic resonance imaging.,,,,C82535,C82535,Test Method,string,MRI
2025-04-01,Proton Density Fat Fraction,C189437,C189437,C96648,Findings;Clinical Test Result;Fat Quantification;Liver Findings;Urinary System Findings,Fat Fraction by Proton Density;PDFF;Proton Density Fat Fraction,Quantitative,An estimated measurement of the fat in a targeted tissue through proton density assessments via magnetic resonance imaging.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Proton Density Fat Fraction,C189437,C189437,C96648,Findings;Clinical Test Result;Fat Quantification;Liver Findings;Urinary System Findings,Fat Fraction by Proton Density;PDFF;Proton Density Fat Fraction,Quantitative,An estimated measurement of the fat in a targeted tissue through proton density assessments via magnetic resonance imaging.,,,,C13717,C13717,Anatomic Site,string,Kidney;Bladder;Liver
2025-04-01,Proton Density Fat Fraction,C189437,C189437,C96648,Findings;Clinical Test Result;Fat Quantification;Liver Findings;Urinary System Findings,Fat Fraction by Proton Density;PDFF;Proton Density Fat Fraction,Quantitative,An estimated measurement of the fat in a targeted tissue through proton density assessments via magnetic resonance imaging.,,,,C48570,C48570,Percent Unit,string,Percent
2025-04-01,Proton Density Fat Fraction,C189437,C189437,C96648,Findings;Clinical Test Result;Fat Quantification;Liver Findings;Urinary System Findings,Fat Fraction by Proton Density;PDFF;Proton Density Fat Fraction,Quantitative,An estimated measurement of the fat in a targeted tissue through proton density assessments via magnetic resonance imaging.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Proton Density Fat Fraction,C189437,C189437,C96648,Findings;Clinical Test Result;Fat Quantification;Liver Findings;Urinary System Findings,Fat Fraction by Proton Density;PDFF;Proton Density Fat Fraction,Quantitative,An estimated measurement of the fat in a targeted tissue through proton density assessments via magnetic resonance imaging.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C43568,C43568,Gene Symbol,string,BRD4;MYO10
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C164528,C164528,Genetic Location,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C164815,C164815,Reference Genome Assembly Version,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C204091,C204091,Genomic Inheritability Type,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C93423,C93423,Reference Result,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C164811,C164811,Genetic Reference Sequence Identifier,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C164813,C164813,Genetic Variation Identifier,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C70713,C70713,Biospecimen Type,string,DNA
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C82535,C82535,Test Method,string,Targeted Genome Sequencing
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Rearrangement Impact Classification;Rearrangement Gene 1;Rearrangement Gene 2;Rearrangement Type;Predicted In-Frame Indicator;Read Depth
2025-04-01,Sequence Rearrangement,C189439,C189439,C17248,Genomic Findings;Genetic Variation,SEQREAR,Quantitative;Nominal,"Any product of a process affecting a nucleic acid sequence that results in the gain, loss, inversion, or translocation of nucleic acid.",,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C164528,C164528,Genetic Location,string,c.52_54;c.52_153
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C117039,C117039,Analysis Method,string,ADME Variant Profile
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C43568,C43568,Gene Symbol,string,HTT
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C70713,C70713,Biospecimen Type,string,gDNA
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C82535,C82535,Test Method,string,Capillary Electrophoresis;Sequencing
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C164815,C164815,Reference Genome Assembly Version,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C204091,C204091,Genomic Inheritability Type,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C93423,C93423,Reference Result,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Number of CAG Repeats;Predicted Number of CAG Repeats;Nucleotide Sequence
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C164533,C164533,Genetic Subregion,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C164811,C164811,Genetic Reference Sequence Identifier,string,LRG_763t1
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C164813,C164813,Genetic Variation Identifier,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C164716,C164716,Chromosome Name,string,
2025-04-01,Variable Number Tandem Repeats Assessment,C189440,C189440,C18302,Genomic Findings;Genetic Variation Analysis,VNTR;Tandem Repeat Variation;Variable Nucleotide Tandem Repeats;Variable Number Tandem Repeats,Quantitative;Nominal,"An assessment of the variations in the number of tandem repeat nucleotide sequences, which are end-to-end adjacent copies of a short (2 to 60 nucleotides) DNA sequence.",,,,C204090,C204090,Copy Identifier,string,1;2
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Predicted Diplotype;Predicted Phenotype;Alelle Type
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C117060,C117060,Sponsor Device Identifier,string,DMET Plus
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C117039,C117039,Analysis Method,string,ADME Variant Profile
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C204092,C204092,Genomic Symbol Entity Type,string,Gene With Protein Product
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C70713,C70713,Biospecimen Type,string,DNA
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C82535,C82535,Test Method,string,Microarray;Sanger Sequencing
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C204090,C204090,Copy Identifier,string,1;2
2025-04-01,Variant Profile Assessment,C189441,C189441,C18302,Genomic Findings;Genetic Variation Analysis,VARPROF;Variant Profile,Nominal,An assessment of the unique pattern of sequence variation of one or more loci associated with a normal or abnormal biological process.,,,,C43568,C43568,Gene Symbol,string,CYP2C19;HLA-A;HLA-B;HLA-C;HLA-DRB1;HLA-DRB1;HLA-DRB3
2025-04-01,Recurrence Risk Score,C190808,C190808,,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures,,,A score that estimates the likelihood that an individual with have a recurrence of a disease.,,,,,,,,
2025-04-01,Alpha Angle of the Hip,C191306,C191306,C110937,Musculoskeletal Finding,ALPHANGL;Alpha Angle,Quantitative,A measurement of the angle between the line from the center of the femoral head to the center of the femoral neck at its narrowest point and the line from the center of the femoral head to a point where the distance from the bone to the center of the head is greater than the radius of the cartilage-covered femoral head.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Alpha Angle of the Hip,C191306,C191306,C110937,Musculoskeletal Finding,ALPHANGL;Alpha Angle,Quantitative,A measurement of the angle between the line from the center of the femoral head to the center of the femoral neck at its narrowest point and the line from the center of the femoral head to a point where the distance from the bone to the center of the head is greater than the radius of the cartilage-covered femoral head.,,,,C82535,C82535,Test Method,string,
2025-04-01,Alpha Angle of the Hip,C191306,C191306,C110937,Musculoskeletal Finding,ALPHANGL;Alpha Angle,Quantitative,A measurement of the angle between the line from the center of the femoral head to the center of the femoral neck at its narrowest point and the line from the center of the femoral head to a point where the distance from the bone to the center of the head is greater than the radius of the cartilage-covered femoral head.,,,,C170500,C170500,Result Anatomical Location,string,Hip
2025-04-01,Alpha Angle of the Hip,C191306,C191306,C110937,Musculoskeletal Finding,ALPHANGL;Alpha Angle,Quantitative,A measurement of the angle between the line from the center of the femoral head to the center of the femoral neck at its narrowest point and the line from the center of the femoral head to a point where the distance from the bone to the center of the head is greater than the radius of the cartilage-covered femoral head.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Alpha Angle of the Hip,C191306,C191306,C110937,Musculoskeletal Finding,ALPHANGL;Alpha Angle,Quantitative,A measurement of the angle between the line from the center of the femoral head to the center of the femoral neck at its narrowest point and the line from the center of the femoral head to a point where the distance from the bone to the center of the head is greater than the radius of the cartilage-covered femoral head.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Alpha Angle of the Hip,C191306,C191306,C110937,Musculoskeletal Finding,ALPHANGL;Alpha Angle,Quantitative,A measurement of the angle between the line from the center of the femoral head to the center of the femoral neck at its narrowest point and the line from the center of the femoral head to a point where the distance from the bone to the center of the head is greater than the radius of the cartilage-covered femoral head.,,,,C68667,C68667,Degree Unit of Plane Angle,string,Degree
2025-04-01,Beta Angle of the Hip,C191307,C191307,C110937,Musculoskeletal Finding,BETAANGL;Beta Angle,Quantitative,A measurement of the angle formed by the cartilaginous roof to the vertical cortex of the ilium.,,,,C68667,C68667,Degree Unit of Plane Angle,string,Degree
2025-04-01,Beta Angle of the Hip,C191307,C191307,C110937,Musculoskeletal Finding,BETAANGL;Beta Angle,Quantitative,A measurement of the angle formed by the cartilaginous roof to the vertical cortex of the ilium.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Beta Angle of the Hip,C191307,C191307,C110937,Musculoskeletal Finding,BETAANGL;Beta Angle,Quantitative,A measurement of the angle formed by the cartilaginous roof to the vertical cortex of the ilium.,,,,C170500,C170500,Result Anatomical Location,string,Hip
2025-04-01,Beta Angle of the Hip,C191307,C191307,C110937,Musculoskeletal Finding,BETAANGL;Beta Angle,Quantitative,A measurement of the angle formed by the cartilaginous roof to the vertical cortex of the ilium.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Beta Angle of the Hip,C191307,C191307,C110937,Musculoskeletal Finding,BETAANGL;Beta Angle,Quantitative,A measurement of the angle formed by the cartilaginous roof to the vertical cortex of the ilium.,,,,C82535,C82535,Test Method,string,
2025-04-01,Beta Angle of the Hip,C191307,C191307,C110937,Musculoskeletal Finding,BETAANGL;Beta Angle,Quantitative,A measurement of the angle formed by the cartilaginous roof to the vertical cortex of the ilium.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Elapsed Time Since Last Menstrual Period,C191351,C191351,C82572,Reproductive Findings,LMPELTM;Elapsed Time Since LMP,Temporal,The interval of time since the individual's last menstrual period.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Elapsed Time Since Last Menstrual Period,C191351,C191351,C82572,Reproductive Findings,LMPELTM;Elapsed Time Since LMP,Temporal,The interval of time since the individual's last menstrual period.,,,,C70856,C70856,Observation Result,duration,
2024-12-17,Elapsed Time Since Last Menstrual Period,C191351,C191351,C82572,Reproductive Findings,LMPELTM;Elapsed Time Since LMP,Temporal,The interval of time since the individual's last menstrual period.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2023-12-12,Pregnant Subject,C191656,C191656,,Subject Disposition;Protocol Disposition Events,Pregnancy,Nominal,An indication that the study subject is pregnant.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Pregnant Subject,C191656,C191656,,Subject Disposition;Protocol Disposition Events,Pregnancy,Nominal,An indication that the study subject is pregnant.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Pregnant Subject,C191656,C191656,,Subject Disposition;Protocol Disposition Events,Pregnancy,Nominal,An indication that the study subject is pregnant.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Pregnant Subject,C191656,C191656,,Subject Disposition;Protocol Disposition Events,Pregnancy,Nominal,An indication that the study subject is pregnant.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Pregnant Subject,C191656,C191656,,Subject Disposition;Protocol Disposition Events,Pregnancy,Nominal,An indication that the study subject is pregnant.,,,,C82977,C82977,Dictionary-derived Term,string,Pregnancy
2025-04-01,Recurrence in Distant Nodes,C192424,C192424,C55073,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C70856,C70856,Observation Result,string,Present;Absent
2025-04-01,Recurrence in Distant Nodes,C192424,C192424,C55073,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C25372,C25372,Category,string,
2025-04-01,Recurrence in Distant Nodes,C192424,C192424,C55073,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Recurrence in Distant Nodes,C192424,C192424,C55073,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrent Disease,Nodal-Distant;Recurrence in Distant Nodes,Ordinal,A recurrence of disease in distant lymph nodes.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Personal Attribute,C19332,C19332,,Musculoskeletal Finding;Personal Attribute,,,The distinguishing qualities or prominent aspects of an individual person.,,,,,,,,
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C117511,C117511,Reported Name of Procedure,string,Diagnostic Ultrasound
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C13717,C13717,Anatomic Site,string,Abdomen;Pelvis;Heart;Breast
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C54215,C54215,Directionality,string,
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C25372,C25372,Category,string,
2025-04-01,Diagnostic Ultrasound,C19337,C19337,C17230,Diagnostic Imaging;Medical Imaging;Diagnostic Procedures;Procedures;Breast Cancer TAUG,Diagnostic Ultrasonography;Diagnosis (US);Ultrasound,Nominal,Use of ultrasound for imaging for diagnostic purposes.,,,,C25692,C25692,Subcategory,string,
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C70856,C70856,Observation Result,string,Present;Absent
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C25372,C25372,Category,string,
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C25692,C25692,Subcategory,string,
2025-04-01,BRCA1 Gene Mutation,C19635,C19635,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA1;BRCA1 Mutation;Breast Cancer 1 Gene Mutation;BROVCA1 Gene Mutation;Mutation of the BRCA1 Gene,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C25372,C25372,Category,string,
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C25692,C25692,Subcategory,string,
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C70713,C70713,Biospecimen Type,string,Blood;Saliva;Tissue
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C70856,C70856,Observation Result,string,Present;Absent
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,BRCA2 Gene Mutation,C19636,C19636,C146692,Oncology Standards;Breast Cancer TAUG;Genetic Testing;Gene Expression Analysis;Molecular Analysis;Genetic Molecular Analysis;Laboratory Procedures,BRCA2;BRCA2 Mutation;Breast Cancer 2 Gene Mutation;BROVCA2 Gene Mutation;Mutation of the BRCA2 Gene;XRCC11 Gene Mutation;BRCC2 Gene Mutation;FANCD1 Gene Mutation,Ordinal,"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Age at Menarche,C19666,C19666,C25150,Reproductive Findings;Age,MENARAGE;Menarche Age,Quantitative,Age of first menstruation.  A risk factor for breast cancer,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Age at Menarche,C19666,C19666,C25150,Reproductive Findings;Age,MENARAGE;Menarche Age,Quantitative,Age of first menstruation.  A risk factor for breast cancer,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Age at Menarche,C19666,C19666,C25150,Reproductive Findings;Age,MENARAGE;Menarche Age,Quantitative,Age of first menstruation.  A risk factor for breast cancer,,,,C50400,C50400,Age Unit,integer,Years
2025-04-01,Molecular Analysis,C19770,C19770,,Laboratory Tests;Laboratory Procedures,Molecular Test;Molecular Procedure;Molecular Assay;Molecular Genetic Analysis,,"A laboratory procedure that involves the study of tissues, cells, and fluids using techniques to analyze biologically active molecules, including nucleic acids, proteins, lipids and carbohydrates, for the identification of processes, characteristics and abnormalities at the molecular level.",,,,,,,,
2024-12-16,Hospitalized at Time of Death Indicator,C198258,C198258,C25180,Death Diagnosis and Details;Indicator,HSDTHIND,Ordinal,An indication as to whether the subject was hospitalized at the time of death.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Hospitalized at Time of Death Indicator,C198258,C198258,C25180,Death Diagnosis and Details;Indicator,HSDTHIND,Ordinal,An indication as to whether the subject was hospitalized at the time of death.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Treponema pallidum DNA Measurement,C198341,C198341,C184647,Laboratory Tests;Microbiology Tests;Immunology Tests,TPADNA;Syphilis DNA,Ordinal,The determination of the amount of Treponema pallidum DNA present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Treponema pallidum DNA Measurement,C198341,C198341,C184647,Laboratory Tests;Microbiology Tests;Immunology Tests,TPADNA;Syphilis DNA,Ordinal,The determination of the amount of Treponema pallidum DNA present in a sample.,,,,C82535,C82535,Test Method,string,Line Probe Assay;Nucleic Acid Amplification (NAA)
2025-04-01,Treponema pallidum DNA Measurement,C198341,C198341,C184647,Laboratory Tests;Microbiology Tests;Immunology Tests,TPADNA;Syphilis DNA,Ordinal,The determination of the amount of Treponema pallidum DNA present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Cerebrospinal Fluid;Body Fluid;Swabbed Material
2025-04-01,Treponema pallidum DNA Measurement,C198341,C198341,C184647,Laboratory Tests;Microbiology Tests;Immunology Tests,TPADNA;Syphilis DNA,Ordinal,The determination of the amount of Treponema pallidum DNA present in a sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Detection
2024-12-17,First Menstrual Period Start Date,C198357,C198357,C68616,Reproductive Findings;Start Date,FMPSTDTC,Temporal,The date of the first day of the first menstrual cycle.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,First Menstrual Period Start Date,C198357,C198357,C68616,Reproductive Findings;Start Date,FMPSTDTC,Temporal,The date of the first day of the first menstrual cycle.,,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Post-Partum Indicator,C198358,C198358,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,PPRTIND,Ordinal,An indication as to whether the subject is in the stages of recovery post pregnancy and birth event.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Post-Partum Indicator,C198358,C198358,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,PPRTIND,Ordinal,An indication as to whether the subject is in the stages of recovery post pregnancy and birth event.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Urinary System Examination,C198401,C198401,C25305,Medical Examination;Urinary System Findings,UREXAM;Urinary System Examination,Narrative,"An observation, assessment or examination of the urinary system.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Urinary System Examination,C198401,C198401,C25305,Medical Examination;Urinary System Findings,UREXAM;Urinary System Examination,Narrative,"An observation, assessment or examination of the urinary system.",,,,C25185,C25185,Laterality,string,Left;Right
2025-04-01,Urinary System Examination,C198401,C198401,C25305,Medical Examination;Urinary System Findings,UREXAM;Urinary System Examination,Narrative,"An observation, assessment or examination of the urinary system.",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,Urinary System Examination,C198401,C198401,C25305,Medical Examination;Urinary System Findings,UREXAM;Urinary System Examination,Narrative,"An observation, assessment or examination of the urinary system.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Urinary System Examination,C198401,C198401,C25305,Medical Examination;Urinary System Findings,UREXAM;Urinary System Examination,Narrative,"An observation, assessment or examination of the urinary system.",,,,C82535,C82535,Test Method,string,X-Ray;CT Scan
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C82535,C82535,Test Method,string,Gene Expression Profiling
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C70856,C70856,Observation Result,string,Low Risk;High Risk;-1.0-+1.0
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C25372,C25372,Category,string,
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C25692,C25692,Subcategory,string,
2025-04-01,MammaPrint Index,C199199,C199199,C190808,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Procedures;Gene Expression Analysis,MammaPrint Index Score;MPI,Quantitative;Nominal,A predictive score for breast cancer reoccurrence based on the expression activity of 70 genes. The results are presented as a score between -1 and 1 with negative scores correlating with low risk of reoccurrence and positive scores correlating with high risk of reoccurrence.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-04-01,Polychromatic Erythrocyte Count,C199683,C199683,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Immature Erythrocytes;Polychromatic Erythrocytes;PCE,Ordinal,The determination of the polychromatic erythrocytes in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Polychromatic Erythrocyte Count,C199683,C199683,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Immature Erythrocytes;Polychromatic Erythrocytes;PCE,Ordinal,The determination of the polychromatic erythrocytes in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Polychromatic Erythrocyte Count,C199683,C199683,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Immature Erythrocytes;Polychromatic Erythrocytes;PCE,Ordinal,The determination of the polychromatic erythrocytes in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2024-12-16,Disease Indication Under Study Contributed to Death Indicator,C199843,C199843,C25180,Death Diagnosis and Details;Indicator,CUSCDIND;Cond Under Study Contrib to Death Ind;Condition Under Study Contributed to Death Indicator,Ordinal,An indication as to whether the disease or condition under study contributed to the cause of death.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Disease Indication Under Study Contributed to Death Indicator,C199843,C199843,C25180,Death Diagnosis and Details;Indicator,CUSCDIND;Cond Under Study Contrib to Death Ind;Condition Under Study Contributed to Death Indicator,Ordinal,An indication as to whether the disease or condition under study contributed to the cause of death.,,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Polychromatic Erythrocytes to Erythrocytes Ratio Measurement,C200008,C200008,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Immature Erythrocytes/Erythrocytes;Polychromatic Erythrocytes/Erythrocytes;Reticulocytes/Erythrocytes;PCERBC,Quantitative,The determination of the ratio of the polychromatic erythrocytes to total erythrocytes in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Polychromatic Erythrocytes to Erythrocytes Ratio Measurement,C200008,C200008,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Immature Erythrocytes/Erythrocytes;Polychromatic Erythrocytes/Erythrocytes;Reticulocytes/Erythrocytes;PCERBC,Quantitative,The determination of the ratio of the polychromatic erythrocytes to total erythrocytes in a sample. The measurement may be expressed as a ratio or percentage.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Polychromatic Erythrocytes to Erythrocytes Ratio Measurement,C200008,C200008,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Immature Erythrocytes/Erythrocytes;Polychromatic Erythrocytes/Erythrocytes;Reticulocytes/Erythrocytes;PCERBC,Quantitative,The determination of the ratio of the polychromatic erythrocytes to total erythrocytes in a sample. The measurement may be expressed as a ratio or percentage.,,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Polychromatic Erythrocytes to Erythrocytes Ratio Measurement,C200008,C200008,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Immature Erythrocytes/Erythrocytes;Polychromatic Erythrocytes/Erythrocytes;Reticulocytes/Erythrocytes;PCERBC,Quantitative,The determination of the ratio of the polychromatic erythrocytes to total erythrocytes in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70713,C70713,Biospecimen Type,string,Blood
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C25372,C25372,Category,string,
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C25692,C25692,Subcategory,string,
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83118,C83118,Medical History Reported Term,string,
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83346,C83346,Medical History Dictionary Derived Term,string,
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83338,C83338,Medical History Event Start Date Time,datetime,
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C82534,C82534,Evaluation Interval,string,During the past year
2023-12-12,Solicited Medical History,C200145,C200145,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;Medical History Collection,Nominal,"Information about an individual's personal medical history that is reported by a healthcare professional, consumer, or patient through an organized data collection system.",,,,C83330,C83330,Medical History Event End Date Time,datetime,
2025-04-01,Soluble Interleukin-6 Receptor Subunit Alpha Measurement,C200249,C200249,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,sIL-6RA Measurement;sIL6RA Measurement;Soluble IL-6RA Measurement;Soluble IL6RA Measurement,Quantitative;Ordinal,The determination of the amount of soluble interleukin 6 receptor subunit alpha present in a sample.,,,,C64571,C64571,Unit of Mass Concentration,string,
2025-04-01,Soluble Interleukin-6 Receptor Subunit Alpha Measurement,C200249,C200249,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,sIL-6RA Measurement;sIL6RA Measurement;Soluble IL-6RA Measurement;Soluble IL6RA Measurement,Quantitative;Ordinal,The determination of the amount of soluble interleukin 6 receptor subunit alpha present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum
2025-04-01,Soluble Interleukin-6 Receptor Subunit Alpha Measurement,C200249,C200249,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,sIL-6RA Measurement;sIL6RA Measurement;Soluble IL-6RA Measurement;Soluble IL6RA Measurement,Quantitative;Ordinal,The determination of the amount of soluble interleukin 6 receptor subunit alpha present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Microcyte to Erythrocyte Ratio Measurement,C201227,C201227,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Microcyte/Erythrocyte;MICRORBC,Quantitative,The determination of the ratio of microcytes compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,74761-8,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Microcyte to Erythrocyte Ratio Measurement,C201227,C201227,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Microcyte/Erythrocyte;MICRORBC,Quantitative,The determination of the ratio of microcytes compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,74761-8,C48570,C48570,Percent Unit,string,%
2025-04-01,Microcyte to Erythrocyte Ratio Measurement,C201227,C201227,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Microcyte/Erythrocyte;MICRORBC,Quantitative,The determination of the ratio of microcytes compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,74761-8,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Microcyte to Erythrocyte Ratio Measurement,C201227,C201227,C51946,Laboratory Tests;Hematology Tests;Erythrocyte Counts;Blood Cell Count Ratio Measurements,Microcyte/Erythrocyte;MICRORBC,Quantitative,The determination of the ratio of microcytes compared to erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.,http://loinc.org/,LOINC,74761-8,C70856,C70856,Observation Result,decimal,
2024-12-17,Number of New Male Sexual Partners,C201474,C201474,C181525,Reproductive Findings,SXPRTNMN,Quantitative,The number of new male sexual partners within a specified time interval.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of New Male Sexual Partners,C201474,C201474,C181525,Reproductive Findings,SXPRTNMN,Quantitative,The number of new male sexual partners within a specified time interval.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of New Female Sexual Partners,C201475,C201475,C181525,Reproductive Findings,SXPRTNFN,Quantitative,The number of new female sexual partners within a specified time interval.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of New Female Sexual Partners,C201475,C201475,C181525,Reproductive Findings,SXPRTNFN,Quantitative,The number of new female sexual partners within a specified time interval.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of New Oral Sexual Partners,C201476,C201476,C181525,Reproductive Findings,SXPRTNON,Quantitative,The number of new individuals with whom one has engaged in oral sex within a specified time interval.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of New Oral Sexual Partners,C201476,C201476,C181525,Reproductive Findings,SXPRTNON,Quantitative,The number of new individuals with whom one has engaged in oral sex within a specified time interval.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Male Sexual Partners,C201477,C201477,C181525,Reproductive Findings,SXPRTMN;Total Number of Male Sexual Partners,Quantitative,The number of males with whom one has engaged in sexual activity within a specified time interval.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Male Sexual Partners,C201477,C201477,C181525,Reproductive Findings,SXPRTMN;Total Number of Male Sexual Partners,Quantitative,The number of males with whom one has engaged in sexual activity within a specified time interval.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Female Sexual Partners,C201478,C201478,C181525,Reproductive Findings,SXPRTFN;Total Number of Female Sexual Partners,Quantitative,The number of females with whom one has engaged in sexual activity within a specified time interval.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Number of Female Sexual Partners,C201478,C201478,C181525,Reproductive Findings,SXPRTFN;Total Number of Female Sexual Partners,Quantitative,The number of females with whom one has engaged in sexual activity within a specified time interval.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Oral Sexual Partners,C201479,C201479,C181525,Reproductive Findings,SXPRTON;Total Number of Oral Sexual Partners,Quantitative,The number of individuals with whom one has engaged in oral sexual activity within a specified time interval.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Number of Oral Sexual Partners,C201479,C201479,C181525,Reproductive Findings,SXPRTON;Total Number of Oral Sexual Partners,Quantitative,The number of individuals with whom one has engaged in oral sexual activity within a specified time interval.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Age at First Sexual Intercourse,C201480,C201480,C25150,Reproductive Findings;Age,FSXIAGE,Quantitative,The age at which first sexual intercourse occurred.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Age at First Sexual Intercourse,C201480,C201480,C25150,Reproductive Findings;Age,FSXIAGE,Quantitative,The age at which first sexual intercourse occurred.,,,,C50400,C50400,Age Unit,integer,Years
2024-12-17,Age at First Sexual Intercourse,C201480,C201480,C25150,Reproductive Findings;Age,FSXIAGE,Quantitative,The age at which first sexual intercourse occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Age at First Oral Sex,C201481,C201481,C25150,Reproductive Findings;Age,FSXOAGE,Quantitative,The age at which first oral sex occurred.,,,,C70856,C70856,Observation Result,integer,
2024-12-17,Age at First Oral Sex,C201481,C201481,C25150,Reproductive Findings;Age,FSXOAGE,Quantitative,The age at which first oral sex occurred.,,,,C50400,C50400,Age Unit,integer,Years
2024-12-17,Age at First Oral Sex,C201481,C201481,C25150,Reproductive Findings;Age,FSXOAGE,Quantitative,The age at which first oral sex occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C25372,C25372,Category,string,Caffeine
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83431,C83431,Substance Use Start Date Time,datetime,
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83419,C83419,Substance Use End Date Time,datetime,
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83044,C83044,Substance Use Dose Frequency,string,Daily;Weekly
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83092,C83092,Substance Use Reported Name,string,Coffee;Tea;Cola
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83416,C83416,Substance Use Dose,integer,
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83041,C83041,Substance Use Dose Description,string,
2023-12-12,Caffeine Use History,C201990,C201990,,Substance Use;Personal Medical History;Medical History,Caffeine History;Caffeine Use,Nominal,A description of an individual's current or previous caffeine consumption.,,,,C83038,C83038,Substance Use Dose Unit,string,Glass;Fluid Ounce;Milliliter;Liter
2025-04-01,Micrometastasis Present Indicator,C202140,C202140,C181043,Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results;Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-04-01,Micrometastasis Present Indicator,C202140,C202140,C181043,Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results;Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Micrometastasis Present Indicator,C202140,C202140,C181043,Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results;Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Micrometastasis Present Indicator,C202140,C202140,C181043,Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results;Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Micrometastasis Present Indicator,C202140,C202140,C181043,Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results;Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C25372,C25372,Category,string,
2025-04-01,Micrometastasis Present Indicator,C202140,C202140,C181043,Oncology Standards;Breast Cancer TAUG;Tumor/Lesion Identification;Tumor Results;Morphologic Findings;Metastasis,Micrometastasis Indicator;Micrometastasis Present,Ordinal,An indication of whether micrometastases were present in a sample.,,,,C25692,C25692,Subcategory,string,
2024-12-17,Menarche Indicator,C204694,C204694,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MENARIND,Ordinal,An indication as to whether the individual's first menstruation event has occurred.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Menarche Indicator,C204694,C204694,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,MENARIND,Ordinal,An indication as to whether the individual's first menstruation event has occurred.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Actively Menstruating Indicator,C204695,C204695,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,AMENSIND,Ordinal,An indication as to whether the subject is menstruating at the time the question is asked.,,,,C70856,C70856,Observation Result,string,N;Y;U
2024-12-17,Actively Menstruating Indicator,C204695,C204695,C25180,Reproductive Findings;Clinical Findings Indicator;Indicator,AMENSIND,Ordinal,An indication as to whether the subject is menstruating at the time the question is asked.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Antibody Measurement,C210010,C210010,,Laboratory Tests;Immunology Tests,,,The determination of the amount of antibodies present in a sample.,,,,,,,,
2024-04-02,Gene Expression Process,C21049,C21049,,Biochemical Process,Gene Expression,,"Any subcellular or molecular event or process specifically, primarily, and directly designed for and involved in the production of mature functional biomolecular products encoded by a gene.",,,,,,,,
2024-04-02,Age,C25150,C25150,,Age,,,How long something has existed; elapsed time since birth.,,,,,,,,
2024-04-02,Indicator,C25180,C25180,,Indicator,,,"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.",,,,,,,,
2024-12-16,Weight,C25208,C25208,,Vital Signs,,Quantitative,The vertical force exerted by a mass as a result of gravity.,,,,,,,,
2023-03-31,Intervention or Procedure,C25218,C25218,,Procedures;Interventions,Procedure;Intervention,,"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.",,,,,,,,
2023-12-12,Complete,C25250,C25250,,Subject Disposition;Protocol Disposition Events,Completed;Completion;Completely,Nominal,To possess every necessary or normal part or component or step; having come or been brought to a conclusion.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Complete,C25250,C25250,,Subject Disposition;Protocol Disposition Events,Completed;Completion;Completely,Nominal,To possess every necessary or normal part or component or step; having come or been brought to a conclusion.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Complete,C25250,C25250,,Subject Disposition;Protocol Disposition Events,Completed;Completion;Completely,Nominal,To possess every necessary or normal part or component or step; having come or been brought to a conclusion.,,,,C82977,C82977,Dictionary-derived Term,string,Completed
2023-12-12,Complete,C25250,C25250,,Subject Disposition;Protocol Disposition Events,Completed;Completion;Completely,Nominal,To possess every necessary or normal part or component or step; having come or been brought to a conclusion.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Complete,C25250,C25250,,Subject Disposition;Protocol Disposition Events,Completed;Completion;Completely,Nominal,To possess every necessary or normal part or component or step; having come or been brought to a conclusion.,,,,C82571,C82571,Reported Event Term,string,
2024-04-02,Type,C25284,C25284,,Type,,,Something distinguishable as an identifiable class based on common qualities.,,,,,,,,
2023-07-06,Diameter,C25285,C25285,,Properties;Quantitative Concepts,,,The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference.,,,,,,,,
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C49669,C49669,Unit of Pressure,string,cmHg;mmHG;Pascal
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C70856,C70856,Observation Result,decimal,
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C13717,C13717,Anatomic Site,string,Arm;Forearm;Thigh;Calf;Artery;Vein
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C25185,C25185,Laterality,string,Left;Right
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C62164,C62164,Body Position,string,Decupitus;Fowlers;Lateral Decupitus;Prone;Reverse Trendelenburg;Semi-Fowlers;Semi-Recumbent;Sitting;Sitting Legs Dependent;Sling;Standing;Supine;Trendelenburg;Unconstrained
2024-12-16,Systolic Blood Pressure,C25298,C25298,C54706,Vital Signs,SYSBP,Quantitative,The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.,http://loinc.org/,LOINC,8480-6,C82535,C82535,Test Method,string,Auscultation automatic;Auscaltation manual;Cuff-manual palpated;Doppler;Oscillometry;Arterial line;Venous line;Continuous noninvasive arterial pressure (CNAP)
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C62164,C62164,Body Position,string,Decupitus;Fowlers;Lateral Decupitus;Prone;Reverse Trendelenburg;Semi-Fowlers;Semi-Recumbent;Sitting;Sitting Legs Dependent;Sling;Standing;Supine;Trendelenburg;Unconstrained
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C82535,C82535,Test Method,string,Auscultation automatic;Auscaltation manual;Cuff-manual palpated;Doppler;Oscillometry;Arterial line;Venous line;Continuous noninvasive arterial pressure (CNAP)
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C25185,C25185,Laterality,string,Left;Right
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C70856,C70856,Observation Result,decimal,
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C49669,C49669,Unit of Pressure,string,cmHg;mmHG;Pascal
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Diastolic Blood Pressure,C25299,C25299,C54706,Vital Signs,DIABP,Quantitative,The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.,http://loinc.org/,LOINC,8462-4,C13717,C13717,Anatomic Site,string,Arm;Artery;Calf;Forearm;Thigh;Vein
2025-04-01,Medical Examination,C25305,C25305,,Medical Examination,,,"An appraisal or evaluation of a patient's condition by a clinician that is based on a physical exam, medical history, and the patient's account of symptoms.",,,,,,,,
2024-12-17,Duration,C25330,C25330,,Temporal Qualifier,,,The period of time during which something continues.,,,,,,,,
2025-04-01,Length,C25334,C25334,,Findings;Clinical Test Result;Urinary System Findings,Length;LENGTH,Quantitative,"The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.",,,,C13717,C13717,Anatomic Site,string,
2025-04-01,Length,C25334,C25334,,Findings;Clinical Test Result;Urinary System Findings,Length;LENGTH,Quantitative,"The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Length,C25334,C25334,,Findings;Clinical Test Result;Urinary System Findings,Length;LENGTH,Quantitative,"The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Length,C25334,C25334,,Findings;Clinical Test Result;Urinary System Findings,Length;LENGTH,Quantitative,"The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.",,,,C42578,C42578,Unit of Length,string,mm;cm;in
2025-04-01,Length,C25334,C25334,,Findings;Clinical Test Result;Urinary System Findings,Length;LENGTH,Quantitative,"The linear extent in space from one end of something to the other end, or the extent of something from beginning to end.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Number,C25337,C25337,,Findings,,,"A numeral or string of numerals expressing value, quantity, or identification.",,,,,,,,
2025-04-01,Score,C25338,C25338,,Musculoskeletal Finding;Score,,,"A number or range of numeric values measuring performance, function, quality, or ability.",,,,,,,,
2024-04-02,Location,C25341,C25341,,Location,,,"A position, site, or point in space where something can be found.",,,,,,,,
2024-12-16,Height,C25347,C25347,,Characteristics,,Quantitative,The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension.,,,,,,,,
2024-12-16,Exclusion Criteria,C25370,C25370,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Exclusion,Ordinal,"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.",,,,C25372,C25372,Category,string,Exclusion
2024-12-16,Exclusion Criteria,C25370,C25370,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Exclusion,Ordinal,"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.",,,,C25692,C25692,Subcategory,string,Major;Minor
2024-12-16,Exclusion Criteria,C25370,C25370,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Exclusion,Ordinal,"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.",,,,C181043,C181043,Clinical Findings Indicator,boolean,Y
2024-12-16,Exclusion Criteria,C25370,C25370,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Exclusion,Ordinal,"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Exclusion Criteria,C25370,C25370,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Exclusion,Ordinal,"Medical and/or social characteristics that prevent a subject from being allowed to participate in a clinical study, as outlined in the study protocol.",,,,C83444,C83444,Trial Inclusion Exclusion Criteria Version,string,1;2.2
2023-03-31,Analysis,C25391,C25391,,Analysis,Analytical;Analyzed,,"Examination and interpretation; the process of identifying an issue to be understood and addressed, modelling the issue, investigating the model results, interpreting the results, and possibly making a recommendation. The concept also refers to the examination and study of a whole in terms of the parts composing it.",,,,,,,,
2023-12-12,Inclusion Criteria,C25532,C25532,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Inclusion,Ordinal,"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.",,,,C25372,C25372,Category,string,Inclusion
2023-12-12,Inclusion Criteria,C25532,C25532,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Inclusion,Ordinal,"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.",,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Inclusion Criteria,C25532,C25532,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Inclusion,Ordinal,"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.",,,,C181043,C181043,Clinical Findings Indicator,boolean,Y;N
2023-12-12,Inclusion Criteria,C25532,C25532,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Inclusion,Ordinal,"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.",,,,C25692,C25692,Subcategory,string,Major;Minor
2023-12-12,Inclusion Criteria,C25532,C25532,C16112,Eligibility Criteria;Inclusion Exclusion Criteria,Inclusion,Ordinal,"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.",,,,C83444,C83444,Trial Inclusion Exclusion Criteria Version,string,1;2.2
2024-04-02,Source,C25683,C25683,,Source,,,Where something is available or from where it originates.,,,,,,,,
2025-04-01,Proliferative Index,C28042,C28042,,Oncology Standards;Tumor Results,,,The percentage of cells in a biological specimen that are dividing.,,,,,,,,
2025-04-01,Blood Cell Count,C28133,C28133,C49286,Laboratory Tests,Complete Blood Count;CBC;Full Blood Count;FBC,,"The determination of the number of red blood cells, white blood cells, and platelets in a biospecimen.",,,,,,,,
2025-04-01,Progression-free Survival,C28234,C28234,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Progression-free Survival,C28234,C28234,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C25372,C25372,Category,string,
2025-04-01,Progression-free Survival,C28234,C28234,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Progression-free Survival,C28234,C28234,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C42574,C42574,Unit of Time,string,Days;Weeks;Months;Years
2025-04-01,Progression-free Survival,C28234,C28234,,Oncology Standards;Breast Cancer TAUG;Disease Response;Disease Response Criteria;Survival,PFS,Temporal,The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Sex,C28421,C28421,,Demographic Data;Demographics;Personal Attribute,,Nominal,"An arbitrary categorization of individuals based on the assemblage of physical properties related to reproduction, and commonly associated with the designation of such categories as female and male. This designation is based on a combination of observable information from organ inventories, morphological assessments, hormone assessments, genetic testing, observed primary and secondary sex characteristics, menstrual status, and/or obstetric history. Current sex designation may or may not be the same as an individual's sex assigned or reported at birth. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.",,,,C28421,C28421,Sex,string,Male;Female;Unknown;Undifferentiated
2025-04-01,Sex,C28421,C28421,,Demographic Data;Demographics;Personal Attribute,,Nominal,"An arbitrary categorization of individuals based on the assemblage of physical properties related to reproduction, and commonly associated with the designation of such categories as female and male. This designation is based on a combination of observable information from organ inventories, morphological assessments, hormone assessments, genetic testing, observed primary and secondary sex characteristics, menstrual status, and/or obstetric history. Current sex designation may or may not be the same as an individual's sex assigned or reported at birth. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.",,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Dead,C28554,C28554,,Subject Disposition;Protocol Disposition Events,Expired;Death;Died,Nominal,The cessation of life.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Dead,C28554,C28554,,Subject Disposition;Protocol Disposition Events,Expired;Death;Died,Nominal,The cessation of life.,,,,C82977,C82977,Dictionary-derived Term,string,Death
2023-12-12,Dead,C28554,C28554,,Subject Disposition;Protocol Disposition Events,Expired;Death;Died,Nominal,The cessation of life.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Dead,C28554,C28554,,Subject Disposition;Protocol Disposition Events,Expired;Death;Died,Nominal,The cessation of life.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Dead,C28554,C28554,,Subject Disposition;Protocol Disposition Events,Expired;Death;Died,Nominal,The cessation of life.,,,,C82517,C82517,Observation Start Date Time,datetime,
2025-04-01,Transcription Process,C28614,C28614,C21049,Genomic Findings;Gene Expression Process;Transcription Process,,,A Transcription Process is any cellular event or activity directly involved in the synthesis a nascent RNA transcript.,,,,,,,,
2023-07-06,Clinical Course of Disease,C35461,C35461,,Findings;Clinical Courses,,,"A term that refers to the nature and/or clinical outcome of a disease (e.g., acute or chronic disease, aggressive or indolent disease, recurrent disease, etc.).",,,,,,,,
2024-04-02,Cardiovascular System Finding,C35552,C35552,,Cardiovascular System Finding,,,"Symptoms, physical examination results, and/or laboratory test results related to the cardiovascular system.",,,,,,,,
2025-04-01,Abnormal Blood Chemistry and Hematology Test Result,C35553,C35553,,Laboratory Tests;Abnormal Laboratory Test Results,,,A laboratory test result that indicates the presence of abnormal blood chemistry and/or hematology values.,,,,,,,,
2023-12-12,Progressive Disease,C35571,C35571,,Subject Disposition;Protocol Disposition Events,Disease Progression;PD,Nominal,"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.",,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Progressive Disease,C35571,C35571,,Subject Disposition;Protocol Disposition Events,Disease Progression;PD,Nominal,"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.",,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Progressive Disease,C35571,C35571,,Subject Disposition;Protocol Disposition Events,Disease Progression;PD,Nominal,"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.",,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Progressive Disease,C35571,C35571,,Subject Disposition;Protocol Disposition Events,Disease Progression;PD,Nominal,"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.",,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Progressive Disease,C35571,C35571,,Subject Disposition;Protocol Disposition Events,Disease Progression;PD,Nominal,"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.",,,,C82977,C82977,Dictionary-derived Term,string,Progressive Disease
2025-04-01,Morphologic Finding,C35867,C35867,,Histopathology Findings;Microscopic Findings,,,A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.,,,,,,,,
2025-04-01,Endocrine System Finding,C36285,C36285,,Endocrine Tests;Hormone Measurements,,,"Symptoms, physical examination results, and/or laboratory test results related to the endocrine system.",,,,,,,,
2023-03-31,Finding by Cause,C36291,C36291,,Findings,,,Finding by cause.,,,,,,,,
2025-04-01,Laboratory Test Result,C36292,C36292,,Laboratory Test Result,,,The outcome of a laboratory test.,,,,,,,,
2025-04-01,Total Bilirubin Measurement,C38037,C38037,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Bilirubin;Total Bilirubin Level,Quantitative;Ordinal,"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Total Bilirubin Measurement,C38037,C38037,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Bilirubin;Total Bilirubin Level,Quantitative;Ordinal,"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Total Bilirubin Measurement,C38037,C38037,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Bilirubin;Total Bilirubin Level,Quantitative;Ordinal,"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.",,,,C48207,C48207,Unit of Concentration,string,umol/L;mg/dL;mg/L
2025-04-01,Total Bilirubin Measurement,C38037,C38037,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Bilirubin;Total Bilirubin Level,Quantitative;Ordinal,"The measurement of the total amount of bilirubin present in a particular substrate. The substrate most often tested is blood, but other fluids extracted from the body may be used periodically depending on the purpose of the test.",,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C25372,C25372,Category,string,
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C117512,C117512,Standardized Name of Procedure,string,
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C25692,C25692,Subcategory,string,
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C13717,C13717,Anatomic Site,string,Chest
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C54215,C54215,Directionality,string,Inner;Outer;Anterior;Dorsal
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C117511,C117511,Reported Name of Procedure,string,
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2023-12-12,X-Ray Imaging,C38101,C38101,C16502,Diagnostic Imaging;Medical Imaging,Conventional X-Ray;Medical Imaging;X-Ray;Static X-Ray,Nominal,A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation.,,,,C25185,C25185,Laterality,string,Right;Left;Bilateral
2025-04-01,Recurrent Disease,C38155,C38155,,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C25372,C25372,Category,string,
2025-04-01,Recurrent Disease,C38155,C38155,,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Recurrent Disease,C38155,C38155,,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Recurrent Disease,C38155,C38155,,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence,Recurrence;Disease Relapse,Ordinal,The return of a disease after a period of remission.,,,,C70856,C70856,Observation Result,string,Positive;Negative;Absent Present
2024-12-17,Thickness,C41145,C41145,,Reproductive Findings;Nervous System Findings;Biospecimen Findings;Microscopic Findings;Ophthalmic Findings,THICK,Quantitative,"The dimension between two surfaces of an object, usually the smallest dimension as opposed to the width or the length: also, viscous consistency.",,,,C70856,C70856,Observation Result,decimal,
2024-12-17,Thickness,C41145,C41145,,Reproductive Findings;Nervous System Findings;Biospecimen Findings;Microscopic Findings;Ophthalmic Findings,THICK,Quantitative,"The dimension between two surfaces of an object, usually the smallest dimension as opposed to the width or the length: also, viscous consistency.",,,,C42578,C42578,Unit of Length,decimal,Centimeter;Inch;Millimeter
2024-12-17,Thickness,C41145,C41145,,Reproductive Findings;Nervous System Findings;Biospecimen Findings;Microscopic Findings;Ophthalmic Findings,THICK,Quantitative,"The dimension between two surfaces of an object, usually the smallest dimension as opposed to the width or the length: also, viscous consistency.",,,,C82515,C82515,Collection Date Time,datetime,
2023-12-12,Adverse Event,C41331,C41331,,Subject Disposition;Protocol Disposition Events,,Nominal,"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Adverse Event,C41331,C41331,,Subject Disposition;Protocol Disposition Events,,Nominal,"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Adverse Event,C41331,C41331,,Subject Disposition;Protocol Disposition Events,,Nominal,"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",,,,C82977,C82977,Dictionary-derived Term,string,Adverse Event
2023-12-12,Adverse Event,C41331,C41331,,Subject Disposition;Protocol Disposition Events,,Nominal,"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Adverse Event,C41331,C41331,,Subject Disposition;Protocol Disposition Events,,Nominal,"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).",,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2025-04-01,Nitrosonornicotine,C44414,C44414,C45398,Laboratory Tests;Nitroso Carcinogens;Carcinogenic Nitrosamines,NNN;N-nitrosonornicotine,Quantitative,"A yellow, oily liquid nitrosamine that solidifies at cold temperatures and emits toxic fumes of nitrogen oxides when heated to decomposition. Nitrosonornicotine is found in tobacco products and is likely produced by the nitrosation of nicotine during the making and smoking of tobacco products. This substance is only used in research to induce tumors in experimental animals. Exposure to nitrosonornicotine affects the liver and nitrosonornicotine is reasonably anticipated to be a human carcinogen. (NCI05)",,,,C48207,C48207,Unit of Concentration,string,ng/mL
2025-04-01,Nitrosonornicotine,C44414,C44414,C45398,Laboratory Tests;Nitroso Carcinogens;Carcinogenic Nitrosamines,NNN;N-nitrosonornicotine,Quantitative,"A yellow, oily liquid nitrosamine that solidifies at cold temperatures and emits toxic fumes of nitrogen oxides when heated to decomposition. Nitrosonornicotine is found in tobacco products and is likely produced by the nitrosation of nicotine during the making and smoking of tobacco products. This substance is only used in research to induce tumors in experimental animals. Exposure to nitrosonornicotine affects the liver and nitrosonornicotine is reasonably anticipated to be a human carcinogen. (NCI05)",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Nitrosonornicotine,C44414,C44414,C45398,Laboratory Tests;Nitroso Carcinogens;Carcinogenic Nitrosamines,NNN;N-nitrosonornicotine,Quantitative,"A yellow, oily liquid nitrosamine that solidifies at cold temperatures and emits toxic fumes of nitrogen oxides when heated to decomposition. Nitrosonornicotine is found in tobacco products and is likely produced by the nitrosation of nicotine during the making and smoking of tobacco products. This substance is only used in research to induce tumors in experimental animals. Exposure to nitrosonornicotine affects the liver and nitrosonornicotine is reasonably anticipated to be a human carcinogen. (NCI05)",,,,C70713,C70713,Biospecimen Type,string,Urine
2025-04-01,Carcinogenic Nitrosamine,C45398,C45398,,Laboratory Tests;Nitroso Carcinogens,,,"An organic N-nitroso compound with possible carcinogenic activity characterized by the group -NNO or -NHNO in its structure, formed by combining nitrates with amines. These compounds are found in various foods and many are carcinogenic or are suspected carcinogens. Cured meats can contain nitrosamines because meats contain amines and can react during cooking with sodium nitrite that is added as a preservative. (NCI05)",,,,,,,,
2025-04-01,pH,C45997,C45997,C158424,Laboratory Tests;Urinalysis,PH;potential of Hydrogen,Quantitative;Ordinal,"Quantity of dimension one used to express on a scale from 0 to 14 the amount-of-substance concentration of hydrogen ion of dilute aqueous solution, calculated as the logarithm of the reciprocal of hydrogen-ion concentration in gram atoms per liter.",,,,C70713,C70713,Biospecimen Type,string,Urine;Blood;Saliva;Bronchial Fluid;Body Fluid;Eyes;Skin
2025-04-01,pH,C45997,C45997,C158424,Laboratory Tests;Urinalysis,PH;potential of Hydrogen,Quantitative;Ordinal,"Quantity of dimension one used to express on a scale from 0 to 14 the amount-of-substance concentration of hydrogen ion of dilute aqueous solution, calculated as the logarithm of the reciprocal of hydrogen-ion concentration in gram atoms per liter.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,pH,C45997,C45997,C158424,Laboratory Tests;Urinalysis,PH;potential of Hydrogen,Quantitative;Ordinal,"Quantity of dimension one used to express on a scale from 0 to 14 the amount-of-substance concentration of hydrogen ion of dilute aqueous solution, calculated as the logarithm of the reciprocal of hydrogen-ion concentration in gram atoms per liter.",,,,C70856,C70856,Observation Result,decimal,
2023-12-12,Lack of Efficacy,C48226,C48226,,Subject Disposition;Protocol Disposition Events,Efficacy Lack;Treatment Failure,Nominal,The lack of expected or desired effect related to a therapy.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Lack of Efficacy,C48226,C48226,,Subject Disposition;Protocol Disposition Events,Efficacy Lack;Treatment Failure,Nominal,The lack of expected or desired effect related to a therapy.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Lack of Efficacy,C48226,C48226,,Subject Disposition;Protocol Disposition Events,Efficacy Lack;Treatment Failure,Nominal,The lack of expected or desired effect related to a therapy.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Lack of Efficacy,C48226,C48226,,Subject Disposition;Protocol Disposition Events,Efficacy Lack;Treatment Failure,Nominal,The lack of expected or desired effect related to a therapy.,,,,C82977,C82977,Dictionary-derived Term,string,Lack of Efficacy
2023-12-12,Lack of Efficacy,C48226,C48226,,Subject Disposition;Protocol Disposition Events,Efficacy Lack;Treatment Failure,Nominal,The lack of expected or desired effect related to a therapy.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Lost To Follow-Up,C48227,C48227,,Subject Disposition;Protocol Disposition Events,Lost to Follow-Up,Nominal,The loss or lack of continuation of subject participation after a study has officially closed.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Lost To Follow-Up,C48227,C48227,,Subject Disposition;Protocol Disposition Events,Lost to Follow-Up,Nominal,The loss or lack of continuation of subject participation after a study has officially closed.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Lost To Follow-Up,C48227,C48227,,Subject Disposition;Protocol Disposition Events,Lost to Follow-Up,Nominal,The loss or lack of continuation of subject participation after a study has officially closed.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Lost To Follow-Up,C48227,C48227,,Subject Disposition;Protocol Disposition Events,Lost to Follow-Up,Nominal,The loss or lack of continuation of subject participation after a study has officially closed.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Lost To Follow-Up,C48227,C48227,,Subject Disposition;Protocol Disposition Events,Lost to Follow-Up,Nominal,The loss or lack of continuation of subject participation after a study has officially closed.,,,,C82977,C82977,Dictionary-derived Term,string,Lost To Follow-Up
2023-12-12,Physician Decision,C48250,C48250,,Subject Disposition;Protocol Disposition Events,,Nominal,"A position, opinion or judgment reached after consideration by a physician with reference to subject.",,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Physician Decision,C48250,C48250,,Subject Disposition;Protocol Disposition Events,,Nominal,"A position, opinion or judgment reached after consideration by a physician with reference to subject.",,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Physician Decision,C48250,C48250,,Subject Disposition;Protocol Disposition Events,,Nominal,"A position, opinion or judgment reached after consideration by a physician with reference to subject.",,,,C82977,C82977,Dictionary-derived Term,string,Physician Decision
2023-12-12,Physician Decision,C48250,C48250,,Subject Disposition;Protocol Disposition Events,,Nominal,"A position, opinion or judgment reached after consideration by a physician with reference to subject.",,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Physician Decision,C48250,C48250,,Subject Disposition;Protocol Disposition Events,,Nominal,"A position, opinion or judgment reached after consideration by a physician with reference to subject.",,,,C82517,C82517,Observation Start Date Time,datetime,
2024-12-17,Grade,C48309,C48309,,Grade,,,A position on a scale of intensity or amount or quality.,,,,,,,,
2025-04-01,Breast Carcinoma,C4872,C4872,,Oncology Standards;Breast Cancer TAUG,Cancer of the Breast,,"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.",,,,,,,,
2024-04-02,Symptom,C4876,C4876,,Symptom,,,Subjective evidence of disease perceived by the patient.,,,,,,,,
2025-04-01,Cell Count,C48938,C48938,,Laboratory Tests;Clinical Pathology Procedures,,,A procedure to determine the number of cells in a sample.,,,,,,,,
2025-04-01,Microbiology Test,C49188,C49188,,Microbiology Tests,Laboratory Testing;Microbiology,,A laboratory procedure to detect microorganisms in a sample.,,,,,,,,
2024-12-17,Therapeutic Procedure,C49236,C49236,,Oncology Standards;Therapeutic Procedure;Radiation Therapy,,,"Medical care intended to treat or cure a condition or lessen its symptoms. This includes the administration of drugs, surgical procedures, physical or psychotherapy, or the use of therapeutic devices.",,,,,,,,
2025-04-01,Chemistry Test,C49237,C49237,,Laboratory Tests,Chemistry Measurement;Chemistry Procedure;Chemistry Technique,,A laboratory test designed for the quantification of an organic or inorganic chemical within a biological specimen.,,,,,,,,
2025-04-01,Hematology Test,C49286,C49286,,Laboratory Tests,Blood Test;Hematology Procedure,,A laboratory test to measure hematopoietic components and investigate hematologic disorders in a blood sample.,,,,,,,,
2023-12-12,Trial Screen Failure,C49628,C49628,,Subject Disposition;Protocol Disposition Events,Screen Failure;Failure to Meet Inclusion/Exclusion Criteria,Nominal,The failure of a potential subject of meeting one or more criteria required for participation in a trial.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Trial Screen Failure,C49628,C49628,,Subject Disposition;Protocol Disposition Events,Screen Failure;Failure to Meet Inclusion/Exclusion Criteria,Nominal,The failure of a potential subject of meeting one or more criteria required for participation in a trial.,,,,C82977,C82977,Dictionary-derived Term,string,Screen Failure
2023-12-12,Trial Screen Failure,C49628,C49628,,Subject Disposition;Protocol Disposition Events,Screen Failure;Failure to Meet Inclusion/Exclusion Criteria,Nominal,The failure of a potential subject of meeting one or more criteria required for participation in a trial.,,,,C25692,C25692,Subcategory,string,Study Participation
2023-12-12,Trial Screen Failure,C49628,C49628,,Subject Disposition;Protocol Disposition Events,Screen Failure;Failure to Meet Inclusion/Exclusion Criteria,Nominal,The failure of a potential subject of meeting one or more criteria required for participation in a trial.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Trial Screen Failure,C49628,C49628,,Subject Disposition;Protocol Disposition Events,Screen Failure;Failure to Meet Inclusion/Exclusion Criteria,Nominal,The failure of a potential subject of meeting one or more criteria required for participation in a trial.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Study Terminated By Sponsor,C49632,C49632,,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that a clinical study was stopped by its sponsor.,,,,C82977,C82977,Dictionary-derived Term,string,Study Terminated By Sponsor
2023-12-12,Study Terminated By Sponsor,C49632,C49632,,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that a clinical study was stopped by its sponsor.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Study Terminated By Sponsor,C49632,C49632,,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that a clinical study was stopped by its sponsor.,,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Study Terminated By Sponsor,C49632,C49632,,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that a clinical study was stopped by its sponsor.,,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Study Terminated By Sponsor,C49632,C49632,,Subject Disposition;Protocol Disposition Events,,Nominal,An indication that a clinical study was stopped by its sponsor.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Withdrawal by Subject,C49634,C49634,,Subject Disposition;Protocol Disposition Events,Subject Withdrawal;Dropout;Subject Dropped Out,Nominal,An indication that a study participant has removed themself from the study or from one or more segments of the study.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Withdrawal by Subject,C49634,C49634,,Subject Disposition;Protocol Disposition Events,Subject Withdrawal;Dropout;Subject Dropped Out,Nominal,An indication that a study participant has removed themself from the study or from one or more segments of the study.,,,,C82977,C82977,Dictionary-derived Term,string,Withdrawal By Subject
2023-12-12,Withdrawal by Subject,C49634,C49634,,Subject Disposition;Protocol Disposition Events,Subject Withdrawal;Dropout;Subject Dropped Out,Nominal,An indication that a study participant has removed themself from the study or from one or more segments of the study.,,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Withdrawal by Subject,C49634,C49634,,Subject Disposition;Protocol Disposition Events,Subject Withdrawal;Dropout;Subject Dropped Out,Nominal,An indication that a study participant has removed themself from the study or from one or more segments of the study.,,,,C82571,C82571,Reported Event Term,string,
2023-12-12,Withdrawal by Subject,C49634,C49634,,Subject Disposition;Protocol Disposition Events,Subject Withdrawal;Dropout;Subject Dropped Out,Nominal,An indication that a study participant has removed themself from the study or from one or more segments of the study.,,,,C82517,C82517,Observation Start Date Time,datetime,
2024-12-16,Vital Signs Measurement,C49672,C49672,,Vital Signs,Vital Signs;VS,,"The act of assessing an individual's current temperature, heart rate, respiratory rate, pulse oxygenation, and blood pressure.",,,,,,,,
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C82535,C82535,Test Method,string,Acoustic Monitoring;Auscaltation Manual;Palpation;Oscillometry;Pulse Oximetry;EKG/ECG
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C25185,C25185,Laterality,string,Left;Right
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C13717,C13717,Anatomic Site,string,Wrist;Neck;Temple;Groin;Behind the knees;On top of the foot
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C73688,C73688,Count per Minute,string,Beats per Minute
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C70856,C70856,Observation Result,integer,
2024-12-16,Pulse Rate,C49676,C49676,C49672,Vital Signs,Pulse,Quantitative,"The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomic sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot.",,,,C62164,C62164,Body Position,string,Decupitus;Fowlers;Lateral Decupitus;Prone;Reverse Trendelenburg;Semi-Fowlers;Semi-Recumbent;Sitting;Sitting Legs Dependent;Sling;Standing;Supine;Trendelenburg;Unconstrained
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C70856,C70856,Observation Result,integer,
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C73688,C73688,Count per Minute,string,Beats per Minute
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C13717,C13717,Anatomic Site,string,Wrist;Neck;Temple;Groin;Behind the knees;On top of the foot
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C25185,C25185,Laterality,string,Left;Right
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C82535,C82535,Test Method,string,Acoustic Monitoring;Auscaltation Manual;Palpation;Oscillometry;Pulse Oximetry;EKG/ECG
2024-12-16,Heart Rate,C49677,C49677,C49672,Vital Signs,HR,Quantitative,"The number of heartbeats per unit of time, usually expressed as beats per minute.",http://loinc.org/,LOINC,8867-4,C62164,C62164,Body Position,string,Decupitus;Fowlers;Lateral Decupitus;Prone;Reverse Trendelenburg;Semi-Fowlers;Semi-Recumbent;Sitting;Sitting Legs Dependent;Sling;Standing;Supine;Trendelenburg;Unconstrained
2024-12-16,Respiratory Rate,C49678,C49678,C49672,Vital Signs,RESP;RESPRATE,Quantitative,"The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute.",http://loinc.org/,LOINC,9279-1,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Respiratory Rate,C49678,C49678,C49672,Vital Signs,RESP;RESPRATE,Quantitative,"The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute.",http://loinc.org/,LOINC,9279-1,C73688,C73688,Count per Minute,string,Breaths per Minute
2024-12-16,Respiratory Rate,C49678,C49678,C49672,Vital Signs,RESP;RESPRATE,Quantitative,"The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute.",http://loinc.org/,LOINC,9279-1,C70856,C70856,Observation Result,integer,
2024-12-16,Body Frame Size,C49680,C49680,,Vital Signs,Frame Size,Ordinal,"The categorization of a person's body frame into small, medium and large based on the measurement of wrist circumference or the breadth of the elbow.",,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Disease Response,C50995,C50995,,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS,,,"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.",,,,,,,,
2023-12-12,Protocol Deviation,C50996,C50996,C74590,Subject Disposition;Protocol Disposition Events,Deviation,Nominal,"A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)",,,,C82517,C82517,Observation Start Date Time,datetime,
2023-12-12,Protocol Deviation,C50996,C50996,C74590,Subject Disposition;Protocol Disposition Events,Deviation,Nominal,"A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)",,,,C25692,C25692,Subcategory,string,Study Participation;Study Treatment
2023-12-12,Protocol Deviation,C50996,C50996,C74590,Subject Disposition;Protocol Disposition Events,Deviation,Nominal,"A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)",,,,C25372,C25372,Category,string,Disposition Event
2023-12-12,Protocol Deviation,C50996,C50996,C74590,Subject Disposition;Protocol Disposition Events,Deviation,Nominal,"A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)",,,,C82977,C82977,Dictionary-derived Term,string,Protocol Deviation
2023-12-12,Protocol Deviation,C50996,C50996,C74590,Subject Disposition;Protocol Disposition Events,Deviation,Nominal,"A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)",,,,C82571,C82571,Reported Event Term,string,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C54215,C54215,Directionality,string,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117511,C117511,Reported Name of Procedure,string,Lymph Node Biopsy
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C25372,C25372,Category,string,
2025-04-01,Lymph Node Biopsy,C51900,C51900,C15189,Diagnostic Procedures;Procedures;Biopsies;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Biopsy of Lymph Node,Nominal,A test in which a lymph node or a piece of a lymph node is removed for examination under a microscope for signs of infection or disease such as cancer.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Erythrocyte Count,C51946,C51946,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,RBC;Red Blood Cells,Quantitative,The determination of the number of erythrocytes in a biospecimen.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Stool
2025-04-01,Erythrocyte Count,C51946,C51946,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,RBC;Red Blood Cells,Quantitative,The determination of the number of erythrocytes in a biospecimen.,,,,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Erythrocyte Count,C51946,C51946,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,RBC;Red Blood Cells,Quantitative,The determination of the number of erythrocytes in a biospecimen.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Erythrocyte Count,C51946,C51946,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,RBC;Red Blood Cells,Quantitative,The determination of the number of erythrocytes in a biospecimen.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Leukocyte Count,C51948,C51948,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,WBC;White Blood Cells,Quantitative,A test to determine the number of leukocytes in a biospecimen.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Leukocyte Count,C51948,C51948,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,WBC;White Blood Cells,Quantitative,A test to determine the number of leukocytes in a biospecimen.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Stool
2025-04-01,Leukocyte Count,C51948,C51948,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,WBC;White Blood Cells,Quantitative,A test to determine the number of leukocytes in a biospecimen.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Leukocyte Count,C51948,C51948,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts,WBC;White Blood Cells,Quantitative,A test to determine the number of leukocytes in a biospecimen.,,,,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Lymphocyte Count,C51949,C51949,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Lymphocytes,Quantitative,The determination of the number of lymphocytes in a blood sample.,http://loinc.org/,LOINC,26474-7,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Lymphocyte Count,C51949,C51949,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Lymphocytes,Quantitative,The determination of the number of lymphocytes in a blood sample.,http://loinc.org/,LOINC,26474-7,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Lymphocyte Count,C51949,C51949,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Lymphocytes,Quantitative,The determination of the number of lymphocytes in a blood sample.,http://loinc.org/,LOINC,26474-7,C70856,C70856,Observation Result,decimal,
2025-04-01,Lymphocyte Count,C51949,C51949,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Lymphocytes,Quantitative,The determination of the number of lymphocytes in a blood sample.,http://loinc.org/,LOINC,26474-7,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Neutrophil Count,C51950,C51950,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts,Neutrophils;NEUT,Quantitative;Ordinal,A test to determine the number of neutrophils in a sample of blood.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Body fluid;Bone Marrow;Stool
2025-04-01,Neutrophil Count,C51950,C51950,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts,Neutrophils;NEUT,Quantitative;Ordinal,A test to determine the number of neutrophils in a sample of blood.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Neutrophil Count,C51950,C51950,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts,Neutrophils;NEUT,Quantitative;Ordinal,A test to determine the number of neutrophils in a sample of blood.,,,,C67391,C67391,Unit of Number Concentration,string,10^9/L;/uL
2025-04-01,Neutrophil Count,C51950,C51950,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts,Neutrophils;NEUT,Quantitative;Ordinal,A test to determine the number of neutrophils in a sample of blood.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Platelet Count,C51951,C51951,C28133,Laboratory Tests;Hematology Tests,Thrombocytes;Platelets;Anucleated Thrombocytes,Quantitative,The determination of the number of platelets in a biospecimen.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Platelet Count,C51951,C51951,C28133,Laboratory Tests;Hematology Tests,Thrombocytes;Platelets;Anucleated Thrombocytes,Quantitative,The determination of the number of platelets in a biospecimen.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Platelet Count,C51951,C51951,C28133,Laboratory Tests;Hematology Tests,Thrombocytes;Platelets;Anucleated Thrombocytes,Quantitative,The determination of the number of platelets in a biospecimen.,,,,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Platelet Count,C51951,C51951,C28133,Laboratory Tests;Hematology Tests,Thrombocytes;Platelets;Anucleated Thrombocytes,Quantitative,The determination of the number of platelets in a biospecimen.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma
2025-04-01,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C70856,C70856,Observation Result,integer,0-100
2025-04-01,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C82535,C82535,Test Method,string,RT-PCR
2025-04-01,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-04-01,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Oncotype DX Breast Cancer Assay,C52159,C52159,C18194,Oncology Standards;Breast Cancer TAUG;Diagnostic Tests;Diagnostic Assays;Diagnostic Procedures;Gene Expression Analysis;Assays,Oncotype DX,Quantitative;Narrative,"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.",,,,C25372,C25372,Category,string,
2025-04-01,HER2-Positive Breast Carcinoma,C53556,C53556,,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C25692,C25692,Subcategory,string,
2025-04-01,HER2-Positive Breast Carcinoma,C53556,C53556,,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C25372,C25372,Category,string,
2025-04-01,HER2-Positive Breast Carcinoma,C53556,C53556,,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-04-01,HER2-Positive Breast Carcinoma,C53556,C53556,,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor tissue
2025-04-01,HER2-Positive Breast Carcinoma,C53556,C53556,,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C70856,C70856,Observation Result,boolean,Y;N
2025-04-01,HER2-Positive Breast Carcinoma,C53556,C53556,,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Overexpressing Subtype of Breast Carcinoma;HER2 Overexpressing Breast Carcinoma;HER2 Overexpressing Subtype of Breast Carcinoma,Quantitative;Ordinal,"A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).",,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83120,C83120,Concomitant Medication Route of Administration,string,Intravenous;Oral;Nasogastric;Subcutaneous;Topical
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83235,C83235,Concomitant Medication Use Start Date Time,datetime,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83225,C83225,Concomitant Medication Use End Date Time,datetime,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83042,C83042,Concomitant Medication Dose Frequency,string,BID;PRN;QD;QID;TID
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83034,C83034,Concomitant Medication Dose Unit,string,ng;mg;mg/kg
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83221,C83221,Concomitant Medication Dose,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83085,C83085,Concomitant Medication Use Indication,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83345,C83345,Concomitant Medication Dictionary Derived Term,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C70902,C70902,Concomitant Agent,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C25692,C25692,Subcategory,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C25372,C25372,Category,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83025,C83025,Concomitant Medication Daily Dose,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83219,C83219,Concomitant Medication Class,string,
2024-12-16,Concomitant Therapy,C53630,C53630,C49236,Interventions;Substance Administration;Medication Administration,Concomitant Medication,Nominal,"Any pharmaceutical agent, other than the primary therapy, that is administered to or used by the subject prior to or during a specified time period.",,,,C83110,C83110,Concomitant Medication Dose Form,string,Capsule;Injection;Patch;Solution;Suppository;Tablet
2024-12-16,Blood Pressure,C54706,C54706,C49672,Vital Signs,BP,,The pressure of the circulating blood against the walls of the blood vessels.,http://loinc.org/,LOINC,55284-4,,,,,
2025-04-01,"Recurrent Disease, Distant Site",C55073,C55073,C38155,Oncology Standards;Recurrent Disease;Disease Response,Distant Disease;Distant Recurrence;Relapse Distant Site,,"Recurrence of symptoms of a disease, at a site different and away from the original site.",,,,,,,,
2025-04-01,Assay,C60819,C60819,,Laboratory Tests;Mixed Category Laboratory Procedure;Assay,,,A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties of a drug.,,,,,,,,
2024-12-16,Oxygen Saturation Measurement,C60832,C60832,C18020,Vital Signs;Oxygen Saturation Measurements;Oximetry Tests,SpO2;OXYSAT;O2 Saturation;Hemoglobin Saturation;Oximetry,Quantitative,The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.,https://loinc.org,LOINC,59408-5,C13717,C13717,Anatomic Site,string,Finger;Earlobe;Radial Artery;Brachial Artery;Femeral Artery
2024-12-16,Oxygen Saturation Measurement,C60832,C60832,C18020,Vital Signs;Oxygen Saturation Measurements;Oximetry Tests,SpO2;OXYSAT;O2 Saturation;Hemoglobin Saturation;Oximetry,Quantitative,The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.,https://loinc.org,LOINC,59408-5,C82535,C82535,Test Method,string,Pulse Oximetry;Arterial Blood Gas (ABG) Stick
2024-12-16,Oxygen Saturation Measurement,C60832,C60832,C18020,Vital Signs;Oxygen Saturation Measurements;Oximetry Tests,SpO2;OXYSAT;O2 Saturation;Hemoglobin Saturation;Oximetry,Quantitative,The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.,https://loinc.org,LOINC,59408-5,C48570,C48570,Percent Unit,string,%
2024-12-16,Oxygen Saturation Measurement,C60832,C60832,C18020,Vital Signs;Oxygen Saturation Measurements;Oximetry Tests,SpO2;OXYSAT;O2 Saturation;Hemoglobin Saturation;Oximetry,Quantitative,The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.,https://loinc.org,LOINC,59408-5,C70856,C70856,Observation Result,integer,
2024-12-16,Oxygen Saturation Measurement,C60832,C60832,C18020,Vital Signs;Oxygen Saturation Measurements;Oximetry Tests,SpO2;OXYSAT;O2 Saturation;Hemoglobin Saturation;Oximetry,Quantitative,The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.,https://loinc.org,LOINC,59408-5,C82515,C82515,Collection Date Time,datetime,
2024-12-16,Oxygen Saturation Measurement,C60832,C60832,C18020,Vital Signs;Oxygen Saturation Measurements;Oximetry Tests,SpO2;OXYSAT;O2 Saturation;Hemoglobin Saturation;Oximetry,Quantitative,The measurement of the ratio of oxygenated hemoglobin to total hemoglobin in the blood.,https://loinc.org,LOINC,59408-5,C25185,C25185,Laterality,string,Left;Right
2025-04-01,Bone Mineral Density Test,C61545,C61545,C18020,Musculoskeletal Finding;Diagnostic Procedure,BMD;Bone Mineral Density;Bone Mass;Bone Density,Quantitative,A scanning procedure used to measure calcium and other minerals present in bone.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Bone Mineral Density Test,C61545,C61545,C18020,Musculoskeletal Finding;Diagnostic Procedure,BMD;Bone Mineral Density;Bone Mass;Bone Density,Quantitative,A scanning procedure used to measure calcium and other minerals present in bone.,,,,C42575,C42575,Unit of Mass Density,string,Gram per Square Meter;Gram per Square Centimeter;Kilogram per Liter;Gram per Liter
2025-04-01,Bone Mineral Density Test,C61545,C61545,C18020,Musculoskeletal Finding;Diagnostic Procedure,BMD;Bone Mineral Density;Bone Mass;Bone Density,Quantitative,A scanning procedure used to measure calcium and other minerals present in bone.,,,,C170500,C170500,Result Anatomical Location,string,Cervical Spine;Lumbar Spine
2025-04-01,Bone Mineral Density Test,C61545,C61545,C18020,Musculoskeletal Finding;Diagnostic Procedure,BMD;Bone Mineral Density;Bone Mass;Bone Density,Quantitative,A scanning procedure used to measure calcium and other minerals present in bone.,,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Bone Mineral Density Test,C61545,C61545,C18020,Musculoskeletal Finding;Diagnostic Procedure,BMD;Bone Mineral Density;Bone Mass;Bone Density,Quantitative,A scanning procedure used to measure calcium and other minerals present in bone.,,,,C82535,C82535,Test Method,string,DXA SCAN
2025-04-01,Bone Mineral Density Test,C61545,C61545,C18020,Musculoskeletal Finding;Diagnostic Procedure,BMD;Bone Mineral Density;Bone Mass;Bone Density,Quantitative,A scanning procedure used to measure calcium and other minerals present in bone.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,ECG Measurement,C62085,C62085,,Electrocardiogram Findings,Electrocardiogram Measurement;EKG Measurement,,Measurements or calculations on measurements obtained from electrocardiographic tracings.,,,,,,,,
2025-04-01,Absolute Neutrophil Count,C63321,C63321,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophils;Total Neutrophil Count;NEUT,Quantitative;Ordinal,"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).",,,,C67391,C67391,Unit of Number Concentration,string,10^9/L;/uL
2025-04-01,Absolute Neutrophil Count,C63321,C63321,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophils;Total Neutrophil Count;NEUT,Quantitative;Ordinal,"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).",,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Body fluid
2025-04-01,Absolute Neutrophil Count,C63321,C63321,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophils;Total Neutrophil Count;NEUT,Quantitative;Ordinal,"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Absolute Neutrophil Count,C63321,C63321,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophils;Total Neutrophil Count;NEUT,Quantitative;Ordinal,"The real number of white blood cells (WBC) that are neutrophils. It is derived by multiplying the WBC count by the percent of neutrophils in the differential WBC count. The normal range for ANC is 1.5 to 8.0 (1,500 to 8,000/mm3).",,,,C70856,C70856,Observation Result,string,
2025-04-01,Microsatellite Instability Analysis,C63331,C63331,,Genomic Findings;Molecular Analysis;Microsatellite Instability Analysis,,,A laboratory procedure to detect microsatellite instability.,,,,,,,,
2025-04-01,Gene Expression Analysis,C63479,C63479,,Genomic Findings;Gene Expression Analysis,,,"Procedures that examine how genes are transcribed to produce functional products. These analyses can include the study of factors that influence gene transcription or the determination of the presence, absence or level of expression for one more genes.",,,,,,,,
2023-07-06,Quick Freeze,C63521,C63521,,Biospecimen Events,Flash Freezing;Flash Freeze;Flash Frozen;Quick Frozen;Snap Freeze;Snap Frozen,Nominal,To freeze rapidly so as to preserve structure and prevent ice crystal formation.,,,,C25372,C25372,Category,string,Preparation
2023-07-06,Quick Freeze,C63521,C63521,,Biospecimen Events,Flash Freezing;Flash Freeze;Flash Frozen;Quick Frozen;Snap Freeze;Snap Frozen,Nominal,To freeze rapidly so as to preserve structure and prevent ice crystal formation.,,,,C82977,C82977,Dictionary-derived Term,string,Flash Freezing
2023-07-06,Quick Freeze,C63521,C63521,,Biospecimen Events,Flash Freezing;Flash Freeze;Flash Frozen;Quick Frozen;Snap Freeze;Snap Frozen,Nominal,To freeze rapidly so as to preserve structure and prevent ice crystal formation.,,,,C82571,C82571,Reported Event Term,string,
2023-07-06,Quick Freeze,C63521,C63521,,Biospecimen Events,Flash Freezing;Flash Freeze;Flash Frozen;Quick Frozen;Snap Freeze;Snap Frozen,Nominal,To freeze rapidly so as to preserve structure and prevent ice crystal formation.,,,,C25692,C25692,Subcategory,string,
2023-07-06,Quick Freeze,C63521,C63521,,Biospecimen Events,Flash Freezing;Flash Freeze;Flash Frozen;Quick Frozen;Snap Freeze;Snap Frozen,Nominal,To freeze rapidly so as to preserve structure and prevent ice crystal formation.,,,,C117052,C117052,Accountable Party,string,Site
2023-07-06,Quick Freeze,C63521,C63521,,Biospecimen Events,Flash Freezing;Flash Freeze;Flash Frozen;Quick Frozen;Snap Freeze;Snap Frozen,Nominal,To freeze rapidly so as to preserve structure and prevent ice crystal formation.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor Tissue;Blood
2025-04-01,Protein or Enzyme Type Measurement,C64430,C64430,,Laboratory Tests;Chemistry Tests,,,A term that refers to a chemistry test measuring a specific protein or enzyme in the peripheral blood or body fluid.,,,,,,,,
2025-04-01,Albumin Measurement,C64431,C64431,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Albumin,Quantitative;Ordinal,A quantitative measurement of albumin present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Albumin Measurement,C64431,C64431,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Albumin,Quantitative;Ordinal,A quantitative measurement of albumin present in a sample.,,,,C48207,C48207,Unit of Concentration,string,g/L;g/dL;mg/dL;umol/L
2025-04-01,Albumin Measurement,C64431,C64431,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Albumin,Quantitative;Ordinal,A quantitative measurement of albumin present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Albumin Measurement,C64431,C64431,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Albumin,Quantitative;Ordinal,A quantitative measurement of albumin present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum;Urine
2025-04-01,Alkaline Phosphatase Measurement,C64432,C64432,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Alkaline Phosphatase,Quantitative,A quantitative measurement of alkaline phosphatase present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Alkaline Phosphatase Measurement,C64432,C64432,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Alkaline Phosphatase,Quantitative,A quantitative measurement of alkaline phosphatase present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Alkaline Phosphatase Measurement,C64432,C64432,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Alkaline Phosphatase,Quantitative,A quantitative measurement of alkaline phosphatase present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Alkaline Phosphatase Measurement,C64432,C64432,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,Alkaline Phosphatase,Quantitative,A quantitative measurement of alkaline phosphatase present in a sample.,,,,C67365,C67365,Unit of Catalytic Activity Concentration,string,
2025-04-01,Alanine Aminotransferase Measurement,C64433,C64433,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,ALT;SGPT,Quantitative,A quantitative measurement of alanine aminotransferase present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Alanine Aminotransferase Measurement,C64433,C64433,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,ALT;SGPT,Quantitative,A quantitative measurement of alanine aminotransferase present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Alanine Aminotransferase Measurement,C64433,C64433,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,ALT;SGPT,Quantitative,A quantitative measurement of alanine aminotransferase present in a sample.,,,,C67365,C67365,Unit of Catalytic Activity Concentration,string,
2025-04-01,Alanine Aminotransferase Measurement,C64433,C64433,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,ALT;SGPT,Quantitative,A quantitative measurement of alanine aminotransferase present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Aspartate Aminotransferase Measurement,C64467,C64467,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,AST;SGOT,Quantitative,A quantitative measurement of aspartate aminotransferase present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Aspartate Aminotransferase Measurement,C64467,C64467,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,AST;SGOT,Quantitative,A quantitative measurement of aspartate aminotransferase present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Aspartate Aminotransferase Measurement,C64467,C64467,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,AST;SGOT,Quantitative,A quantitative measurement of aspartate aminotransferase present in a sample.,,,,C67365,C67365,Unit of Catalytic Activity Concentration,string,
2025-04-01,Aspartate Aminotransferase Measurement,C64467,C64467,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests,AST;SGOT,Quantitative,A quantitative measurement of aspartate aminotransferase present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Absolute Basophil Count,C64470,C64470,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Basophils;Total Basophil Count,Quantitative,The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Absolute Basophil Count,C64470,C64470,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Basophils;Total Basophil Count,Quantitative,The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.,,,,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Absolute Basophil Count,C64470,C64470,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Basophils;Total Basophil Count,Quantitative,The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.,,,,C70713,C70713,Biospecimen Type,string,Blood;Body fluid
2025-04-01,Absolute Basophil Count,C64470,C64470,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Basophils;Total Basophil Count,Quantitative,The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Calcium Measurement,C64488,C64488,C49237,Laboratory Tests;Chemistry Tests,Calcium;CA,Quantitative;Ordinal,A quantitative measurement of the amount of calcium present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Calcium Measurement,C64488,C64488,C49237,Laboratory Tests;Chemistry Tests,Calcium;CA,Quantitative;Ordinal,A quantitative measurement of the amount of calcium present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Calcium Measurement,C64488,C64488,C49237,Laboratory Tests;Chemistry Tests,Calcium;CA,Quantitative;Ordinal,A quantitative measurement of the amount of calcium present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;mg/L;mmol/L;mEq/dL;mEq/L
2025-04-01,Calcium Measurement,C64488,C64488,C49237,Laboratory Tests;Chemistry Tests,Calcium;CA,Quantitative;Ordinal,A quantitative measurement of the amount of calcium present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Serum;Plasma;Urine
2025-04-01,Chloride Measurement,C64495,C64495,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Chloride;CL,Quantitative,A quantitative measurement of the amount of chloride present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Chloride Measurement,C64495,C64495,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Chloride;CL,Quantitative,A quantitative measurement of the amount of chloride present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Chloride Measurement,C64495,C64495,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Chloride;CL,Quantitative,A quantitative measurement of the amount of chloride present in a sample.,,,,C64567,C64567,Molarity Unit,string,
2025-04-01,Chloride Measurement,C64495,C64495,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Chloride;CL,Quantitative,A quantitative measurement of the amount of chloride present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Carbon Dioxide Measurement,C64545,C64545,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Dioxide;CO2,Quantitative,A quantitative measurement of the gas carbon dioxide present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Serum;Plasma;Urine
2025-04-01,Carbon Dioxide Measurement,C64545,C64545,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Dioxide;CO2,Quantitative,A quantitative measurement of the gas carbon dioxide present in a sample.,,,,C64567,C64567,Molarity Unit,string,
2025-04-01,Carbon Dioxide Measurement,C64545,C64545,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Dioxide;CO2,Quantitative,A quantitative measurement of the gas carbon dioxide present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Carbon Dioxide Measurement,C64545,C64545,C82624,Laboratory Tests;Chemistry Tests;Gas Measurements,Carbon Dioxide;CO2,Quantitative,A quantitative measurement of the gas carbon dioxide present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Color Assessment,C64546,C64546,,Laboratory Tests;Urinalysis;Urinary System Findings,COLOR;Color,Nominal,A qualitative assessment of the color of a biological specimen.,http://loinc.org/,LOINC,5778-6,C70856,C70856,Observation Result,string,
2025-04-01,Color Assessment,C64546,C64546,,Laboratory Tests;Urinalysis;Urinary System Findings,COLOR;Color,Nominal,A qualitative assessment of the color of a biological specimen.,http://loinc.org/,LOINC,5778-6,C70713,C70713,Biospecimen Type,string,Urine;Sputum;Stool;Body Fluid;Eyes;Skin
2025-04-01,Color Assessment,C64546,C64546,,Laboratory Tests;Urinalysis;Urinary System Findings,COLOR;Color,Nominal,A qualitative assessment of the color of a biological specimen.,http://loinc.org/,LOINC,5778-6,C82535,C82535,Test Method,string,
2025-04-01,Color Assessment,C64546,C64546,,Laboratory Tests;Urinalysis;Urinary System Findings,COLOR;Color,Nominal,A qualitative assessment of the color of a biological specimen.,http://loinc.org/,LOINC,5778-6,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Creatinine Measurement,C64547,C64547,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Creatinine,Quantitative;Nominal,A quantitative measurement of the amount of creatinine present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Creatinine Measurement,C64547,C64547,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Creatinine,Quantitative;Nominal,A quantitative measurement of the amount of creatinine present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Creatinine Measurement,C64547,C64547,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Creatinine,Quantitative;Nominal,A quantitative measurement of the amount of creatinine present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;mg/L;mmol/L;umol/L
2025-04-01,Creatinine Measurement,C64547,C64547,C49237,Laboratory Tests;Chemistry Tests;Renal Function Tests,Creatinine,Quantitative;Nominal,A quantitative measurement of the amount of creatinine present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum;Urine
2025-04-01,C-Reactive Protein Measurement,C64548,C64548,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,CRP;C Reactive Protein,Quantitative;Ordinal,A quantitative measurement of the amount of C-reactive protein present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-04-01,C-Reactive Protein Measurement,C64548,C64548,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,CRP;C Reactive Protein,Quantitative;Ordinal,A quantitative measurement of the amount of C-reactive protein present in a sample.,,,,C48207,C48207,Unit of Concentration,string,
2025-04-01,C-Reactive Protein Measurement,C64548,C64548,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,CRP;C Reactive Protein,Quantitative;Ordinal,A quantitative measurement of the amount of C-reactive protein present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,C-Reactive Protein Measurement,C64548,C64548,C64430,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,CRP;C Reactive Protein,Quantitative;Ordinal,A quantitative measurement of the amount of C-reactive protein present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Eosinophil Count,C64550,C64550,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Eosinophils,Quantitative,The determination of the number of eosinophils in a blood sample.,http://loinc.org/,LOINC,26449-9,C70856,C70856,Observation Result,decimal,
2025-04-01,Eosinophil Count,C64550,C64550,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Eosinophils,Quantitative,The determination of the number of eosinophils in a blood sample.,http://loinc.org/,LOINC,26449-9,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Eosinophil Count,C64550,C64550,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Eosinophils,Quantitative,The determination of the number of eosinophils in a blood sample.,http://loinc.org/,LOINC,26449-9,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Eosinophil Count,C64550,C64550,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Eosinophils,Quantitative,The determination of the number of eosinophils in a blood sample.,http://loinc.org/,LOINC,26449-9,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Hematocrit Measurement,C64796,C64796,C49286,Laboratory Tests;Hematology Tests,Hematocrit;Packed Cell Volume;PCV;Erythrocyte Volume Fraction;EVF,Quantitative,"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Hematocrit Measurement,C64796,C64796,C49286,Laboratory Tests;Hematology Tests,Hematocrit;Packed Cell Volume;PCV;Erythrocyte Volume Fraction;EVF,Quantitative,"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Hematocrit Measurement,C64796,C64796,C49286,Laboratory Tests;Hematology Tests,Hematocrit;Packed Cell Volume;PCV;Erythrocyte Volume Fraction;EVF,Quantitative,"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.",,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Body fluid
2025-04-01,Hematocrit Measurement,C64796,C64796,C49286,Laboratory Tests;Hematology Tests,Hematocrit;Packed Cell Volume;PCV;Erythrocyte Volume Fraction;EVF,Quantitative,"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.",,,,C69174,C69174,Unit of Volume Fraction,string,%
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin,C64797,C64797,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin;MCH,Quantitative,"The mean cell hemoglobin (MCH), which is the average amount of hemoglobin in the average red cell. The MCH is a calculated value derived from the measurement of hemoglobin and the red cell count.",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin,C64797,C64797,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin;MCH,Quantitative,"The mean cell hemoglobin (MCH), which is the average amount of hemoglobin in the average red cell. The MCH is a calculated value derived from the measurement of hemoglobin and the red cell count.",,,,C25709,C25709,Unit of Measure,string,pg;fmol
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin,C64797,C64797,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin;MCH,Quantitative,"The mean cell hemoglobin (MCH), which is the average amount of hemoglobin in the average red cell. The MCH is a calculated value derived from the measurement of hemoglobin and the red cell count.",,,,C70713,C70713,Biospecimen Type,string,Red Blood Cells
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin,C64797,C64797,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin;MCH,Quantitative,"The mean cell hemoglobin (MCH), which is the average amount of hemoglobin in the average red cell. The MCH is a calculated value derived from the measurement of hemoglobin and the red cell count.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin Concentration,C64798,C64798,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin Concentration;MCHC,Quantitative,"The mean cell hemoglobin concentration (MCHC), which is the average concentration of hemoglobin in a given volume of blood. The MCHC is a calculated value derived from the measurement of hemoglobin and the hematocrit.",,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin Concentration,C64798,C64798,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin Concentration;MCHC,Quantitative,"The mean cell hemoglobin concentration (MCHC), which is the average concentration of hemoglobin in a given volume of blood. The MCHC is a calculated value derived from the measurement of hemoglobin and the hematocrit.",,,,C48207,C48207,Unit of Concentration,string,g/dL;mmol/L
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin Concentration,C64798,C64798,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin Concentration;MCHC,Quantitative,"The mean cell hemoglobin concentration (MCHC), which is the average concentration of hemoglobin in a given volume of blood. The MCHC is a calculated value derived from the measurement of hemoglobin and the hematocrit.",,,,C70713,C70713,Biospecimen Type,string,Red Blood Cells
2025-04-01,Erythrocyte Mean Corpuscular Hemoglobin Concentration,C64798,C64798,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Hemoglobin Concentration;MCHC,Quantitative,"The mean cell hemoglobin concentration (MCHC), which is the average concentration of hemoglobin in a given volume of blood. The MCHC is a calculated value derived from the measurement of hemoglobin and the hematocrit.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Erythrocyte Mean Corpuscular Volume,C64799,C64799,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Volume;MCV,Quantitative,The mean cell volume is the average volume of a red blood cell. This is a calculated value derived from the hematocrit and the red cell count.,,,,C44279,C44279,Unit of Volume,string,fL
2025-04-01,Erythrocyte Mean Corpuscular Volume,C64799,C64799,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Volume;MCV,Quantitative,The mean cell volume is the average volume of a red blood cell. This is a calculated value derived from the hematocrit and the red cell count.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Erythrocyte Mean Corpuscular Volume,C64799,C64799,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Volume;MCV,Quantitative,The mean cell volume is the average volume of a red blood cell. This is a calculated value derived from the hematocrit and the red cell count.,,,,C70713,C70713,Biospecimen Type,string,Red Blood Cells
2025-04-01,Erythrocyte Mean Corpuscular Volume,C64799,C64799,C49286,Laboratory Tests;Hematology Tests,RBC Mean Corpuscular Volume;MCV,Quantitative,The mean cell volume is the average volume of a red blood cell. This is a calculated value derived from the hematocrit and the red cell count.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Polychromasia,C64803,C64803,C35553,Laboratory Tests;Hematology Tests;Abnormal Blood Chemistry and Hematology Test Results,POLYCHR,Quantitative;Ordinal,The reaction of red cells to stain as indicated by the appearance of bluish or grayish colored erythrocytes.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Polychromasia,C64803,C64803,C35553,Laboratory Tests;Hematology Tests;Abnormal Blood Chemistry and Hematology Test Results,POLYCHR,Quantitative;Ordinal,The reaction of red cells to stain as indicated by the appearance of bluish or grayish colored erythrocytes.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Polychromasia,C64803,C64803,C35553,Laboratory Tests;Hematology Tests;Abnormal Blood Chemistry and Hematology Test Results,POLYCHR,Quantitative;Ordinal,The reaction of red cells to stain as indicated by the appearance of bluish or grayish colored erythrocytes.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Sodium Measurement,C64809,C64809,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Sodium;NA,Quantitative,A quantitative measurement of the amount of sodium present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Sodium Measurement,C64809,C64809,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Sodium;NA,Quantitative,A quantitative measurement of the amount of sodium present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Sodium Measurement,C64809,C64809,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Sodium;NA,Quantitative,A quantitative measurement of the amount of sodium present in a sample.,,,,C64567,C64567,Molarity Unit,string,
2025-04-01,Sodium Measurement,C64809,C64809,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Sodium;NA,Quantitative,A quantitative measurement of the amount of sodium present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Nitrite Measurement,C64810,C64810,C49237,Laboratory Tests;Chemistry Tests,NITRITE,Quantitative;Ordinal,A quantitative measurement of the amount of nitrite present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Nitrite Measurement,C64810,C64810,C49237,Laboratory Tests;Chemistry Tests,NITRITE,Quantitative;Ordinal,A quantitative measurement of the amount of nitrite present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Nitrite Measurement,C64810,C64810,C49237,Laboratory Tests;Chemistry Tests,NITRITE,Quantitative;Ordinal,A quantitative measurement of the amount of nitrite present in a sample.,,,,C48207,C48207,Unit of Concentration,string,g/dL
2025-04-01,Nitrite Measurement,C64810,C64810,C49237,Laboratory Tests;Chemistry Tests,NITRITE,Quantitative;Ordinal,A quantitative measurement of the amount of nitrite present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Serum;Plasma;Urine;Dialysis Fluid
2025-04-01,Triglyceride Measurement,C64812,C64812,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,TRIG;Triglycerides,Quantitative;Ordinal,A quantitative measurement of the amount of triglyceride present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Triglyceride Measurement,C64812,C64812,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,TRIG;Triglycerides,Quantitative;Ordinal,A quantitative measurement of the amount of triglyceride present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Triglyceride Measurement,C64812,C64812,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,TRIG;Triglycerides,Quantitative;Ordinal,A quantitative measurement of the amount of triglyceride present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum;Blood
2025-04-01,Triglyceride Measurement,C64812,C64812,C74949,Laboratory Tests;Chemistry Tests;Lipid Measurements,TRIG;Triglycerides,Quantitative;Ordinal,A quantitative measurement of the amount of triglyceride present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mmol/L;umol/L;mg/dL;ug/dL
2025-04-01,Thyrotropin Measurement,C64813,C64813,C75385,Laboratory Tests;Protein or Riboprotein Complexes,TSH;Thyrotropin,Quantitative;Ordinal,A quantitative measurement of the amount of thyrotropin present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Thyrotropin Measurement,C64813,C64813,C75385,Laboratory Tests;Protein or Riboprotein Complexes,TSH;Thyrotropin,Quantitative;Ordinal,A quantitative measurement of the amount of thyrotropin present in a sample.,,,,C67365,C67365,Unit of Catalytic Activity Concentration,string,mU/L;mIU/L
2025-04-01,Thyrotropin Measurement,C64813,C64813,C75385,Laboratory Tests;Protein or Riboprotein Complexes,TSH;Thyrotropin,Quantitative;Ordinal,A quantitative measurement of the amount of thyrotropin present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Blood;Saliva
2025-04-01,Thyrotropin Measurement,C64813,C64813,C75385,Laboratory Tests;Protein or Riboprotein Complexes,TSH;Thyrotropin,Quantitative;Ordinal,A quantitative measurement of the amount of thyrotropin present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Urate Measurement,C64814,C64814,C49237,Laboratory Tests;Chemistry Tests,Urate;Uric Acid,Quantitative;Ordinal,A quantitative measurement of the amount of urate present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Urate Measurement,C64814,C64814,C49237,Laboratory Tests;Chemistry Tests,Urate;Uric Acid,Quantitative;Ordinal,A quantitative measurement of the amount of urate present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;mg/L;umol/L;mmol/L
2025-04-01,Urate Measurement,C64814,C64814,C49237,Laboratory Tests;Chemistry Tests,Urate;Uric Acid,Quantitative;Ordinal,A quantitative measurement of the amount of urate present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Urate Measurement,C64814,C64814,C49237,Laboratory Tests;Chemistry Tests,Urate;Uric Acid,Quantitative;Ordinal,A quantitative measurement of the amount of urate present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Urobilinogen Measurement,C64816,C64816,C49237,Laboratory Tests;Chemistry Tests,Urobilinogen;UROBIL,Quantitative;Ordinal,A quantitative measurement of the amount of urobilinogen present in a sample.,,,,C48207,C48207,Unit of Concentration,string,{Ehrlich'U}/dL;mg/dL;umol/L
2025-04-01,Urobilinogen Measurement,C64816,C64816,C49237,Laboratory Tests;Chemistry Tests,Urobilinogen;UROBIL,Quantitative;Ordinal,A quantitative measurement of the amount of urobilinogen present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Urine;Stool;Body Fluid
2025-04-01,Urobilinogen Measurement,C64816,C64816,C49237,Laboratory Tests;Chemistry Tests,Urobilinogen;UROBIL,Quantitative;Ordinal,A quantitative measurement of the amount of urobilinogen present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Urobilinogen Measurement,C64816,C64816,C49237,Laboratory Tests;Chemistry Tests,Urobilinogen;UROBIL,Quantitative;Ordinal,A quantitative measurement of the amount of urobilinogen present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Vitamin B12 Measurement,C64817,C64817,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Cobalamin;Vitamin B12;VITB12,Quantitative;Ordinal,A quantitative measurement of the amount of vitamin B12 present in a sample.,,,,C48207,C48207,Unit of Concentration,string,pmol/L;nmol/L;ng/L;ug/L
2025-04-01,Vitamin B12 Measurement,C64817,C64817,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Cobalamin;Vitamin B12;VITB12,Quantitative;Ordinal,A quantitative measurement of the amount of vitamin B12 present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Blood;Urine;Body Fluid
2025-04-01,Vitamin B12 Measurement,C64817,C64817,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Cobalamin;Vitamin B12;VITB12,Quantitative;Ordinal,A quantitative measurement of the amount of vitamin B12 present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Vitamin B12 Measurement,C64817,C64817,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Cobalamin;Vitamin B12;VITB12,Quantitative;Ordinal,A quantitative measurement of the amount of vitamin B12 present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Macrocyte Count,C64821,C64821,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Macrocytes;MACROCY,Ordinal,The determination of the number of macrocytes in a blood sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Macrocyte Count,C64821,C64821,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Macrocytes;MACROCY,Ordinal,The determination of the number of macrocytes in a blood sample.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-04-01,Macrocyte Count,C64821,C64821,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Macrocytes;MACROCY,Ordinal,The determination of the number of macrocytes in a blood sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine Sediment
2025-04-01,Microcyte Count,C64822,C64822,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Microcytes;MICROCY,Ordinal,The determination of the number of microcytes in a blood sample.,,,,C70856,C70856,Observation Result,string,Absent;Present
2025-04-01,Microcyte Count,C64822,C64822,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Microcytes;MICROCY,Ordinal,The determination of the number of microcytes in a blood sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine;Urine Sediment
2025-04-01,Microcyte Count,C64822,C64822,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Microcytes;MICROCY,Ordinal,The determination of the number of microcytes in a blood sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Monocyte Count,C64823,C64823,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Monocytes,Quantitative,The determination of the number of monocytes in a blood sample.,http://loinc.org/,LOINC,26484-6,C70856,C70856,Observation Result,decimal,
2025-04-01,Monocyte Count,C64823,C64823,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Monocytes,Quantitative,The determination of the number of monocytes in a blood sample.,http://loinc.org/,LOINC,26484-6,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Monocyte Count,C64823,C64823,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Monocytes,Quantitative,The determination of the number of monocytes in a blood sample.,http://loinc.org/,LOINC,26484-6,C67391,C67391,Unit of Number Concentration,string,
2025-04-01,Monocyte Count,C64823,C64823,C51948,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Monocytes,Quantitative,The determination of the number of monocytes in a blood sample.,http://loinc.org/,LOINC,26484-6,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Neutrophil to Leukocyte Ratio Measurement,C64827,C64827,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils/Leukocytes;NEUTLE,Quantitative,The determination of the ratio of neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Neutrophil to Leukocyte Ratio Measurement,C64827,C64827,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils/Leukocytes;NEUTLE,Quantitative,The determination of the ratio of neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Neutrophil to Leukocyte Ratio Measurement,C64827,C64827,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils/Leukocytes;NEUTLE,Quantitative,The determination of the ratio of neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70713,C70713,Biospecimen Type,string,Blood;Body fluid;Bone Marrow
2025-04-01,Neutrophil to Leukocyte Ratio Measurement,C64827,C64827,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils/Leukocytes;NEUTLE,Quantitative,The determination of the ratio of neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Neutrophil Band Form Count,C64830,C64830,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophil Bands;Bands;NEUTB,Quantitative,The determination of the number of band neutrophils in a blood sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Body fluid;Bone Marrow
2025-04-01,Neutrophil Band Form Count,C64830,C64830,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophil Bands;Bands;NEUTB,Quantitative,The determination of the number of band neutrophils in a blood sample.,,,,C67391,C67391,Unit of Number Concentration,string,10^6/L;/uL
2025-04-01,Neutrophil Band Form Count,C64830,C64830,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophil Bands;Bands;NEUTB,Quantitative,The determination of the number of band neutrophils in a blood sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Neutrophil Band Form Count,C64830,C64830,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Neutrophil Bands;Bands;NEUTB,Quantitative,The determination of the number of band neutrophils in a blood sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Neutrophil Band Form to Leukocyte Ratio,C64831,C64831,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils Band Form/Leukocytes;NEUTBLE,Quantitative,The determination of the ratio of band neutrophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.,,,,C70713,C70713,Biospecimen Type,string,Blood;Body fluid;Bone Marrow
2025-04-01,Neutrophil Band Form to Leukocyte Ratio,C64831,C64831,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils Band Form/Leukocytes;NEUTBLE,Quantitative,The determination of the ratio of band neutrophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.,,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Neutrophil Band Form to Leukocyte Ratio,C64831,C64831,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils Band Form/Leukocytes;NEUTBLE,Quantitative,The determination of the ratio of band neutrophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Neutrophil Band Form to Leukocyte Ratio,C64831,C64831,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Neutrophils Band Form/Leukocytes;NEUTBLE,Quantitative,The determination of the ratio of band neutrophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Specific Gravity,C64832,C64832,C60819,Laboratory Tests;Urinalysis;Assay,SPGRAV,Quantitative,The density (mass per unit volume) of any material divided by that of water at a standard temperature.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Specific Gravity,C64832,C64832,C60819,Laboratory Tests;Urinalysis;Assay,SPGRAV,Quantitative,The density (mass per unit volume) of any material divided by that of water at a standard temperature.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Specific Gravity,C64832,C64832,C60819,Laboratory Tests;Urinalysis;Assay,SPGRAV,Quantitative,The density (mass per unit volume) of any material divided by that of water at a standard temperature.,,,,C70713,C70713,Biospecimen Type,string,Urine;Body Fluid;Red Blood Cells
2025-04-01,Gamma Glutamyl Transpeptidase Measurement,C64847,C64847,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests;Protein or Enzyme Type Measurements,Gamma Glutamyl Transferase;GGT;GGTP,Quantitative,A quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Gamma Glutamyl Transpeptidase Measurement,C64847,C64847,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests;Protein or Enzyme Type Measurements,Gamma Glutamyl Transferase;GGT;GGTP,Quantitative,A quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Gamma Glutamyl Transpeptidase Measurement,C64847,C64847,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests;Protein or Enzyme Type Measurements,Gamma Glutamyl Transferase;GGT;GGTP,Quantitative,A quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample.,,,,C67365,C67365,Unit of Catalytic Activity Concentration,string,U/L;IU/L;nkat/L;ukat/L
2025-04-01,Gamma Glutamyl Transpeptidase Measurement,C64847,C64847,C74954,Laboratory Tests;Chemistry Tests;Liver Function Tests;Protein or Enzyme Type Measurements,Gamma Glutamyl Transferase;GGT;GGTP,Quantitative,A quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Urine;Body Fluid
2025-04-01,Hemoglobin Measurement,C64848,C64848,C49286,Laboratory Tests;Hematology Tests,Hemoglobin;HGB,Quantitative,A quantitative measurement of the amount of hemoglobin present in a biospecimen.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine
2025-04-01,Hemoglobin Measurement,C64848,C64848,C49286,Laboratory Tests;Hematology Tests,Hemoglobin;HGB,Quantitative,A quantitative measurement of the amount of hemoglobin present in a biospecimen.,,,,C64571,C64571,Unit of Mass Concentration,string,
2025-04-01,Hemoglobin Measurement,C64848,C64848,C49286,Laboratory Tests;Hematology Tests,Hemoglobin;HGB,Quantitative,A quantitative measurement of the amount of hemoglobin present in a biospecimen.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Hemoglobin Measurement,C64848,C64848,C49286,Laboratory Tests;Hematology Tests,Hemoglobin;HGB,Quantitative,A quantitative measurement of the amount of hemoglobin present in a biospecimen.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Hemoglobin Measurement,C64848,C64848,C49286,Laboratory Tests;Hematology Tests,Hemoglobin;HGB,Quantitative,A quantitative measurement of the amount of hemoglobin present in a biospecimen.,,,,C82535,C82535,Test Method,string,Test Strip;Dipstick
2025-04-01,Hemoglobin A1C Measurement,C64849,C64849,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C;HBA1C;Glycosylated Hemoglobin A1C,Quantitative,The determination of the amount of hemoglobin A1C present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Hemoglobin A1C Measurement,C64849,C64849,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C;HBA1C;Glycosylated Hemoglobin A1C,Quantitative,The determination of the amount of hemoglobin A1C present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Hemoglobin A1C Measurement,C64849,C64849,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C;HBA1C;Glycosylated Hemoglobin A1C,Quantitative,The determination of the amount of hemoglobin A1C present in a sample.,,,,C64571,C64571,Unit of Mass Concentration,string,g/dL
2025-04-01,Hemoglobin A1C Measurement,C64849,C64849,C64848,Laboratory Tests;Hematology Tests;Hemoglobin Measurements,Hemoglobin A1C;HBA1C;Glycosylated Hemoglobin A1C,Quantitative,The determination of the amount of hemoglobin A1C present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Choriogonadotropin Beta Measurement,C64851,C64851,C147128,Laboratory Tests;Chemistry Tests;Hormone Measurements;Choriogonadotropin Measurements;HCG Measurements,beta-hCG;Choriogonadotropin Beta;Pregnancy Test;HCG,Ordinal,A determination of the presence of Choriogonadotropin Beta protein.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Choriogonadotropin Beta Measurement,C64851,C64851,C147128,Laboratory Tests;Chemistry Tests;Hormone Measurements;Choriogonadotropin Measurements;HCG Measurements,beta-hCG;Choriogonadotropin Beta;Pregnancy Test;HCG,Ordinal,A determination of the presence of Choriogonadotropin Beta protein.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Urine
2025-04-01,Potassium Measurement,C64853,C64853,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Potassium;K,Quantitative,A quantitative measurement of the amount of potassium present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Potassium Measurement,C64853,C64853,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Potassium;K,Quantitative,A quantitative measurement of the amount of potassium present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Potassium Measurement,C64853,C64853,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Potassium;K,Quantitative,A quantitative measurement of the amount of potassium present in a sample.,,,,C64567,C64567,Molarity Unit,string,
2025-04-01,Potassium Measurement,C64853,C64853,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Potassium;K,Quantitative,A quantitative measurement of the amount of potassium present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Ketone Measurement,C64854,C64854,C49237,Laboratory Tests;Chemistry Tests,Ketones,Quantitative;Ordinal,A quantitative measurement of the amount of ketones present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Ketone Measurement,C64854,C64854,C49237,Laboratory Tests;Chemistry Tests,Ketones,Quantitative;Ordinal,A quantitative measurement of the amount of ketones present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;mmol/L
2025-04-01,Ketone Measurement,C64854,C64854,C49237,Laboratory Tests;Chemistry Tests,Ketones,Quantitative;Ordinal,A quantitative measurement of the amount of ketones present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Serum;Plasma;Urine;Vitreous Fluid
2025-04-01,Ketone Measurement,C64854,C64854,C49237,Laboratory Tests;Chemistry Tests,Ketones,Quantitative;Ordinal,A quantitative measurement of the amount of ketones present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Lactate Dehydrogenase Measurement,C64855,C64855,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Lactate Dehydrogenase;LDH,Quantitative,A quantitative measurement of the amount of lactate dehydrogenase present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Lactate Dehydrogenase Measurement,C64855,C64855,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Lactate Dehydrogenase;LDH,Quantitative,A quantitative measurement of the amount of lactate dehydrogenase present in a sample.,,,,C67365,C67365,Unit of Catalytic Activity Concentration,string,U/L;ukat/L;IU/L
2025-04-01,Lactate Dehydrogenase Measurement,C64855,C64855,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Lactate Dehydrogenase;LDH,Quantitative,A quantitative measurement of the amount of lactate dehydrogenase present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Lactate Dehydrogenase Measurement,C64855,C64855,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Lactate Dehydrogenase;LDH,Quantitative,A quantitative measurement of the amount of lactate dehydrogenase present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Phosphate Measurement,C64857,C64857,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Phosphorus;Phosphate,Quantitative;Ordinal,A quantitative measurement of the amount of phosphate present in a sample.,,,,C48207,C48207,Unit of Concentration,string,mg/dL;mg/L;umol/L;mmol/L
2025-04-01,Phosphate Measurement,C64857,C64857,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Phosphorus;Phosphate,Quantitative;Ordinal,A quantitative measurement of the amount of phosphate present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Plasma;Serum;Urine
2025-04-01,Phosphate Measurement,C64857,C64857,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Phosphorus;Phosphate,Quantitative;Ordinal,A quantitative measurement of the amount of phosphate present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Phosphate Measurement,C64857,C64857,C74946,Laboratory Tests;Chemistry Tests;Electrolyte Measurements,Phosphorus;Phosphate,Quantitative;Ordinal,A quantitative measurement of the amount of phosphate present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Total Protein Measurement,C64858,C64858,C49237,Laboratory Tests;Chemistry Tests;Protein Measurements,Protein,Quantitative;Ordinal;Nominal,A quantitative measurement of the amount of total protein present in a sample.,,,,C64571,C64571,Unit of Mass Concentration,string,
2025-04-01,Total Protein Measurement,C64858,C64858,C49237,Laboratory Tests;Chemistry Tests;Protein Measurements,Protein,Quantitative;Ordinal;Nominal,A quantitative measurement of the amount of total protein present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Plasma;Serum;Urine;Body Fluid
2025-04-01,Total Protein Measurement,C64858,C64858,C49237,Laboratory Tests;Chemistry Tests;Protein Measurements,Protein,Quantitative;Ordinal;Nominal,A quantitative measurement of the amount of total protein present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Total Protein Measurement,C64858,C64858,C49237,Laboratory Tests;Chemistry Tests;Protein Measurements,Protein,Quantitative;Ordinal;Nominal,A quantitative measurement of the amount of total protein present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Blood Cell Count Ratio Measurement,C67208,C67208,C28133,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,,,The determination of the ratio of one blood cell component to another in a blood sample. The measurement may be expressed as either a ratio or a percentage.,,,,,,,,
2024-12-17,Start Date,C68616,C68616,,Date,Starting Date,Temporal,The calendar date on which something is to start or did start.,,,,,,,,
2024-12-17,End Date,C68617,C68617,,Date,Stopping Date,Temporal,The calendar date on which something is to terminate or did terminate.,,,,,,,,
2025-04-01,Z-Score,C68741,C68741,,Musculoskeletal Finding;Z-Score,,,"A method for converting an individual score into a standard form. The z-score indicates how far and in what direction an item deviates from its distribution's mean, expressed in units of standard deviation. Calculation of a z-score requires knowledge about the population's standard deviation and mean.",,,,,,,,
2025-04-01,HER2/Neu Positive,C68748,C68748,C16152,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C70856,C70856,Observation Result,boolean,Y;N
2025-04-01,HER2/Neu Positive,C68748,C68748,C16152,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,HER2/Neu Positive,C68748,C68748,C16152,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C25372,C25372,Category,string,
2025-04-01,HER2/Neu Positive,C68748,C68748,C16152,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,HER2/Neu Positive,C68748,C68748,C16152,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C70713,C70713,Biospecimen Type,string,Tissue
2025-04-01,HER2/Neu Positive,C68748,C68748,C16152,Oncology Standards;Genetic Testing;Gene Expression Analysis;Gene Products;Genetic Variation;Genetic Variation Analysis;Cancer Biomarkers;Breast Cancer TAUG,ERBB2 Positive;HER-2 Positive;HER2 Positive,Quantitative;Ordinal,A laboratory test result indicating the presence of HER2/Neu in a tissue sample.,,,,C25692,C25692,Subcategory,string,
2024-12-17,Age Started,C69217,C69217,,Age,Age at Onset,Quantitative,The age of a person at the start of a specific event.,,,,,,,,
2025-04-01,Subject Age,C69260,C69260,C25150,Demographic Data;Demographics;Personal Attribute;Age,Age,Quantitative,The age of a person who is the subject in a study.,,,,C50400,C50400,Age Unit,string,Years;Months;Weeks;Days
2025-04-01,Subject Age,C69260,C69260,C25150,Demographic Data;Demographics;Personal Attribute;Age,Age,Quantitative,The age of a person who is the subject in a study.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Subject Age,C69260,C69260,C25150,Demographic Data;Demographics;Personal Attribute;Age,Age,Quantitative,The age of a person who is the subject in a study.,,,,C170981,C170981,Numeric Age for Data Tabulation,decimal,
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C82571,C82571,Reported Event Term,string,
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C25372,C25372,Category,string,Collection
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor Tisue
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C117052,C117052,Accountable Party,string,Site
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C171435,C171435,Sample Anatomic Site,string,Brain;Lung
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C25692,C25692,Subcategory,string,
2023-07-06,Biospecimen Collection,C70945,C70945,,Biospecimen Events,Collecting;Collected;Sample Collection,Nominal,"The act or process of gathering biospecimens for testing, diagnostic, propagation, treatment or research purposes.",,,,C82977,C82977,Dictionary-derived Term,string,Collecting
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C117062,C117062,"Measurement, Test or Examination Detail",string,Overall Status
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C70713,C70713,Biospecimen Type,string,Tissue;Tumor tissue
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C171435,C171435,Specimen Anatomic Site,string,Breast
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C25372,C25372,Category,string,
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Triple-Negative Breast Cancer Finding,C71428,C71428,C94299,Oncology Standards;Breast Cancer TAUG;Receptor Status,ER-Negative PR-Negative ERBB2-Negative;ER-negative PR-negative HER2/neu-negative;ER/PR/HER2 Negative;ESR1/PGR/ERBB2 Negative Finding;TNBC;Triple Negative Breast Cancer Result,Ordinal,Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.,,,,C70856,C70856,Observation Result,string,Positive;Negative
2024-12-17,Method,C71460,C71460,,Means,,,"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.",,,,,,,,
2024-12-17,Gravida,C73435,C73435,C19332,Reproductive Findings,GRAVIND;PREGNANT;Gravida Indicator,Ordinal,"A woman who currently is pregnant or has been in the past, irrespective of the pregnancy outcome.",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Gravida,C73435,C73435,C19332,Reproductive Findings,GRAVIND;PREGNANT;Gravida Indicator,Ordinal,"A woman who currently is pregnant or has been in the past, irrespective of the pregnancy outcome.",,,,C70856,C70856,Observation Result,string,N;Y;U
2025-04-01,Serum HCG Measurement,C73495,C73495,C147128,Laboratory Tests;Chemistry Tests;Hormone Measurements;Choriogonadotropin Measurements;HCG Measurements,Serum Pregnancy Test;Serum Human Chorionic Gonadotropin;Serum HCG,Quantitative,A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum.,,,,C48207,C48207,Unit of Concentration,string,pmol/L;mmol/L;Arbitrary U/mL;IU/L;mIU/mL
2025-04-01,Serum HCG Measurement,C73495,C73495,C147128,Laboratory Tests;Chemistry Tests;Hormone Measurements;Choriogonadotropin Measurements;HCG Measurements,Serum Pregnancy Test;Serum Human Chorionic Gonadotropin;Serum HCG,Quantitative,A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Urine;Body fluid
2025-04-01,Serum HCG Measurement,C73495,C73495,C147128,Laboratory Tests;Chemistry Tests;Hormone Measurements;Choriogonadotropin Measurements;HCG Measurements,Serum Pregnancy Test;Serum Human Chorionic Gonadotropin;Serum HCG,Quantitative,A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum.,,,,C70856,C70856,Observation Result,decimal,
2023-03-31,Protocol Milestone,C74588,C74588,,Subject Disposition;Protocol Milestones,,,"Occurrences within some epochs that are initiated by a protocol-specified event. The most common protocol milestone is ""Informed Consent Obtained"" which usually documents the start of the study.",,,,,,,,
2023-03-31,Protocol Disposition Event,C74590,C74590,,Subject Disposition;Protocol Disposition Events,Disposition Event,,The group of incidents that occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur. The subject's disposition is often described for each phase of the study.,,,,,,,,
2025-04-01,Bicarbonate Measurement,C74667,C74667,C49237,Laboratory Tests;Chemistry Tests,Bicarbonate;HCO3,Quantitative,The determination of the amount of bicarbonate present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Bicarbonate Measurement,C74667,C74667,C49237,Laboratory Tests;Chemistry Tests,Bicarbonate;HCO3,Quantitative,The determination of the amount of bicarbonate present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Bicarbonate Measurement,C74667,C74667,C49237,Laboratory Tests;Chemistry Tests,Bicarbonate;HCO3,Quantitative,The determination of the amount of bicarbonate present in a sample.,,,,C64567,C64567,Molarity Unit,string,
2025-04-01,Bicarbonate Measurement,C74667,C74667,C49237,Laboratory Tests;Chemistry Tests,Bicarbonate;HCO3,Quantitative,The determination of the amount of bicarbonate present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Urine
2025-04-01,Drug Class Measurement,C74675,C74675,C49237,Laboratory Tests;Chemistry Tests,,,The determination of the levels of all members of a specific drug class present in a sample.,,,,,,,,
2025-04-01,Folic Acid Measurement,C74676,C74676,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Folate;Folic Acid;Vitamin B9;VITB9,Quantitative;Ordinal,The determination of the amount of folic acid present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Blood;Red Blood Cells;Body Fluid
2025-04-01,Folic Acid Measurement,C74676,C74676,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Folate;Folic Acid;Vitamin B9;VITB9,Quantitative;Ordinal,The determination of the amount of folic acid present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Folic Acid Measurement,C74676,C74676,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Folate;Folic Acid;Vitamin B9;VITB9,Quantitative;Ordinal,The determination of the amount of folic acid present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Folic Acid Measurement,C74676,C74676,C74803,Laboratory Tests;Chemistry Tests;Vitamin Measurements,Folate;Folic Acid;Vitamin B9;VITB9,Quantitative;Ordinal,The determination of the amount of folic acid present in a sample.,,,,C48207,C48207,Unit of Concentration,string,nmol/L;ng/mL;ug/L
2025-04-01,Occult Blood Measurement,C74686,C74686,C49237,Laboratory Tests;Chemistry Tests,Occult Blood;OCCBLD,Ordinal,"A measurement of the blood in body products such as a urine or stool sample, not detectable on gross examination.",,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Occult Blood Measurement,C74686,C74686,C49237,Laboratory Tests;Chemistry Tests,Occult Blood;OCCBLD,Ordinal,"A measurement of the blood in body products such as a urine or stool sample, not detectable on gross examination.",,,,C48207,C48207,Unit of Concentration,string,
2025-04-01,Occult Blood Measurement,C74686,C74686,C49237,Laboratory Tests;Chemistry Tests,Occult Blood;OCCBLD,Ordinal,"A measurement of the blood in body products such as a urine or stool sample, not detectable on gross examination.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Occult Blood Measurement,C74686,C74686,C49237,Laboratory Tests;Chemistry Tests,Occult Blood;OCCBLD,Ordinal,"A measurement of the blood in body products such as a urine or stool sample, not detectable on gross examination.",,,,C70713,C70713,Biospecimen Type,string,Stool;Gastric Fluid
2025-04-01,Ferritin Measurement,C74737,C74737,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Ferritin,Quantitative;Nominal,The determination of the amount of ferritin present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Serum;Plasma;Body Fluid
2025-04-01,Ferritin Measurement,C74737,C74737,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Ferritin,Quantitative;Nominal,The determination of the amount of ferritin present in a sample.,,,,C48207,C48207,Unit of Concentration,string,ug/L;ng/mL;pmol/L
2025-04-01,Ferritin Measurement,C74737,C74737,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Ferritin,Quantitative;Nominal,The determination of the amount of ferritin present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Ferritin Measurement,C74737,C74737,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements,Ferritin,Quantitative;Nominal,The determination of the amount of ferritin present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Hormone Measurement,C74742,C74742,,Laboratory Tests;Chemistry Tests;Endocrine Tests,,,The determination of the amount of hormone present in a sample.,,,,,,,,
2025-04-01,Triiodothyronine Measurement,C74747,C74747,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3;Total T3,Quantitative,The determination of the amount of free and bound triiodothyronine present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Triiodothyronine Measurement,C74747,C74747,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3;Total T3,Quantitative,The determination of the amount of free and bound triiodothyronine present in a sample.,,,,C48207,C48207,Unit of Concentration,string,ng/dL;ng/L;ug/L;nmol/L
2025-04-01,Triiodothyronine Measurement,C74747,C74747,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3;Total T3,Quantitative,The determination of the amount of free and bound triiodothyronine present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-04-01,Triiodothyronine Measurement,C74747,C74747,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3;Total T3,Quantitative,The determination of the amount of free and bound triiodothyronine present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Triiodothyronine Uptake Measurement,C74748,C74748,C74747,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3UP;T3U;Triiodothyronine Resin Uptake,Quantitative,The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Triiodothyronine Uptake Measurement,C74748,C74748,C74747,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3UP;T3U;Triiodothyronine Resin Uptake,Quantitative,The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Triiodothyronine Uptake Measurement,C74748,C74748,C74747,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3UP;T3U;Triiodothyronine Resin Uptake,Quantitative,The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample.,,,,C48570,C48570,Percent Unit,string,%
2025-04-01,Triiodothyronine Uptake Measurement,C74748,C74748,C74747,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,T3UP;T3U;Triiodothyronine Resin Uptake,Quantitative,The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-04-01,Free Thyroxine Measurement,C74786,C74786,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,Free T4;T4FR,Quantitative,The determination of the amount of free thyroxine present in a sample.,,,,C48207,C48207,Unit of Concentration,string,ng/dL;ng/L;pmol/L
2025-04-01,Free Thyroxine Measurement,C74786,C74786,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,Free T4;T4FR,Quantitative,The determination of the amount of free thyroxine present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Free Thyroxine Measurement,C74786,C74786,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,Free T4;T4FR,Quantitative,The determination of the amount of free thyroxine present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma
2025-04-01,Free Thyroxine Measurement,C74786,C74786,C74742,Laboratory Tests;Chemistry Tests;Endocrine Tests;Hormone Measurements,Free T4;T4FR,Quantitative,The determination of the amount of free thyroxine present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Anisocyte Measurement,C74797,C74797,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Anisocytes;Anisocytosis;ANISO,Ordinal,The determination of the number of anisocytes present in a sample.,http://loinc.org/,LOINC,38892-6,C70856,C70856,Observation Result,string,Absent;Present
2025-04-01,Anisocyte Measurement,C74797,C74797,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Anisocytes;Anisocytosis;ANISO,Ordinal,The determination of the number of anisocytes present in a sample.,http://loinc.org/,LOINC,38892-6,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Anisocyte Measurement,C74797,C74797,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,Anisocytes;Anisocytosis;ANISO,Ordinal,The determination of the number of anisocytes present in a sample.,http://loinc.org/,LOINC,38892-6,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Vitamin Measurement,C74803,C74803,C49237,Laboratory Tests;Chemistry Tests,,,The determination of the type and amount of vitamins in a sample.,,,,,,,,
2025-04-01,Cytokine Measurement,C74804,C74804,,Laboratory Tests;Chemistry Tests,,,The determination of type and amount of cytokines in a sample.,,,,,,,,
2025-04-01,Interleukin 6 Measurement,C74834,C74834,C74804,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,INTLK6;Interleukin 6,Quantitative;Ordinal,The determination of the amount of interleukin 6 present in a sample.,,,,C64571,C64571,Unit of Mass Concentration,string,ng/L;pg/L
2025-04-01,Interleukin 6 Measurement,C74834,C74834,C74804,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,INTLK6;Interleukin 6,Quantitative;Ordinal,The determination of the amount of interleukin 6 present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Body fluid;CSF
2025-04-01,Interleukin 6 Measurement,C74834,C74834,C74804,Laboratory Tests;Protein or Enzyme Measurements;Chemistry Tests,INTLK6;Interleukin 6,Quantitative;Ordinal,The determination of the amount of interleukin 6 present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Electrolyte Measurement,C74946,C74946,C49237,Laboratory Tests,,Quantitative,A quantitative measurement of the amount of an electrolyte present in a sample.,,,,,,,,
2025-04-01,Lipid Measurement,C74949,C74949,C49237,Laboratory Tests;Chemistry Tests;Lipid Measurements,LIPID;Total Lipid,Quantitative,"A quantitative measurement of the amount of lipids (cholesterol, lipoproteins, and triglycerides) present in a sample.",,,,,,,,
2025-04-01,Liver Function Test,C74954,C74954,C49237,Laboratory Tests,,Quantitative,"The quantitative measurement of liver enzymes in the blood, which is useful in assessing the functional state of a patient's liver. Liver function tests include the measurement of albumin, alanine transaminase, aspartate transaminase, alkaline phosphatase, bilirubin, and gamma glutamyl transferase.",,,,,,,,
2025-04-01,Mixed Category Laboratory Procedure,C74957,C74957,,Laboratory Tests;Mixed Category Laboratory Procedure,,,"A laboratory procedure that is performed in more than one of these laboratory specializations: anatomic pathology, clinical pathology, or molecular pathology.",,,,,,,,
2025-04-01,CNS Stimulant Drug Measurement,C75342,C75342,C74675,Laboratory Tests;Chemistry Tests;Drug Class Measurements,,,The determination of the amount of any drug that stimulates the central nervous system (CNS) present in a sample.,,,,,,,,
2025-04-01,Peptide Hormone Measurement,C75385,C75385,C74742,Laboratory Tests;Gene Products,,,The determination of the amount of any peptide hormone present in a sample.,,,,,,,,
2024-04-02,Clinical Test Result,C77140,C77140,,Clinical Test Result,,,"The result of a laboratory, radiologic, or other clinical test performed to determine the presence, absence, or degree of a condition.",,,,,,,,
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117511,C117511,Reported Name of Procedure,string,Diagnostic Mammography
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C25372,C25372,Category,string,
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117512,C117512,Standardized Name of Procedure,string,
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C13717,C13717,Anatomic Site,string,Breast
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C25185,C25185,Laterality,string,Left;Right;Bilateral
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C54215,C54215,Directionality,string,
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117529,C117529,Start Date and Time of Procedure,datetime,
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C117530,C117530,End Date and Time of Procedure,datetime,
2025-04-01,Diagnostic Mammography,C79416,C79416,C16818,Diagnostic Imaging;Medical Imaging;Breast Cancer Diagnostic Procedures;Breast Cancer TAUG,Diagnostic Mammogram,Nominal,Mammography done after suspicious results on a screening mammogram or after other signs of possible breast cancer.,,,,C25692,C25692,Subcategory,string,
2025-04-01,Poikilocyte Measurement,C79602,C79602,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,POIKILO;Poikilocytes,Ordinal,The determination of the number of poikilocytes present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Poikilocyte Measurement,C79602,C79602,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,POIKILO;Poikilocytes,Ordinal,The determination of the number of poikilocytes present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Poikilocyte Measurement,C79602,C79602,C51946,Laboratory Tests;Hematology Tests;Blood Cell Counts;Erythrocyte Counts,POIKILO;Poikilocytes,Ordinal,The determination of the number of poikilocytes present in a sample.,,,,C70856,C70856,Observation Result,string,
2024-12-17,Delivery Procedure,C81179,C81179,C89340,Reproductive Findings,DLVRMODE;Mode of Delivery;Birth Method of Delivery,Nominal,Description of the method by which a fetus is delivered.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Delivery Procedure,C81179,C81179,C89340,Reproductive Findings,DLVRMODE;Mode of Delivery;Birth Method of Delivery,Nominal,Description of the method by which a fetus is delivered.,,,,C70856,C70856,Observation Result,string,Breech Extraction;Delivery by Destructive Operation;Cesarean Section;Vaginal Assisted Delivery;Vaginal Birth After Cesarean Delivery;Vaginal Delivery
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C171000,C171000,Prespecified Event or Intervention Indicator,boolean,Y;N
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83416,C83416,Substance Use Dose,integer,
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83092,C83092,Substance Use Reported Name,string,Beer;Wine;Spirits
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C25692,C25692,Subcategory,string,
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C25372,C25372,Category,string,Alcohol
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83038,C83038,Substance Use Dose Unit,string,Drink;Glass;Fluid Ounce;Milliliter;Liter
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83044,C83044,Substance Use Dose Frequency,string,Daily;Weekly
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83431,C83431,Substance Use Start Date Time,datetime,
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83041,C83041,Substance Use Dose Description,string,
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C83419,C83419,Substance Use End Date Time,datetime,
2023-12-12,Alcohol Use History,C81229,C81229,,Substance Use;Personal Medical History;Medical History,Alcohol History;Alcohol Use,Nominal,A description of an individual's current and past experience with alcoholic beverage consumption.,,,,C127786,C127786,Occurrence Indicator,boolean,Y;N
2024-04-02,Cause of Death,C81239,C81239,,Cause of Death,,,The circumstance or condition that results in the death of a living being.,,,,,,,,
2024-12-17,Expected Date of Confinement,C81247,C81247,,Reproductive Findings,EDLVRDTC;EDD;EDC;Estimated Date of Delivery;Estimated Date of Confinement;Estimated Due Date,Temporal,"The best estimated due date is determined by: last menstrual period (LMP) if confirmed by early ultrasound or no ultrasound performed, or early ultrasound if no known LMP or the ultrasound is not consistent with LMP, or known date of fertilization (e.g. Assisted Reproductive Technology (ART), Intrauterine Insemination (IUI)). Notes: 1. Ultrasound margin of error and ""early"" to be defined by SMFM/ACOG/NICHD workshop. 2. Pregnancy should not be re-dated by a later ultrasound after a best obstetrical estimate of EDD has been established. (adapted from reVITALize)",,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Expected Date of Confinement,C81247,C81247,,Reproductive Findings,EDLVRDTC;EDD;EDC;Estimated Date of Delivery;Estimated Date of Confinement;Estimated Due Date,Temporal,"The best estimated due date is determined by: last menstrual period (LMP) if confirmed by early ultrasound or no ultrasound performed, or early ultrasound if no known LMP or the ultrasound is not consistent with LMP, or known date of fertilization (e.g. Assisted Reproductive Technology (ART), Intrauterine Insemination (IUI)). Notes: 1. Ultrasound margin of error and ""early"" to be defined by SMFM/ACOG/NICHD workshop. 2. Pregnancy should not be re-dated by a later ultrasound after a best obstetrical estimate of EDD has been established. (adapted from reVITALize)",,,,C70856,C70856,Observation Result,datetime,
2024-12-17,Last Menstrual Period,C81257,C81257,C117720,Reproductive Findings;Start Date,LMPSTDTC;LMP;Last Menstrual Period Start Date,Temporal,The date of the first day of the most recent menstrual cycle.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Last Menstrual Period,C81257,C81257,C117720,Reproductive Findings;Start Date,LMPSTDTC;LMP;Last Menstrual Period Start Date,Temporal,The date of the first day of the most recent menstrual cycle.,,,,C70856,C70856,Observation Result,datetime,
2024-12-16,Body Weight,C81328,C81328,C25208,Vital Signs,WEIGHT,Quantitative,The weight of a subject.,http://loinc.org/,LOINC,29463-7,C70856,C70856,Observation Result,decimal,
2024-12-16,Body Weight,C81328,C81328,C25208,Vital Signs,WEIGHT,Quantitative,The weight of a subject.,http://loinc.org/,LOINC,29463-7,C48208,C48208,Unit of Weight,string,Kilogram;Gram;Pound
2024-12-16,Body Weight,C81328,C81328,C25208,Vital Signs,WEIGHT,Quantitative,The weight of a subject.,http://loinc.org/,LOINC,29463-7,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Segmented Neutrophil Count,C81997,C81997,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Segmented Neutrophils;NEUTSG,Quantitative,The determination of the amount of segmented neutrophils present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Segmented Neutrophil Count,C81997,C81997,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Segmented Neutrophils;NEUTSG,Quantitative,The determination of the amount of segmented neutrophils present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Segmented Neutrophil Count,C81997,C81997,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Segmented Neutrophils;NEUTSG,Quantitative,The determination of the amount of segmented neutrophils present in a sample.,,,,C67391,C67391,Unit of Number Concentration,string,10^9/L;/uL
2025-04-01,Segmented Neutrophil Count,C81997,C81997,C51950,Laboratory Tests;Hematology Tests;Blood Cell Counts;Leukocyte Counts;Neutrophil Counts,Segmented Neutrophils;NEUTSG,Quantitative,The determination of the amount of segmented neutrophils present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood;Body fluid;Bone Marrow
2025-04-01,Segmented Neutrophil to Leukocyte Ratio Measurement,C82045,C82045,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Segmented Neutrophils/Leukocytes;NEUTSGLE,Quantitative,The determination of the ratio of segmented neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Segmented Neutrophil to Leukocyte Ratio Measurement,C82045,C82045,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Segmented Neutrophils/Leukocytes;NEUTSGLE,Quantitative,The determination of the ratio of segmented neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,Segmented Neutrophil to Leukocyte Ratio Measurement,C82045,C82045,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Segmented Neutrophils/Leukocytes;NEUTSGLE,Quantitative,The determination of the ratio of segmented neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C70713,C70713,Biospecimen Type,string,Blood;Body fluid;Bone Marrow
2025-04-01,Segmented Neutrophil to Leukocyte Ratio Measurement,C82045,C82045,C67208,Laboratory Tests;Hematology Tests;Blood Cell Counts;Blood Cell Count Ratio Measurements,Segmented Neutrophils/Leukocytes;NEUTSGLE,Quantitative,The determination of the ratio of segmented neutrophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.,,,,C48570,C48570,Percent Unit,string,%
2023-07-06,Abnormal Finding,C82547,C82547,,Findings;Clinical Test Results,,,A decision that an observation or result is outside the parameters considered normal.,,,,,,,,
2025-04-01,Flow Rate,C82554,C82554,,Findings;Clinical Test Result,,,The speed of movement of a liquid.,,,,,,,,
2023-03-31,Reported Event Term,C82571,C82571,,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,,,The collected name for an event observation.,,,,,,,,
2024-12-17,Elapsed Time,C82572,C82572,,Time,,,The interval between two reference points in time.,,,,,,,,
2025-04-01,D-Dimer Measurement,C82621,C82621,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements;Fibrin Degragation Products,D-Dimer;DDIMER;FDP;Fibrin Degragation Products,Quantitative,The determination of the amount of d-dimers present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,D-Dimer Measurement,C82621,C82621,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements;Fibrin Degragation Products,D-Dimer;DDIMER;FDP;Fibrin Degragation Products,Quantitative,The determination of the amount of d-dimers present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2025-04-01,D-Dimer Measurement,C82621,C82621,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements;Fibrin Degragation Products,D-Dimer;DDIMER;FDP;Fibrin Degragation Products,Quantitative,The determination of the amount of d-dimers present in a sample.,,,,C64571,C64571,Unit of Mass Concentration,string,ug/L DDU;ug/L FEU;mg/L FEU
2025-04-01,D-Dimer Measurement,C82621,C82621,C49237,Laboratory Tests;Chemistry Tests;Protein or Enzyme Measurements;Fibrin Degragation Products,D-Dimer;DDIMER;FDP;Fibrin Degragation Products,Quantitative,The determination of the amount of d-dimers present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Platelet Poor Plasma
2025-04-01,Gas Measurement,C82624,C82624,C49237,Laboratory Tests;Chemistry Tests;Gas Measurements,Gas,,A measurement of the gas in a sample.,,,,,,,,
2023-03-31,Medical History Reported Term,C83118,C83118,C82571,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;MHTERM,Nominal,The verbatim description of the medical history being reported.,,,,C83118,C83118,Medical History Reported Term,string,
2023-03-31,Medical History Reported Term,C83118,C83118,C82571,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;MHTERM,Nominal,The verbatim description of the medical history being reported.,,,,C83346,C83346,Medical History Dictionary Derived Term,string,
2023-03-31,Medical History Reported Term,C83118,C83118,C82571,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;MHTERM,Nominal,The verbatim description of the medical history being reported.,,,,C83018,C83018,Medical History Category,string,
2023-03-31,Medical History Reported Term,C83118,C83118,C82571,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;MHTERM,Nominal,The verbatim description of the medical history being reported.,,,,C83143,C83143,Medical History Subcategory,string,
2023-03-31,Medical History Reported Term,C83118,C83118,C82571,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;MHTERM,Nominal,The verbatim description of the medical history being reported.,,,,C87897,C87897,Medical History Pre-specified,boolean,Y;N
2023-03-31,Medical History Reported Term,C83118,C83118,C82571,Reported Events;Medical History Events;Medical Conditions;Presenting Conditions,Medical History;MHTERM,Nominal,The verbatim description of the medical history being reported.,,,,C83067,C83067,Medical History Occurrence,boolean,Y;N
2024-04-02,Physical Examination Finding,C83119,C83119,,Physical Examination Finding,,,"The result of an evaluation of the body and its functions using visual inspection, palpation, percussion, or auscultation that is performed to determine the presence, absence, or degree of a condition.",,,,,,,,
2023-07-06,Electrocardiogram Test,C83146,C83146,,Test Names,EGTEST,,A character or string that represents the full name of the ECG assessment.,,,,,,,,
2024-06-27,Substance Use Status,C83430,C83430,,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS,,,A term used to describe the state or condition of substance use data.,,,,,,,,
2025-04-01,Physical Strength,C87802,C87802,,Musculoskeletal Finding;Physical Strength,,,Degree of intensity or force in regard to a physical activity.,,,,,,,,
2024-12-17,Obstetric Procedure,C89340,C89340,,Reproductive Findings;Intervention or Procedure,,,Any pregnancy or childbirth related procedure associated with a mother during her reproductive years.,,,,,,,,
2024-12-17,Pregnancy Outcome,C90491,C90491,C92720,Reproductive Findings,PRGOUT,Narrative,Findings observed at the end of a pregnancy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-12-17,Pregnancy Outcome,C90491,C90491,C92720,Reproductive Findings,PRGOUT,Narrative,Findings observed at the end of a pregnancy.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Cotinine Measurement,C92249,C92249,C49237,Laboratory Tests;Chemistry Tests,Cotinine,Quantitative;Ordinal,The determination of the amount of cotinine present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Serum;Plasma;Urine;Hair
2025-04-01,Cotinine Measurement,C92249,C92249,C49237,Laboratory Tests;Chemistry Tests,Cotinine,Quantitative;Ordinal,The determination of the amount of cotinine present in a sample.,,,,C70856,C70856,Observation Result,string,
2025-04-01,Cotinine Measurement,C92249,C92249,C49237,Laboratory Tests;Chemistry Tests,Cotinine,Quantitative;Ordinal,The determination of the amount of cotinine present in a sample.,,,,C48207,C48207,Unit of Concentration,string,nmol/L;ug/L
2024-12-17,Pregnancy Finding,C92720,C92720,,Reproductive Findings,,,"Symptoms, signs, diagnostic examinations or a test results in a pregnant mother.",,,,,,,,
2024-12-17,Abnormal Indicator,C93491,C93491,,Clinical Findings Indicator;Indicator,,,Specifies whether an interpreted event or entity is abnormal.,,,,,,,,
2024-04-02,Death Indicator,C93546,C93546,,Death Indicator,,,Specifies whether the life of an entity has ceased.,,,,,,,,
2024-04-02,Expected Indicator,C93565,C93565,,Expected Indicator,,,"Specifies whether the entity, event or activity is considered probable or likely.",,,,,,,,
2025-04-01,Recurrence Indicator,C93645,C93645,C25180,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Recurrence Indicator,C93645,C93645,C25180,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C70856,C70856,Observation Result,string,Positive;Negative
2025-04-01,Recurrence Indicator,C93645,C93645,C25180,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Recurrence Indicator,C93645,C93645,C25180,Oncology Standards;Breast Cancer TAUG;Disease Response;Recurrence;Indicators,Recurrence,Ordinal,"Specifies whether this is a reappearance of an entity, event or activity.",,,,C25372,C25372,Category,string,
2023-07-06,Lesion Identification,C94189,C94189,,Findings;Identification;Work-ups,,,The identification of a non-neoplastic or neoplastic pathologic process during the diagnostic work-up of a disease.,,,,,,,,
2025-04-01,Receptor Status,C94299,C94299,,Laboratory Tests,,,Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.,,,,,,,,
2025-04-01,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.",,,,C25372,C25372,Category,string,
2025-04-01,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.",,,,C171435,C171435,Specimen Anatomic Site,string,
2025-04-01,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.",,,,C25692,C25692,Subcategory,string,
2025-04-01,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.",,,,C70713,C70713,Biospecimen Type,string,
2025-04-01,Genomic Profile,C94411,C94411,C19770,Genetic Testing;Gene Expression Analysis;Genetic Variation;Genetic Variation Analysis;Oncology Standards;Breast Cancer TAUG,Genomic Profiling;Genomic Test;Genomic Testing,Narrative,"Information about all the genes in an organism, including variations, gene expression, and the way those genes interact with each other and with the environment. A genomic profile may be used to discover why some people get certain diseases while other people do not, or why people respond differently to the same drug.",,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C117442,C117442,Tumor Identifier Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C117436,C117436,Tumor Identifier Link Identifier,string,T01;NT01;NEW01
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C70856,C70856,Observation Result,string,Target;Non-target;New
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C170500,C170500,Result Anatomical Location,string,"Supraclavicular Lymph Node;Thoracic Lymph Node;Thyroid Gland;Skin of the Trunk;Mediastinal Lymph Node;Cerebellum;Lung, Left Lower Lobe;Femoral Lymph Node"
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C25185,C25185,Laterality,string,Right;Left
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C54215,C54215,Directionality,string,Upper
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Tumor Identification,C94523,C94523,C94189,Oncology Standards;Tumor/Lesion Identification;TU,TUMIDENT,Nominal,A diagnostic procedure to localize and characterize a tumor.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C117436,C117436,Tumor Identifier Link Identifier,string,T02/T03
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C70856,C70856,Observation Result,string,Target
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C170500,C170500,Result Anatomical Location,string,"Supraclavicular Lymph Node;Thoracic Lymph Node;Thyroid Gland;Skin of the Trunk;Mediastinal Lymph Node;Cerebellum;Lung, Left Lower Lobe;Femoral Lymph Node"
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C25185,C25185,Laterality,string,Right;Left
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C54215,C54215,Directionality,string,Upper
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Matted Tumor Mass Present,C94525,C94525,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUMERGE;Tumor Merged,Nominal,A finding indicating that two or more tumors have merged to create a single cancerous mass.,,,,C117442,C117442,Tumor Identifier Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Response in Target Lesion,C94534,C94534,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,TRGRESP;Target Response,Nominal,A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Response in Target Lesion,C94534,C94534,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,TRGRESP;Target Response,Nominal,A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Response in Target Lesion,C94534,C94534,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,TRGRESP;Target Response,Nominal,A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Response in Target Lesion,C94534,C94534,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,TRGRESP;Target Response,Nominal,A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.,,,,C25372,C25372,Category,string,RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015
2024-06-27,Response in Target Lesion,C94534,C94534,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015,TRGRESP;Target Response,Nominal,A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.,,,,C70856,C70856,Observation Result,string,SD;PR;CR;PD;iCR;iPR;iSD;iUPD;iCPD;NE
2024-06-27,Response in Non-Target Lesion,C94535,C94535,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION,NTRGRESP;Non-Target Response,Nominal,A qualitative or quantitative measurement of the response of a non-target lesion(s) to the therapy.,,,,C25372,C25372,Category,string,RECIST 1.1;iRECIST;LUGANO CLASSIFICATION
2024-06-27,Response in Non-Target Lesion,C94535,C94535,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION,NTRGRESP;Non-Target Response,Nominal,A qualitative or quantitative measurement of the response of a non-target lesion(s) to the therapy.,,,,C70856,C70856,Observation Result,string,NON-CR/NON-PD;PD;CR;iCR;iUPD;iCPD;NON-iCR/NON-iUPD;NE;SD
2024-06-27,Response in Non-Target Lesion,C94535,C94535,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION,NTRGRESP;Non-Target Response,Nominal,A qualitative or quantitative measurement of the response of a non-target lesion(s) to the therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Response in Non-Target Lesion,C94535,C94535,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION,NTRGRESP;Non-Target Response,Nominal,A qualitative or quantitative measurement of the response of a non-target lesion(s) to the therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Response in Non-Target Lesion,C94535,C94535,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION,NTRGRESP;Non-Target Response,Nominal,A qualitative or quantitative measurement of the response of a non-target lesion(s) to the therapy.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C70856,C70856,Observation Result,string,CR;PR;SD;NON-CR/NON-PD;PD;NE;NED;iCR;iPR;iSD;iUPD;iCPD;NON-iCR/NON-iUPD;NE
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C51824,C51824,Evaluator,string,Investigator;Independent Assessor
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3;Hematologist 1;Hematologist 2;Oncologist 1;Oncologist 2
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C117394,C117394,Disease Response Link Group,string,A1;A2;A3
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C25372,C25372,Category,string,RECIST 1.1;iRECIST
2024-06-27,Best Overall Response,C94536,C94536,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST,BESTRESP,Nominal,The most clinically favorable response recorded from the start of the study treatment until the end of treatment.,,,,C71738,C71738,Clinical Trial Epoch,string,Treatment
2025-04-01,Blood Flow Rate,C94866,C94866,C82554,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings,Blood Flow Rate;BLDFLRT,Quantitative,"The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.",,,,C13717,C13717,Anatomic Site,string,Kidney
2025-04-01,Blood Flow Rate,C94866,C94866,C82554,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings,Blood Flow Rate;BLDFLRT,Quantitative,"The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.",,,,C25185,C25185,Laterality,string,Right;Left
2025-04-01,Blood Flow Rate,C94866,C94866,C82554,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings,Blood Flow Rate;BLDFLRT,Quantitative,"The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.",,,,C82535,C82535,Test Method,string,
2025-04-01,Blood Flow Rate,C94866,C94866,C82554,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings,Blood Flow Rate;BLDFLRT,Quantitative,"The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.",,,,C70856,C70856,Observation Result,string,
2025-04-01,Blood Flow Rate,C94866,C94866,C82554,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings,Blood Flow Rate;BLDFLRT,Quantitative,"The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.",,,,C48568,C48568,Unit of Volumetric Flow Rate,string,mL/s;L/min;mL/min;L/h
2025-04-01,Blood Flow Rate,C94866,C94866,C82554,Findings;Clinical Test Result;Renal Function Tests;Urinary System Findings,Blood Flow Rate;BLDFLRT,Quantitative,"The volume of blood per unit time passing through a specified location, such as a point in a blood vessel or an entire organ. Units are ml/sec.",,,,C82515,C82515,Collection Date Time,datetime,
2023-07-06,Perpendicular,C96557,C96557,,Findings;Properties,,,At a right angle to a given line or plane.,,,,,,,,
2025-04-01,Carboxyhemoglobin Measurement,C96591,C96591,C64848,Laboratory Tests;Chemistry Tests;Hemoglobin Measurements,Carboxyhemoglobin,Quantitative,The determination of the amount of carboxyhemoglobin present in a sample.,http://loinc.org/,LOINC,31157-1,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Carboxyhemoglobin Measurement,C96591,C96591,C64848,Laboratory Tests;Chemistry Tests;Hemoglobin Measurements,Carboxyhemoglobin,Quantitative,The determination of the amount of carboxyhemoglobin present in a sample.,http://loinc.org/,LOINC,31157-1,C70856,C70856,Observation Result,decimal,
2025-04-01,Carboxyhemoglobin Measurement,C96591,C96591,C64848,Laboratory Tests;Chemistry Tests;Hemoglobin Measurements,Carboxyhemoglobin,Quantitative,The determination of the amount of carboxyhemoglobin present in a sample.,http://loinc.org/,LOINC,31157-1,C64571,C64571,Unit of Mass Concentration,string,
2024-06-27,Overall Response,C96613,C96613,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022;RAJKUMAR MYELOMA 2011,OVRLRESP,Nominal,An assessment of the overall response of the disease to the therapy.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Overall Response,C96613,C96613,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022;RAJKUMAR MYELOMA 2011,OVRLRESP,Nominal,An assessment of the overall response of the disease to the therapy.,,,,C117394,C117394,Disease Response Link Group,string,A1;A2;A3
2024-06-27,Overall Response,C96613,C96613,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022;RAJKUMAR MYELOMA 2011,OVRLRESP,Nominal,An assessment of the overall response of the disease to the therapy.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Overall Response,C96613,C96613,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022;RAJKUMAR MYELOMA 2011,OVRLRESP,Nominal,An assessment of the overall response of the disease to the therapy.,,,,C25372,C25372,Category,string,RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RAJKUMAR MYELOMA 2011;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022
2024-06-27,Overall Response,C96613,C96613,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022;RAJKUMAR MYELOMA 2011,OVRLRESP,Nominal,An assessment of the overall response of the disease to the therapy.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Overall Response,C96613,C96613,C50995,Oncology Standards;Disease Response;Disease Response Criteria;Disease Response and Clinical Classification;RS;RECIST 1.1;iRECIST;LUGANO CLASSIFICATION;RANO;IRANO 2015;PONTE-DI-LEGNO CONSORTIUM 2022;RAJKUMAR MYELOMA 2011,OVRLRESP,Nominal,An assessment of the overall response of the disease to the therapy.,,,,C70856,C70856,Observation Result,string,CR;PR;SD;NON-CR/NON-PD;PD;NE;NED;iCR;iPR;iSD;iUPD;iCPD;NON-iCR/NON-iUPD;NE
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C170500,C170500,Result Anatomical Location,string,"Supraclavicular Lymph Node;Thoracic Lymph Node;Thyroid Gland;Skin of the Trunk;Mediastinal Lymph Node;Cerebellum;Lung, Left Lower Lobe;Femoral Lymph Node"
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C117442,C117442,Tumor Identifier Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C70856,C70856,Observation Result,string,Target
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C54215,C54215,Directionality,string,Upper
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C25185,C25185,Laterality,string,Right;Left
2024-06-27,Tumor Fragmentation,C96642,C96642,C82547,Oncology Standards;Tumor/Lesion Identification;TU,TUSPLIT;Tumor Split,Nominal,A finding indicating that a tumor mass has been divided into two or more tumors.,,,,C117436,C117436,Tumor Identifier Link Identifier,string,T04.1;T04.2
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C117411,C117411,Tumor Results Group Identifier,string,Target;Non-target;New
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C117419,C117419,Tumor Results Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C117413,C117413,Tumor Results Link Identifier,string,T01;NT01;NEW01
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C70856,C70856,Observation Result,string,Present;Absent;Unequivocal;Equivocal
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Tumor Status,C96643,C96643,C171082,Oncology Standards;Tumor/Lesion Results;TR,TUMSTATE;Tumor State,Nominal,The condition or state of the tumor at a particular time.,,,,C117412,C117412,Tumor Results Link Group,string,A1;A2;A3
2025-04-01,Fat Measurement,C96648,C96648,,Findings;Clinical Test Result,,,The determination of the amount of fat present in a sample.,,,,,,,,
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C117413,C117413,Tumor Results Link Identifier,string,T01;NEW01
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C117411,C117411,Tumor Results Group Identifier,string,Target;New
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C117419,C117419,Tumor Results Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C117412,C117412,Tumor Results Link Group,string,A1;A2;A3
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C70856,C70856,Observation Result,string,12;15;17;Too Small to Measure
2024-06-27,Longest Diameter,C96684,C96684,C25285,Oncology Standards;Tumor/Lesion Results;TR,LDIAM,Quantitative,The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.,,,,C42578,C42578,Unit of Length,string,mm
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C82535,C82535,Test Method,string,MRI;CT Scan;Ultrasound;Photography
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C117412,C117412,Tumor Results Link Group,string,A1;A2;A3
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C117419,C117419,Tumor Results Reference Identifier,string,IMG-00001;IMG-00002
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C117411,C117411,Tumor Results Group Identifier,string,Target;New
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C117413,C117413,Tumor Results Link Identifier,string,T01;NEW01
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C51824,C51824,Evaluator,string,Investigator
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C117043,C117043,Evaluator Identifier,string,Radiologist 1;Radiologist 2;Radiologist 3
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C82515,C82515,Collection Date Time,datetime,
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C70856,C70856,Observation Result,string,12;15;17
2024-06-27,Longest Perpendicular,C96685,C96685,C96557,Oncology Standards;Tumor/Lesion Results;TR,LPERP;Short Axis Diameter,Quantitative,The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane.,,,,C42578,C42578,Unit of Length,string,mm
2025-04-01,Natural Killer Cell Count,C98762,C98762,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Natural Killer Cells,Quantitative,The determination of the amount of natural killer cells present in a sample.,,,,C70713,C70713,Biospecimen Type,string,Blood
2025-04-01,Natural Killer Cell Count,C98762,C98762,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Natural Killer Cells,Quantitative,The determination of the amount of natural killer cells present in a sample.,,,,C67391,C67391,Unit of Number Concentration,string,10^9/L
2025-04-01,Natural Killer Cell Count,C98762,C98762,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Natural Killer Cells,Quantitative,The determination of the amount of natural killer cells present in a sample.,,,,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Natural Killer Cell Count,C98762,C98762,C51949,Laboratory Tests;Hematology Tests;Blood Cell Counts;White Blood Cell Counts,Natural Killer Cells,Quantitative,The determination of the amount of natural killer cells present in a sample.,,,,C70856,C70856,Observation Result,decimal,
2024-12-16,Primary Cause of Death,C99531,C99531,C81239,Death Diagnosis and Details;Cause of Death,PRCDTH;Primary,Nominal,The first significant event which ultimately led to death.,,,,C70856,C70856,Observation Result,string,Sudden Cardiac Death;Cardiac Arrhythmia
2024-12-16,Primary Cause of Death,C99531,C99531,C81239,Death Diagnosis and Details;Cause of Death,PRCDTH;Primary,Nominal,The first significant event which ultimately led to death.,,,,C82515,C82515,Collection Date Time,datetime,
2025-04-01,Urine Glucose Test Strip Measurement (Retired),NEW_1,,C147905,Laboratory Tests,Urine Glucose Dipstick,Ordinal,An ordinal measurement of glucose present in a sample (retired),http://loinc.org/,LOINC,2349-9,C70856,C70856,Observation Result,string,
2025-04-01,Urine Glucose Test Strip Measurement (Retired),NEW_1,,C147905,Laboratory Tests,Urine Glucose Dipstick,Ordinal,An ordinal measurement of glucose present in a sample (retired),http://loinc.org/,LOINC,2349-9,C93566,C93566,Fasting Status Indicator,boolean,
2025-04-01,Urine Glucose Test Strip Measurement (Retired),NEW_1,,C147905,Laboratory Tests,Urine Glucose Dipstick,Ordinal,An ordinal measurement of glucose present in a sample (retired),http://loinc.org/,LOINC,2349-9,C82535,C82535,Test Method,string,Test Strip;Dipstick
2025-04-01,Urine Glucose Test Strip Measurement (Retired),NEW_1,,C147905,Laboratory Tests,Urine Glucose Dipstick,Ordinal,An ordinal measurement of glucose present in a sample (retired),http://loinc.org/,LOINC,2349-9,C70713,C70713,Biospecimen Type,string,Urine
2023-12-12,TTS Acceptability Survey,NEW_LZZT,,,Questionnaires;Surveys;Informational Interventions,,,A survey to assess a caregiver's response about the acceptability of using a transdermal patch to treat Alzheimer's patients.,,,,,,,,
2023-12-12,TTS Acceptability Survey -  Patch Appearance,NEW_LZZT1,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the appearance of a transdermal patch,,,,C51824,C51824,Evaluator,string,Caregiver
2023-12-12,TTS Acceptability Survey -  Patch Appearance,NEW_LZZT1,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the appearance of a transdermal patch,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2023-12-12,TTS Acceptability Survey -  Patch Appearance,NEW_LZZT1,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the appearance of a transdermal patch,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1 Strongly Disagree;2;3;4 Neutral;5;6;7 Strongly Agree
2023-12-12,TTS Acceptability Survey -  Patch Size,NEW_LZZT2,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the size of a transdermal patch,,,,C51824,C51824,Evaluator,string,Caregiver
2023-12-12,TTS Acceptability Survey -  Patch Size,NEW_LZZT2,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the size of a transdermal patch,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1 Strongly Disagree;2;3;4 Neutral;5;6;7 Strongly Agree
2023-12-12,TTS Acceptability Survey -  Patch Size,NEW_LZZT2,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the size of a transdermal patch,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2023-12-12,TTS Acceptability Survey -  Patch Durability,NEW_LZZT3,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the durability of a transdermal patch,,,,C51824,C51824,Evaluator,string,Caregiver
2023-12-12,TTS Acceptability Survey -  Patch Durability,NEW_LZZT3,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the durability of a transdermal patch,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5;6;7
2023-12-12,TTS Acceptability Survey -  Patch Durability,NEW_LZZT3,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of the durability of a transdermal patch,,,,C91106,C91106,Clinical or Research Assessment Answer,string,1 Strongly Disagree;2;3;4 Neutral;5;6;7 Strongly Agree
2023-12-12,TTS Acceptability Survey -  Patch Acceptability,NEW_LZZT4,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of using a transdermal patch compared to oral medication,,,,C51824,C51824,Evaluator,string,Caregiver
2023-12-12,TTS Acceptability Survey -  Patch Acceptability,NEW_LZZT4,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of using a transdermal patch compared to oral medication,,,,C46126,C46126,Ordinal Position,integer,1;2;3;4;5
2023-12-12,TTS Acceptability Survey -  Patch Acceptability,NEW_LZZT4,,NEW_LZZT,Questionnaires;Surveys;Acceptability Surveys,,Ordinal,A survey question to assess acceptability of using a transdermal patch compared to oral medication,,,,C91106,C91106,Clinical or Research Assessment Answer,string,Insist that the patient receive an oral pill;Prefer that the patient receive an oral pill;Have no preference (neutral) for an oral or patch formulation;Prefer that the patient receive a patch;Insist that the patient receive a patch
